The diverse roles of the \textit{Pseudomonas aeruginosa} phospholipase PlcH and the \textit{Toxoplasma gondii} serine palmitoyltransferase in sphingolipid biochemistry. by THYE, JULIE,KRISTINE
Durham E-Theses
The diverse roles of the \textit{Pseudomonas
aeruginosa} phospholipase PlcH and the
\textit{Toxoplasma gondii} serine palmitoyltransferase
in sphingolipid biochemistry.
THYE, JULIE,KRISTINE
How to cite:
THYE, JULIE,KRISTINE (2014) The diverse roles of the \textit{Pseudomonas aeruginosa} phospholipase
PlcH and the \textit{Toxoplasma gondii} serine palmitoyltransferase in sphingolipid biochemistry., Durham
theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/10860/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Oﬃce, Durham University, University Oﬃce, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
2
The diverse roles of the Pseudomonas
aeruginosa phospholipase PlcH and the
Toxoplasma gondii serine
palmitoyltransferase in sphingolipid
biochemistry
A thesis submitted in partial fulfilment of the requirements for the
degree of Doctor of Philosophy in the University of Durham by
Julie Kristine Thye
July 2014
Department of Chemistry
University of Durham, Van Mildert College
Abstract
Sphingolipids are essential for cell survival for almost all eukaryotic cells. Due
to the large variety in sphingolipid structure, they possess a wide range of functions
from acting as structural components of membranes to participating in cell signalling
pathways. Sphingolipid metabolism and catabolism can occur via numerous routes
and the disruption of sphingolipids or sphingolipid biosynthetic pathways is there-
fore detrimental to cells.
The vast majority of prokaryotes do not utilise sphingolipids, however certain prokary-
otic enzymes which posses similar functionality to those involved in sphingolipid
biosynthesis, are crucial to pathogen-host interactions. For instance, the opportunis-
tic human pathogen, Pseudomonas aeruginosa, which represents a particular threat
to cystic fibrosis patients, expresses a variety of virulence factors. One of these,
the heterodimeric complex, PlcHR2, is a phospholipase C. It also possesses sphin-
gomyelinase properties which has been suggested to be responsible for the highly
specific cytotoxic effects of the enzyme. The first aim of the thesis was to express
and purify the PlcH part of the complex in order to functionally and biophysically
characterise it, laying the foundation towards the crystal structure determination.
Furthermore, the sphingomyelinase activity assay was established, utilising PlcHR2,
in order to screen several commercially available compounds and an in-house library
of ceramide analogues for potential inhibitory effect on the enzyme. Five inhibitory
and five activating compounds were identified.
Sphingolipids also play crucial roles in more complex human pathogens, includ-
ing the apicomplexan protozoan parasite, Toxoplasma gondii, which causes a life-
threatening disease, toxoplasmosis, in animals and humans. The first step in the
sphingolipid biosynthetic pathway is catalysed by serine palmitoyltransferase (SPT),
making it an important drug target in several parasites as preventing this step from
occurring in the biosynthesis will result in an incapability of the parasite to pro-
liferate. Several constructs of the SPT from T. gondii were designed in order to
establish the smallest catalytically active domain. The constructs were expressed
and purified in order to characterise the enzyme by a range of biochemical and bio-
physical methods, with the ultimate aim of obtaining a crystal structure for the
enzyme.
The final part of the thesis focussed on the crystallisation and crystal structure
determination of a triosephosphate isomerase (TPI) from a hyperthermophilic ar-
chaeon, Sulfolobus solfataricus. The TPI protein assumes a (β α)8-barrel fold, the
most common protein fold. It is thus an ideal target to study to gain an understand-
ing of the evolutionary process that enzymes undergo to stabilise their structure and
function at the extreme conditions they are subjected to in extremophiles.
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Chapter 1
The biochemistry of sphingolipids
1.1 Introduction
Sphingolipids are a specific subclass of lipids which play many important roles
within cells being both involved in the physiological as well as the pathophysiologi-
cal aspects.1, 2 Sphingolipids are important structural components of eukaryotic cell
membranes but are also involved in a number of intracellular processes.
In order to survive and proliferate, parasites rely on complex lipid metabolic path-
ways to aid rapid cellular division. These pathways are catalysed by a vast variety
of enzymes, many of which have been identified as potential drug targets.3, 4
1.1.1 Sphingolipid structure and classification
Sphingolipids consist of a long-chain base (also known as a sphingoid base) back-
bone such as sphingosine ((2S,3R,4E )-2-aminooctadec-4-ene-1,3-diol)5 (Figure 1.1),
the most common sphingoid base in mammals.6, 7 To this backbone, several moi-
eties - neutral, charged, phosphorylated and/or glycosylated - can be attached to
form the complex sphingolipid.7 Due to the difference in polarity in the molecules
arising from the various moieties and long-chain fatty acid, most sphingolipids are
amphipathic in nature.
Sphingolipids were first discovered by J. L. W. Thudichum in 1884,8 who isolated
three compounds; sphingomyelin (SM), cerebroside and cerebrosulphatide (Fig-
ure 1.2) from human brain tissue. They belong to the three known types of sphin-
golipids9 namely the phosphosphingolipids (Figure 1.2 a), neutral glycosphingolipids
(Figure 1.2 b) and acidic glycosphingolipids (Figure 1.2 c).10
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Figure 1.1: The chemical structure of sphingosine, also known as D-erythro-
sphingosine, (2S,3R,4E )-2-aminooctadec-4-ene-1,3-diol or sphing-4-enine.
(a)
(b) (c)
Figure 1.2: The chemical structures of a) sphingomyelin; b) cerebroside and c)
cerebrosulphatide.
Due to the large number of processes and biological functions that sphingolipids
are involved in (section 1.1.3), this area of biology has been growing rapidly in the
last decade.6, 11
1.1.1.1 Lipid structure and classification
Lipids have been defined as small hydrophobic molecules insoluble in water
but soluble in organic solvents.10, 12 The huge variety in structure and functionality
of lipids means that a comprehensive classification system is necessary in order
to define each lipid. Current nomenclature and classification of the various lipids is
based on the classification outlined by the Lipid Metabolites and Pathways Strategy
(LIPID MAPS) Consortium.13 More than 37,000 lipids are classified out of which
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more than 4000 are sphingolipids. The common notation is based on the notion that
lipids are constructed from ketoacyl and isoprene as building blocks assuming that all
lipids are products of condensation reactions of ketoacyl thioesters and/or isoprene
unit condensations.12 Chain extensions with ketoacyl units are based on a Claisen
condensation which occurs via a carbanion intermediate and chain extension with
isoprene units is an alkylation reaction which occurs via a carbocation intermediate.
The building block structures are shown in Figure 1.3.
(a) (b) (c)
Figure 1.3: The chemical structures of two ketoacyl building blocks a) acetyl; b)
propionyl and c) an isoprene building block.12
The classification system is based on the subdivision into eight categories ac-
cording to their structure. These categories are the fatty acyls (FA), glycerolipids
(GL), glycerophospholipids (GP), sphingolipids (SP), saccharolipids (SL), polyke-
tides (PK), sterol lipids (ST) and prenol lipids (PR), as shown below in
Figure 1.4.12
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1.4: Structures of representative examples of the eight LIPID MAPS lipid
categories. a) Fatty Acyls: hexanedecanoic acid; b) Glycerolipids: 1-hexadecanoyl-
2-(9Z -octadecenoyl)-sn-glycerol; c) Glycerophospholipids: 1-hexadecanoyl-2-(9Z -
octadecenoyl)-sn-glycero-3-phosphocholine; d) Sphingolipids: N -(tetradecanoyl)-
sphing-4-enine; e) Saccharolipids: UPD-3-O-(3R-hydroxy-tetradecanoyl)-αD-N -
acetylglucosamine; f) Polyketides: aflatoxin B1; g) Sterol Lipids: cholest-5-en-3β-ol
and h) Prenol Lipids: 2E,6E -farnesol. Each of these classes can be further divided
into subclasses.
From the eight categories, the sterol and prenol lipids are derived from isoprene
building blocks whereas all the other six categories are biosynthetically based on
condensation reactions between ketoacyl building blocks. The glycerolipids, glyc-
erophospholipids and the sphingolipids all contain long chain fatty acid backbones
with various moieties attached, leading to their unique functionalities.
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1.1.1.2 Sphingolipid structure
The sphingolipid family has a common structure, namely a sphingoid base
backbone to which amide bonds link various moieties.14 Sphingoid bases are struc-
turally very similar to sphingosine.15 They represent a large variety of 2-amino-1,3-
dihydroxyalkanes and -enes; alkyl chains varying between 14 to 22 carbons; 0, 1
or 2 double bonds and (2S,3R)-erythro stereochemistry. At the 4 and 6 position,
hydroxyl groups and other modifications are generally found and at either ω-1 (iso),
ω-2 (anti-iso) or at another position, branching methyl groups are often located.16
The most common sphingoid bases are sphinganine or sphingosine;2, 15 the difference
between the two consists of a trans 4 - 5 double bond in sphingosine, which affects
processes the lipid is involved in.
The sphingolipid family is further subdivided into multiple major classes. These
are the sphingoid bases and the simple derivatives thereof such as 1-phosphate;
sphingoid bases which contain an amide-linked fatty acid such as ceramides; and
the complex sphingolipids which contain phosphodiester-linked head groups such
as phosphosphingolipids; head groups attached by glycosidic bonds (the glycosph-
ingolipids which can be subdivided into the simple (cerebrosides) and the complex
(gangliosides) glycerosphingolipids); and last but not least the arseno- and phospho-
nosphingolipids which contain other head groups.14
1.1.2 Metabolic pathways of sphingolipids
The biosynthesis of sphingolipids is highly complex and involves a number of
intersecting and branching pathways.6 Synthesis and degradation typically occurs
in several intracellular sites such as the endoplasmic reticulum (ER), the Golgi
apparatus or in lysosomes.17, 18 The sphingolipid metabolic pathway has been of
special interest to scientists for the last few decades resulting in the characterisation
of most enzymes involved in the specific steps.2 Due to the nature of the lipid
products of the pathway, most of the enzymes catalysing the various reactions are
integral membrane proteins.
Ceramide is the central compound in the sphingolipid metabolism as it links both
synthesis and catabolism.1 In Figure 1.5, a small part of the eukaryotic sphingolipid
metabolism is summarised, showing the first steps towards ceramide synthesis and
the branch points from this central position.
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Figure 1.5: The sphingolipid metabolic pathways in mammalian cells. Words in bold
are product compound names, words in italics are the names of enzymes catalysing
specific reactions. Adapted from Figures 1 and 2 by Merrill15 and Lahiri et al,2
respectively.
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1.1.2.1 Ceramide - a central compound in the sphingolipid metabolism
Ceramide, the simplest sphingolipid, is the central molecule in the sphingolipid
metabolic pathway2 as it acts as a precursor for the complex sphingolipids as well
as playing an important role as a signalling molecule, regulating cellular func-
tions.1, 15, 19, 20, 21 Ceramides are a subclass of the sphingoid bases, which has an
amide-linked fatty acid and are thus known as N-acyl-sphingoid bases. The fatty
acid can be both mono-unsaturated or saturated and the chain lengths are generally
between 14 and 26 carbons. A wide range of processes involve ceramide, such as cell
growth, apoptosis, neurodegenerative disorders, inflammation, insulin resistance and
diabetes to name a few.1, 21, 22 It is typically associated with apoptosis and blocking
the cell cycle.
Ceramide can be generated by de novo synthesis, by recycling other lipid compo-
nents within the cell or by degradation of more complex sphingolipids,23 but it has
still not been determined how it is split between separate pools for the various func-
tionalities even though the separation into specific pools for cell usage is vital.21
1.1.2.2 De novo sphingolipid biosynthesis
De novo synthesis of sphingolipids has been discovered in eukaryotes includ-
ing fungi as well as in bacterial species. The first two steps in the metabolism
of sphingolipids is highly conserved across the eukaryotes capable of de novo sphin-
golipid biosynthesis.2, 24 The first step is the condensation reaction of palmitoyl-CoA
and L-serine to form 3-ketodihydrosphingosine (KDS, also commonly referred to as
3-ketosphinganine), catalysed by serine palmitoyltransferase (SPT).25, 26, 27 The sec-
ond step consists of the reduction of KDS by 3-ketosphinganine reductase, resulting
in D-erythro-sphinganine. These two steps are shown below in Figure 1.6.
The first step is the rate-limiting step to all sphingolipid synthesis, making SPT a
remarkable drug target as loss of this mechanism without an outside sphingolipid
source will prevent normal cellular function.15
31
Figure 1.6: Diagram of the synthesis of D-erythro-sphinganine in mammalian sys-
tems.
Ceramide defines a central point in the sphingolipid metabolic pathway as it
functions as a precursor for at least five different products.2 Sphinganine is a precur-
sor to ceramide and it can be acylated by dihydroceramide synthase (which is known
as CerS or Lass ) resulting in the formation of dihydroceramide (Figure 1.5). Fol-
lowing the pathway outlined in Figure 1.5, dihydroceramide desaturases/reductases
result in a trans 4 - 5 double bond insertion in dihydroceramide to form ceramide
at the cytosolic side of the ER. (i) Galactosylceramide (GalCer) can be synthesised
by glycosylation of ceramide by a UDP-galactose donor transferring galactose to ce-
ramide, which takes place at the ER’s lumenal leaflet, catalysed by galactoceramide
synthase (GalCerS). (ii) Ceramide-1-phosphate is formed when a ceramide kinase
phosphorylates ceramide. (iii) Deacylation by ceramidases of ceramide can result in
sphingosine and free fatty acids.
The various members of the CerS family have different preferences for the subsets of
acyl CoAs utilised for synthesising dihydroceramide resulting in specific ceramides,
which in turn possess different properties as this is linked to regulation of differ-
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ent cell functions23 and therefore localise in different parts of the cell.2 They are
thus distributed in the tissue to optimise synthesis. CerSs are divided according
to which pH they function at. Neutral CerSs are found in the plasma membrane
(PM), acidic ones are associated with lysosomes2 and alkaline CerSs are generally
found at the ER/Golgi complex. (iv) Sphingomyelin can be formed in the Golgi
apparatus from ceramide via an SM synthase when phosphocholine is transferred
from phosphatidylcholine to ceramide by sphingomyelin synthase (SMS) resulting in
ceramide and diacylglycerol (DAG).1, 4 (v) Last but not least, ceramide can be gly-
cosylated by glucosylceramide synthase (GlcCerS) in the Golgi apparatus, resulting
in glucosylceramide (GlcCer).4
One process which influences the ceramide levels is the degradation of it to sphin-
gosine by particular ceramidases whereafter sphingosine can be phosphorylated to
form sphingosine-1-phosphate (S1P).
As sphingomyelin synthase (SMS) regulates both ceramide and diacylglycerol (DAG)
levels in cells, it has been linked to both cell regulation and transformation, and it
is also believed to affect processes which have usually been linked to phosphatidyl-
choline specific phospholipase C.28
1.1.2.3 Catabolism of sphingomyelin to ceramide
The intracellular levels of sphingolipids are also maintained by recycling and
degradation pathways where ceramide is regenerated from more complex sphin-
golpids such as sphingomyelin (SM), sphingosine or glycosphingolipids.1 This can
occur via reservoirs of complex sphingolipids that are catabolised by hydrolases,
forming glycosylceramide or galactosylceramide whereafter β-glycosidases and galac-
tosidases cleave off the sugars resulting in ceramide. This is known as lysosomal
degradation. An alternative is an SMase catabolic pathway, known as non-lysosomal
degradation.23, 29 Sphingomyelinase (SMases) (neutral, acidic or alkaline) are phos-
phodiesterases and they catalyse the catabolism of SM to ceramide and phospho-
choline, whereafter the produced ceramide can be further degraded to sphingosine
or can be utilised for further sphingolipid formation. This process can lead to apop-
tosis which has been observed during infection with the opportunistic pathogen, P.
aeruginosa. It has been associated with the enzyme PlcHR2 which possesses SMase
activity and which has been linked to the mortality from P. aeruginosa infections
due to poor wound healing and vasculitis, as PlcHR2 is lethal to endothelial cells.
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Cellular ceramide levels are also affected by the sphingosine salvage pathway where
sphingosine can be recycled to ceramide as a result of ceramide synthases.1
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1.1.3 Biological function of sphingolipids
Sphingolipids have numerous functions both structurally as well as involvement
in intracellular processes, as outlined briefly below.
1.1.3.1 Structural components of membranes
Eukaryotic cell membranes consist of a complex lipid bilayer usually contain-
ing lipids from three main classes; glycerolipids, sterols and sphingolipids, which
form the outer leaflet of the plasma membrane lipid bilayer.2, 4 These lipids pro-
vide structure and architectural stability to the cell due to their bonding abilities
associated with the difference in polarity across the molecules. Moreover, they play
a role in chemical resistance as the lipid bilayer protects against harmful substances.
1.1.3.2 Lipid rafts
Lipid rafts are small microdomains that can form at the cell surface from sph-
ingolipids and sterols1, 31 and are usually identified by their content of cholesterol,
saturated fatty acids and sphingolipids. Ceramide can, in the lipid membrane sur-
face, associate with itself to create rafts containing cholesterol and glycosphingolipids
which can fuse together to form large signalling macrodomains.32 Acidic SMase at
the plasma membrane can be triggered by external stimuli leading to the formation
of ceramide-enriched areas of the membrane. Specific proteins with an ability to
change both composition and size according to stimuli, are incorporated into these
rafts. This supports certain protein-protein interactions and can lead to signalling
cascades being initiated33 and thus lipid rafts are believed to play an important role
in cell signalling as proteins are very concentrated in these areas allowing for signal
amplification.
This is, however, a controversial topic as scientists are divided on whether these
structures exist in biological systems, as they are difficult to quantify size-wise and
in terms of lifespan.34 However, recent studies have utilised direct imaging to detect
lipid domains with sizes in the µm range.35
1.1.3.3 Sphingolipids in other biological processes - signalling agents
Simple sphingolipids such as sphingosine, sphingosine-1-phosphate, ceramide
and ceramide-1-phosphate have been linked to several cellular processes such as
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growth, differentiation, motility, proliferation, apoptosis and function characteristic
deterioration (senescence).2, 36, 22 In these processes, sphingosine-1-phosphate and
ceramide have been identified as having opposite effects.
Ceramide has been shown to play an important role in cell apoptosis and thus higher
levels of the compound leads to cell death. Intracellular ceramide levels are affected
by both extracellular stimuli and signals such as oxidative stress, heat-shock, ionis-
ing radiation, nitric oxide and many more. Ceramide levels are believed to increase
either due to sphingomyelin hydrolysis degradation by either neutral or acidic sph-
ingomyelinases (nSMases and aSMases) or by de novo synthesis.2 Two different
mechanisms have been suggested for its involvement in apoptosis. Ceramide has
been suggested to either bind to specific proteins after being formed in the plasma
membrane, whereupon it influences their activity, behaving as a secondary messen-
ger. The second suggestion involves its behaviour as a signalling lipid due to its
biophysical properties. Sphingosine and ceramide both are cytotoxic and can cause
growth arrest whereas sphingosine-1-phosphate can inhibit apoptosis and can stim-
ulate growth.15 Sphingosine-1-phosphate is known to be involved in tumorigenesis
and inflammation but also supports the survival of cells.1
Even though no confirmation of glycosphingolipid degradation leading to ceramide
formation has yet been found the complex glycosphingolipids themselves are vital
for gangliosides.2 The glycosphingolipids play a role in cell physiology and possess
functionality to act as antigens, growth factors, binding agents for microbial toxins,
cell adhesion mediators as well as being capable of mediating cell signal transduction.
Complex glycosphingolipids are important for cell recognition and cell signalling as
lipids and proteins in nearby cells can interact with the glycan structures.
It is important to note that the complex and wide range of sphingolipids are all
based on the relatively simple and central molecules sphingomyelin and ceramide,
formed and degraded by the processes described above.
1.1.3.4 Sphingolipid biosynthesis as a drug target
Sphingolipid metabolism contains many possible drug targets involved in the
intricate pathway system. More importantly, this is an ideal way to target pathogens
as their sphingolipid biosynthetic pathways often differ significantly from mammals,
which has lead to the development of drugs which can target most enzymes involved
in this pathway.37
The two pathogenic protein targets discussed in Chapter 3 and Chapter 4 are both
involved in sphingolipid metabolism and catabolism. PlcHR2 from the opportunistic
pathogen, P. aeruginosa, is a haemolytic heterodimeric complex possessing phos-
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pholipase C and SMase activity. The SMase activity contributes to inhibition of
angiogensis and cytotoxicity to endothelial cells.30 P. aeruginosa poses a particu-
lar threat to cystic fibrosis patients as they can not clear the bacteria from their
pathways, leading to chronic infection. Release of the cytotoxic SMase, PlcHR2, is
threatening to patient health and inhibition of the enzyme’s SMase activity could
potentially lower the number of deaths associated with P. aeruginosa infection. The
SMase is therefore an extremely desirable drug target.
SPT from T. gondii, an apicomplexan protozoan parasite which causes a life-threatening
disease in animals and humans (toxoplasmosis), has been chosen as a viable drug
target as the enzyme differs sufficiently from that of the host.
1.1.4 Project objectives
The project focusses on two enzymes with key roles in sphingolipid metabolism
and pathogen-host interactions. The objective of the first part of the project
is to biochemically and biophysically characterise the haemolytic phospholipase
C/sphingomyelinase PlcHR2 from the opportunistic pathogen Pseudomonas aerug-
inosa. This important virulence factor has been shown to be one of the key com-
ponents in the invasion of the pathogen into its mammalian host. The first step
includes the cloning, overexpression and characterisation of various constructs of
the catalytic subunit PlcH. A biochemical assay is established for the PlcHR2 en-
zyme. This assay is then utilised to identify new inhibitors as lead compounds for
drug development with the help of an in-house chemical library of new substrate
analogues. The expression and purification will lead to initial crystallisation exper-
iments laying the foundation of a high-resolution crystal structure analysis of PlcH
as well as the PlcHR2 complex.
The second part of the project focusses on the serine palmitoyltransferase (SPT)
from the apicomplexan protozoan parasite, Toxoplasma gondii. SPT catalyses the
first, rate limiting step in the de novo biosynthesis of ceramide, the key compound
in sphingolipid metabolism. Similar cloning and expression strategies to the ones
employed for PlcH are used to express and purify a number SPT constructs. These
proteins are characterised biochemically in order to identify the catalytic domain
and unravel the catalytic mechanism. Additional biophysical experiments includ-
ing preliminary small-angle X-ray scattering experiments are performed in order to
identify the quaternary arrangement of the protein. Extensive crystallisation ex-
periments are leading the way to a full structure determination by NMR or X-ray
crystallography.
The objective of the third part of the project is the crystal structure determination
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of a triosephosphate isomerase (TPI) from the hyperthermophilic archaeon, Sul-
folobus solfataricus. It is crystallised (without and with bound phosphoenol pyru-
vate (PEP)) and the the 3D structures determined. TPI adapts the most common
protein fold, the (β α)8-barrel. This makes it a model enzyme to study for evolu-
tionary purposes. The crystal structure reveals that, as in other hyperthermophilic
archaea, SsTPI forms a tetramer in solution, in order to stabilise the enzyme under
the extreme conditions it is exposed to. Furthermore, a PEP bound crystal form
with PEP in the active site shows conservation of the active site residues when
compared with other TPIs from hyperthermophilic organisms.
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Chapter 2
Materials and Methods -
Experimental procedure
2.1 Materials
All chemicals and materials utilised were purchased from Sigma-Aldrich unless
otherwise stated.
2.2 Cloning and small-scale expression procedures
at the OPPF
Initial cloning experiments of PaPlcH and TgSPT constructs were carried out
at the OPPF (Oxford Protein Production Facility) using HTP methods. For detailed
description of procedures refer to the OPPF Standard Protocol for using a ligation-
independent cloning method.38, 39
2.2.1 Polymerase chain reaction (PCR)
All the polymerase chain reactions (PCR) at the OPPF were performed in 96
well microplates.
Polymerase chain reactions using Phusion Flash Mastermix (NEB) were set up on ice
following the manufacturer’s protocol. Reactions typically contained 25 µL (bring-
ing it to a final concentration of 1X Phusion Flash Mastermix) 2X Phusion Flash
Mastermix, 17 µL sterile H2O, 3 µL (10 µM) of each primer and 2 µL of template
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plasmid (provided by Dr Martin Walsh) for each 50 µL reaction. A summary of
the plasmids can be found in Appendix A, Table A.1. PCR was typically cycled as
listed in Table 2.1 below.
Time Temperature/ ◦C
Initial denaturation 10 secs 98
Denaturation 0 - 1 secs 98
Annealing 5 secs 60
Elongation (repeat 30 times from step number 2) 15 secs/k bp 72
Final elongation 2 mins 72
Table 2.1: Cycling conditions for PCR using Phusion Flash Mastermix. Once the
final elongation had taken place, the samples were cooled to 4 ◦C.
Results were analysed by agarose gel electrophoresis (section 2.2.2).
2.2.2 Agarose gels
1.25% (w/V) agarose gels in 0.5X TBE buffer (5.4 g Tris base, 2.75 g boric
acid and 2 mL 0.5 M EDTA dissolved in 1 L MilliQ H2O) were run at 100 V for
30 minutes. The DNA sample was mixed 5 : 2 (sample : buffer) with 5 x DNA
loading buffer (0.25% (w/V) Bromophenol Blue in 30% (V/V) glycerol) prior to
loading. HyperLadderTM I (Bioline Ltd.) was used as a DNA marker ladder to
estimate DNA sizes. Visualisation of DNA was attained through the presence of
SYBR R© Safe DNA stain (Invitrogen Life TechnologiesTM) in the gel and a UV
transilluminator.
2.2.3 Purification of the PCR products by AMPure XP
Magnetic Bead Purification
The PCR product was mixed thoroughly with 90 µL resuspended AMPure
magnetic beads ensuring a homogenous colour. The mixture was incubated for 5
minutes at room temperature (ensuring the binding of any PCR products larger
than 100 bps to the beads). The PCR plate was placed on a magnet plate for 5
minutes or until the solution became clear. Primers and unbound PCR product
were removed and discarded with the clear solution whilst the plate remained on
the magnet.
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200 µL 70% C2H5OH was added to each well and plates were incubated for 30
seconds at room temperature whereafter the C2H5OH was removed and discarded.
This washing step was repeated 2 times. The plates were air-dried for 15 minutes to
ensure complete evaporation of the C2H5OH. The PCR products were isolated by
adding 30 µL of elution buffer (EB), (10 mM Tris pH 8.0), to each well and mixing
thoroughly (the beads do not have to go into solution for complete elution). 40 µL
of the supernatant was transferred to another PCR plate for later use. Another
agarose gel was run as described in section 2.2.2.
2.2.4 In-Fusion reactions
10 µL of InFusion cloning reactions were set up, containing 1 µL (100 ng) of
appropriate linearised pOPIN vector (a summary of the vectors can be found in
Appendix A, Table A.1), 2 µL of purified PCR product (ranging from 10 to 250
ng), made up to final volume of 10 µL with H2O. Contents were mixed by pipetting,
transferred to a PCR plate and sealed. The reactions were run in a thermocycler at
42 ◦C for 30 minutes. The InFusion reactions were put on ice once the reaction was
complete and immediately diluted with 40 µL of TE (10 mM Tris-Cl pH 7.5 and 1
mM EDTA). 3 - 5 µL aliquots of the diluted In-Fusion reactions were transformed
into OmniMaxII (phage resistant) chemically competent E. coli cells (section 2.2.5).
2.2.5 HTP Transformation of chemically competent cells
Frozen 50 µL aliquots of chemically competent E. coli cells were thawed on ice.
3 - 5 µL of purified DNA expression plasmid (or diluted InFusion reaction, section
2.2.4) was added, gently mixed, and left on ice for 30 minutes. Cells were heat-
shocked for 45 seconds in a 42 ◦C water bath and immediately placed back on ice
for 2 minutes. 300 µL Power Broth (PB) medium was added to the cells and then
cultured at 37 ◦C for 1 hour (2 hours for InFusion reactions) before plating onto LB
agar plates containing required antibiotic. Plates were grown at 37 ◦C overnight.
2.2.6 Colony selection using Blue/White screening
Following transformation of InFusion reactions, the cells were spread onto Lysogeny
Broth (LB) agar plates. Two replicates were performed for each experiment. A
mixture containing antibiotics (carbenicillin at a final concentration of 50 µg/mL
or kanamycin at a final concentration of 35 µg/mL), 20% X-Gal in DMF as stock,
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resulting in a final concentration of 0.02%, and IPTG (500 mM stock) to a final
concentration of 1 mM was prepared. 20 µL PB/LB was added to half of the 1
mL agar plate as growth medium before spreading 5 µL cells. The other half were
supplemented with the appropriate antibiotic, X-Gal and IPTG mixture and 25 µL
cells were spread onto those agar plates without further addition of media. The
plates were shaken to ensure spreading and were then left to dry for 15 minutes.
The plates were incubated overnight at 37 ◦C. For each of the constructs, two white
colonies were picked.
2.2.7 HTP culture and glycerol stock preparation
Two white colonies were picked after Blue/White screening and grown in 1.5 mL
PB supplemented with antibiotic in a shaker-incubator at 37 ◦C overnight. Glycerol
stocks were prepared by adding 100 µL of the overnight culture to 100 µL of LB
with 30% glycerol. Stocks were stored at −80 ◦C.
2.2.8 Purification of plasmid DNA
The overnight cultures of E. coli (grown from two white colonies, OPPF stan-
dard protocol, ensuring positive clones for 95% of PCR products) were centrifuged
at 5,000 × g for 3 minutes at room temperature and the pellets were processed
using a commercial plasmid miniprep kit (Qiagen QIAprep R© Spin Miniprep Kit)
according to the manufacturer’s protocol.
2.2.9 Verification PCR
After extracting DNA following plasmid purification by miniprep, two clones of
each construct were verified by a PCR screen. Positive colonies were identified by
PCR as described below.
Reactions using KOD XtremeTM Hot Start DNA Polymerase (Novagen) Master
Mix were set up on ice. The KOD Polymerase Master Mix was made in bulk for
52 reactions of 25 µL each (130 µL 10 X KOD buffer, 130 µL 10 x dNTP mix, 52
µL 25 mM MgCl2, 11 µL KOD (2.5 U/µL), 814 µL MilliQ H2O and 7 µL pOPIN
forward primer at 100 µL. Reactions typically contained 22 µL Master Mix, 1.5 µL
of 10 µM reverse primer and 1.5 µL of the appropriate construct plasmid. PCR was
typically cycled as listed in Table 2.2 below.
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Time Temperature/ ◦C
Initial denaturation 2 mins 94
Denaturation 30 secs 94
Annealing 30 secs 60
Elongation (repeat 30 times) 1 mins/k bp 68
Final elongation 4 mins 68
Table 2.2: Cycling conditions for PCR using KOD XtremeTM Hot Start DNA Poly-
merase. Once the final elongation had taken place, the samples were cooled to 4 ◦C.
Results were analysed by agarose gel electrophoresis (section 2.2.2).
2.2.10 Small-scale expression trial
Expression screens were set up using two strains of E. coli (B834 (DE3) and
Rosetta I (DE3) LysS) and two different induction media (IPTG induction medium
([IPTG]final = 0.5 mM, 20
◦C overnight), and Overnight ExpressTM Instant TB
Medium (autoinduction,40 25 ◦C overnight)) for each PCR product in 24 deep-well
plates. Appropriate antibiotics were added. Transformation was carried out accord-
ing to section 2.2.5. 1.5 mL of culture was centrifuged at 5,000× g for 15 minutes and
pellets frozen at −80 ◦C (for at least 20 minutes before robotic Ni2+-NTA screening
(section 2.2.10.1)) to ensure efficient lysis.
2.2.10.1 Ni+2- NTA Miniature Expression Screen
Cells were completely resuspended in 210 µL Lysis Buffer (NPI-10-Tween) (50
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 1% (V/V) Tween 20, pH 8.0
(adjusted using NaOH), filtered and stored at 4 ◦C) with 1 mg/mL lysozyme to
Buffer NPI-10-Tween) and 400 units/mL of DNAse Type I. This was left for 30
minutes before centrifuging at 5,000 × g for 30 minutes at 4 ◦C. The supernatant
was put over Ni+2-NTA magnetic beads and purified using a Qiagen Ni+2-NTA
Superflow 96 BioRobot Kit which was slightly modified.
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2.2.10.2 Sodium Dodecyl Sulphate Poly-Acrylamide Electrophoresis
(SDS-PAGE)
0.75 mm precast polyacrylamide gels (Invitrogen) were used. Samples were
mixed 1 : 1 with loading buffer (100 mM Tris-HCl pH 6.8, 4% (w/V) SDS, 0.2%
(w/V) bromophenol blue and 20% (V/V) glycerol) incubated at 95 ◦C for 3 min-
utes to denature the protein and run at 200 V for 30 minutes. Protein sizes were
estimated relative to a protein marker ladder (Wide Range (MW 6,500-200,000 Da)
SigmaMarkerTM). Gels were stained with Instant Blue (Expedeon) dye, left for 30
minutes and destained by covering with water for 10 minutes.
2.3 Protein expression and purification prepara-
tion
Whereas initial expression trials were performed at the OPPF, the subsequent
scale-up experiments were performed in the Durham University Department of
Chemistry.
2.3.1 Preparation of chemically competent cells
Cells of the required E. coli strain (usually Rosetta II (DE3) pLysS) were
streaked onto LB agar plates containing the appropriate antibiotics (chloramphenicol
at 17 µg/mL), and incubated at 37 ◦C overnight. A single colony was transferred
to 5 mL LB medium (with appropriate antibiotics added; ampicillin for DH5α and
chloramphenicol for Rosetta II (DE3) pLysS) and the culture was incubated at 37 ◦C
overnight, 200 rpm. In a 100 mL sterile flask, 0.5 mL of the overnight culture was
added to 50 mL of inoculated LB media. The new culture was incubated at 37 ◦C,
200 rpm, until an OD600 = 0.5 was reached. The culture was left on ice for 30
minutes and then centrifuged at 3,350 × g at 4 ◦C for 10 minutes in a sterile 50
mL Falcon tube. All the supernatant was discarded and 50 mL 80 mM MgCl2,
20 mM CaCl2 (ice cold) was added to the pellet. The pellet was resuspended by
shaking, then left on ice for 20 minutes. The suspension was centrifuged at 3,350
× g at 4 ◦C for 10 minutes, the supernatant was discarded and the remaining pellet
resuspended in 2 mL 10 mM CaCl2, 10% glycerol (ice cold). The cell aliquots were
stored at −80 ◦C.
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2.3.1.1 Transformation of chemically competent cells
200 µL of competent cells were thawed on ice and 2 µL of plasmid, containing
the gene of interest, was added, gently mixed and left to incubate on ice for 20 - 30
minutes. Cells were heat-shocked at 42 ◦C for 45 seconds and replaced on ice. 800 µL
of LB media was added to the cells within 2 minutes of heat-shocking and cultured
at 37 ◦C for 1 hour, shaking at 200 rpm, before plating approximately 100 µL onto
LB agar plates supplemented with the correct antibiotic. Plates were incubated at
37 ◦C overnight.
2.3.2 Plasmid preparation
Transformed DH5α cells containing the plasmid of interest were plated onto
LB agar plates supplemented with 50 µg/mL of ampicillin and incubated at 37 ◦C
overnight. A single colony was transferred to a 15 mL Falcon tube containing 3 mL
of LB medium, with 50 µg/mL ampicillin, and incubated at 37 ◦C overnight, shaking
at 200 rpm.) A 5 mL overnight culture of DH5α cells was centrifuged at 5,000 × g
for 10 minutes and the pellet was processed using commercially available miniprep
kits (Plasmid Miniprep Kit No. 2, Biomega Inc.) according to the manufaturer’s
protocol. Plasmids were stored at −20 ◦C.
2.3.3 Agarose gels
1.25% (w/V) agarose gels were prepared in 1X TAE buffer (242 g Tris, 57.1 g
acetic acid and 18.6 g EDTA in 900 mL dH2O). 0.01% (V/V) of ethidium bromide
(DNA stain) was added to the agarose gel mix. The gel was run in TAE buffer. Each
lane was loaded with 6 µL of DNA sample mixed with loading buffer (0.25% (w/V)
bromophenol blue, 30% (V/V) glycerol) in a 5 : 1 ratio (5 µL of genetic material
and 1 µL loading buffer). A molecular weight marker (Fermentas 1 kb ladder) was
used as a reference. Gels were run at 100 V for 1 hour and visualised using a UV
transilluminator.
2.3.4 Restriction digest of plasmids
2 µL of pOPINF (for PlcH) and pOPINS3C (for SPT) plasmid containing the
desired truncation gene were mixed with 1.5 µL E1 buffer (Promega) and 1 µL
HindIII enzyme (Promega). The total volume was made up to 15 µL with dH2O
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whereafter the reaction was incubated at 37 ◦C for 2 hours and then run on an
agarose gel to verify the plasmid size (section 2.3.3).
2.3.5 Colony PCR
Colony PCR was used to check that a specific colony of E. coli on an LB agar
plate contained the desired gene (expected size) for protein expression.
9 µL of dH2O was mixed with 0.5 µL of forward primer and 0.5 µL reverse primer
(stock concentrations approximately 10 µM (from OPPF), giving final concentra-
tions of 0.25 µM) in a PCR tube (primers corresponding to the individual gene
truncations) and a single colony was added. 10 µL of Taq polymerase in buffer was
added to the reaction. In a TC-312 PCR machine (Techne), 35 PCR cycles were
carried out; denaturation at 94 ◦C for 30 seconds, annealing at 55 ◦C for 45 seconds
and extension at 68 ◦C for 100 seconds. The products were analysed by agarose gel
(see section 2.3.3).
2.3.6 Plasmid sequencing
All plasmids (PlcH and SPT constructs) were sequenced. This was carried out
by DBS genomics, Durham University, using the T7 promoter primer and the T7
reverse primer.
2.4 Protein expression
2.4.1 Small-scale protein expression
Small-scale expression screens were carried out in 15 mL Falcon tubes contain-
ing 2.5 mL PB (containing 1% (w/V) glucose, 0.4% (V/V) glycerol), 50 µg/mL
ampicillin, 17 µg/mL chloramphenicol and a single E. coli colony (containing the
plasmid of interest). This was incubated overnight at 37 ◦C, 200 rpm. 312.5 µL
of the culture was tranferred to 12.5 mL Overnight ExpresTM Instant TB Medium
(TBonex) or YT medium (used as control), 50 µg/mL ampicillin, 17 µg/mL chlo-
ramphenicol, all in a 50 mL Falcon tube. The cultures were shaken at 37 ◦C at 150
rpm for 5 hours (for TgSPT the culture was left at 37 ◦C until the OD600 reached
0.5) whereafter the temperature was reduced to 25 ◦C and incubation continued for
a further 22 - 24 hours. No IPTG was added to the tubes with YT media in order
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to not start induction.
2.4.2 Small-scale initial expression assay
Glycerol stocks of PlcH 1, PlcH 2, PlcH 3 and PlcH 4 all in Rosetta I (DE3)
pLysS cells (treated at the OPPF) were streaked onto LB agar plates. The procedure
for small-scale expression was followed (section 2.4.1). The cultures were centrifuged
at
3,350 × g at 4 ◦C for 20 minutes. The pellets and supernatant medium were stored
separately at −80 ◦C. The pellets (250 - 270 mg) and media were thawed on ice.
The pellets were lysed with 1 mL lysis buffer (50 mM Tris pH 7.5, 500 mM NaCl,
20 mM imidazole, 0.2 % Tween R© 20 (V/V)), containing 1 EDTA-free protease
inhibitor tablet (Roche) and 50 µL each of DNAse and RNAse (5 mg/mL) per 15
mL buffer, vortexed thouroughly and sonicated in an Ultrawave water bath for 2 ×
3 minutes. The lysate was centrifuged at 18,400 × g at 4 ◦C for 30 minutes to pellet
the insoluble fraction.
2.4.3 Large-scale protein expression
20 mL cultures were grown up in 50 mL sterile Falcon tubes containing 20
ml PB medium (containing 1% (w/V) glucose, 0.4% (V/V) glycerol), 50 µg/mL
ampicillin, 17 µg/mL chloramphenicol and one colony. These small cultures were
shaken overnight at 175 rpm at 37 ◦C. 500 mL of Overnight ExpresTM Instant
TB Medium (TBonex, a granulated autoinduction culture medium for high-level
protein production in pET and other IPTG-inducible bacterial expression systems)
was prepared according to manufacturer’s instructions in 2 L baﬄed glass flasks. 50
µg/mL ampicillin, 17 µg/mL chloramphenicol and 10 mL of the inoculating culture
were added. The culture was shaken at 37 ◦C at 150 rpm for 5 hours (for TgSPT the
culture was left at 37 ◦C until the OD600 reached 0.5) whereafter the temperature
was reduced to 25 ◦C and incubation continued for a further 22 - 24 hours (for PlcH
constructs, SPT ∆159, SPT ∆176 and SPT ∆180). For SPT ∆143, the temperature
was reduced to 15 ◦C and incubation continued for a further 48 hours to maximise
expression. Cells were harvested by centrifuging at 4,500 × g at 4 ◦C for 30 minutes.
Cell pellets were frozen at −80 ◦C.
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2.5 Protein purification
During all steps of the purification, the relevant sample fractions were stored
and analysed by SDS-PAGE gel (section 2.5.6).
2.5.1 Bacterial lysis
Frozen bacterial cell pellets were thawed on ice and suspended in lysis buffer (50
mM Tris pH 7.5, 500 mM NaCl, 20 mM imidazole, 0.2% Tween R© 20 (V/V)). One
EDTA-free protease inhibitor tablet (Roche), 50 mg/mL DNAses and 50 mg/mL
RNAses were added per 15 mL lysis buffer. Lysis buffer was utilised in a ratio of 1 :
1.5 (pellet mass (g) : Lysis buffer (mL)). The suspension was vortexed and sonicated
(3 × 2.5 minutes, 37%, 2 pulses per second). The insoluble fraction was removed by
centrifugation at 42,000 × g at 4 ◦C for 30 minutes. The supernatant was filtered,
using a 0.22 µm syringe-filter to remove cell debris and larger aggregates.
2.5.2 Immobilised Metal Affinity Chromatography (IMAC)
The cell lysate was loaded onto an FPLC (A¨kta) and injected onto a His trap
FF 5 mL column (GE Healthcare Life Sciences) already equilibrated with wash
buffer (for PlcH constructs: 50 mM Tris pH 7.5, 500 mM NaCl, 20 mM imidazole
and for SPT constructs: 50 mM Tris pH 7.6, 500 mM NaCl, 20 mM imidazole,
25 µM pyridoxal-5-phosphate (PLP) and 5% glycerol (V/V)). The column was run
with a gradient of 0 - 100% of elution buffer (for PlcH constructs: 50 mM Tris pH
7.5, 500 mM NaCl, 1 M imidazole and for SPT constructs: 50 mM Tris pH 7.6, 500
mM NaCl, 1 M imidazole, 25 µM PLP and 5% glycerol (V/V)) at a flowrate of 5
mL/min.
Fractions and column flow-through (while loading sample) were collected for
analysis. Fractions containing protein (verified by SDS-PAGE gel, section 2.5.6)
were dialysed against dialysis buffer (for PlcH constructs: 10 mM Tris pH 8, 200 mM
NaCl and for SPT constructs: 10 mM Tris pH 7.6, 150 mM NaCl, 25 µM, 5% glyc-
erol (V/V)), using Slide-A-Lyzer cassettes of appropriate molecular weight cut-off
(Thermo Scientific), dialysis tubing (Fischer Scientific) or dialysis tubes (Generon).
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2.5.3 Anion exchange chromatography
The dialysed fractions were concentrated using a vivaspin centrifugal concen-
trator (Generon) or a spin concentrator (Fischer Scientific or Agilent Technologies)
as per the manufacturers’ instructions, ensuring appropriate MWCO for PlcH and
SPT constructs. Concentrated samples and loaded onto an FPLC (A¨kta) and
injected onto a 1 mL MonoQ 5/50 GL anion exchange column (GE Healthcare Life
Sciences) pre-equilibrated with wash buffer (10 mM Tris pH 8, 100 mM NaCl). The
column was run with a gradient of 0-100% of elution buffer (10 mM Tris pH 8, 1 M
NaCl) at a flowrate of 1 mL/min. Fractions of 1 mL as well as column flow-through
(while loading sample) were collected for analysis. This procedure as only used for
PlcH 2 and PlcH 4.
Fractions containing protein (verified by SDS-PAGE gel, section 2.5.6) were dialysed
against dialysis buffer (10 mM Tris pH 8, 200 mM NaCl) using Slide-A-Lyzer cas-
settes of appropriate molecular weight cut-off (Thermo Scientific), dialysis tubing
(Fischer Scientific) or dialysis tubes (Generon).
2.5.4 Size exclusion chromatography
The appropriate fractions containing protein were concentrated (see 2.5.3) to
approximately 2 mL and loaded onto an FPLC (A¨kta) and injected onto a 120 mL
HiLoad 16/60 Superdex 200 column (GE Healthcare Life Sciences) pre-equilibrated
with buffer (for PlcH constructs: 20 mM Tris pH 8, 200 mM NaCl and for SPT
constructs: 20 mM Tris pH 7.5, 200 mM NaCl, 25 µM PLP, 5% glycerol (V/V)) at
a flowrate of 1 mL/min. Fractions of 1 mL were collected.
2.5.5 Protease cleavage
In order to assess the activity of Human rhinovirus 3C (HRV 3C) protease
(Qiagen), before attempting protein cleavage, three reactions were carried out (it
is used to cleave between Gln and Gly in the Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro
site).41 Three Eppendorf tubes were used, each containing 5 µL of HRV 3C protease
10X Buffer (Qiagen), 44 µL dH2O and 1 µL HRV 3C protease (cstock= 2 units/µL).
TgSPT ∆143 (purified on an IMAC column, see 2.5.2) column and dialysed against
appropriate dialysis buffer (10 mM Tris pH 7.6, 150 mM NaCl, 25 µM, 5% glycerol
(V/V)) was added to the tubes; 10 µg, 50 µg and 100 µg respectively. The reactions
were incubated at 4 ◦C for 18 hours with samples being taken at 1 hour, 3 hours,
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5 hours and 18 hours for analysis by SDS-PAGE gel (see 2.5.6). When performing
tag-cleavage on large scale, the protein sample (with HRV 3 C protease added) was
incubated in Slide-A-Lyzer cassettes (Thermo Scientific), dialysis tubing (Fischer
Scientific) or dialysis tubes (Generon) of appropriate molecular weight cut-off, im-
mersed in dialysis buffer (10 mM Tris pH 7.6, 150 mM NaCl, 25 µM, 5% glycerol
(V/V)) (this step was performed simultaneously to dialysis) at 4 ◦C for 18 hours.
The HRV 3C protease was used at a concentration of 1 µL per 50 µg of protein
((1 unit per 25 µg of protein). The samples were concentrated and loaded onto an
FPLC (A¨kta) and injected onto a His trap FF 5 mL column (GE Healthcare Life
Sciences) as described in 2.5.2. This step was only performed for SPT constructs.
2.5.6 Sodium Dodecyl Sulphate Poly-Acrylamide
Electrophoresis (SDS - PAGE)
(Modifications to section 2.2.10.2) 0.75 to 1 mm polyacrylamide gels (12%
(V/V) bis-acrylamide resolving and 5% bisacrylamide stacking) were poured us-
ing the Mini-Protean Tetra Electrophoresis System. Samples were mixed 1 : 1 with
loading buffer (VWR), denatured at 95 ◦C for 3 minutes and run at 200 V for 35
minutes in 1X SDS Running buffer (10X SDS Running buffer: 144.0 g glycine, 30.2
g Tris and 10.0 g SDS was dissolved in 1 L of dH2O). Protein sizes were estimated
relative to a protein marker ladder as stated in figures. Gels were stained by in-
cubation for 1 - 12 hours in 20 mL Instant Blue (Expedeon) dye and destained by
covering with water for 10 minutes.
2.5.7 Native gel
0.75 - 1 mm non-denaturing polyacrylamide gels (separating gel: 1.5 M Tris-
HCl pH 8.8, and 0.5 M Tris-HCl pH 6.8, stacking gel) were poured using the Mini-
Protean Tetra Electrophoresis System. Samples were mixed 1 : 1 with 1X loading
buffer (5X loading buffer: 0.31 mM Tris-HCl pH 6.8, 0.05% (w/V) bromophenol
blue, 50% (V/V) glycerol), denatured at 95 ◦C for 3 minutes and run at 200 V for
35 minutes in 1 x electrophoresis buffer (10 X electrophoresis buffer: 14.4 g glycine
and 3.0 g Tris in 1 L of dH2O). Protein sizes were estimated relative to a protein
marker ladder as stated in figures. Gels were stained by incubation for 1 - 12 hours
in 20 mL Instant Blue (Expedeon) dye and destained by covering with water for 10
minutes.
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2.5.8 Determination of protein concentration
For a quick determination of protein concentration, the absorbance at 280 nm
was measured by Nanodrop (Thermo Scientific). To determine a more accurate
protein concentration, UV-Vis spectra of a series of dilutions of the protein of interest
were taken using a Cary 50 Bio spectrophotometer (Varian). 6 M guanidinium
chloride (a denaturant which unfolds the protein) was added to the protein sample
and to the buffer blank, in a 500 µL cuvette. Absorbance at 280 nm was measured.
Using the Beer-Lambert law (A =  × c × l) and the value for the extinction
coefficient (from the Expasy Prot Param tool (http://web.expasy.org/protparam/),
the concentration was determined. The values obtained using the above-mentioned
methods differed by less than 10%.
2.6 Mass spectrometry
All samples prepared for analysis by mass spectrometry were submitted to the
Mass Spectrometry Service, Department of Chemistry, Durham University, unless
otherwise stated.
2.6.1 Tryptic digest
A tryptic digest was performed to prepare the cleaved protein, PlcH 4, for
MALDI-ToF (matrix assisted laster desorption/ionisation time-of-flight) (Autoflex
II ToF/ToF, Bruker Daltonik GmBH) using a linear detector. The protein was made
up to a concentration of 50 mg/mL in a 50 mM TrisHCl pH 7.55, 10 mM CaCl2
buffer. To a 20 µL (1 mg) aliquot of protein, 1 µL of trypsin solution (20 µg of
trypsin, 2 µL of 1% acetic acid and 78 µL of buffer (as above)) was added. The
mixture was incubated at 37 ◦C for 2 - 3 hours wherafter 0.3 mg of dithiothreitol
(DTT) was added to the mixture. The final mixture was incubated and agitated at
37 ◦C for 1 hour.
2.6.2 Mass spectrometry to determine oligomerisation state
of SPT
Samples of purified SPT ∆158 at 4.64 mg were dialysed into two different sys-
tems using a Slide-A-Lyzer dialysis cassette. One sample was dialysed into MilliQ
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H2O pH 5.65 with 25 µM PLP added, and 4.64 mg of SPT ∆158 was dialysed into
40 mM ammonium acetate pH 6.99 with 25 µM PLP added overnight at 4 ◦C. The
sample in MilliQ H2O precipitated overnight but was easily redissolved. The sample
in ammonium acetate had become cloudy and was filtered to remove aggregates. 1
mL of 3.57 mg/mL of SPT ∆158 in MilliQ H2O with 25 µM PLP and 1 mL of 0.75
mg/mL SPT ∆158 in 40 mM ammonium acetate with 25 µM PLP was submitted
to the mass spectrometry service at the Department of Chemistry at Durham Uni-
versity.
Samples were analysed LC-ESI-QToF Premier (Waters Ltd.) (liquid chromatogra-
phy electro spray ionisation) to determine the accurate mass.
2.7 Circular dichroism spectrometry
The protein was diluted in a buffer suitable for taking CD measurements (30
mM Na2HPO4, pH 8) utilising Mini Clarification Spin Columns (Generon) and wash-
ing through with the same buffer. The protein in CD buffer was diluted further with
CD buffer in the cuvette.
A 500 µL cuvette with 1 cm pathlength was used for all CD data collections. Data
for PlcH 2 and PlcH 4 samples were collected at a concentration of 58 nM and
119 nM respectively. Data for SPT ∆158, SPT ∆176 and SPT ∆180 samples were
collected at 0.18 µM, 0.25 µM and 0.23 µM respectively. A Cary 50 Bio Spectropho-
tometer (Varian) was used to measure the absorbance of the protein between 200
and 800 nm. The spectra were obtained using a Jasco 710 spectrapolarimeter with
a thermostat-controlled cell compartment at 20 ◦C. Three CD runs were carried out
for each protein sample (a buffer blank, protein sample followed by a buffer blank).
8 spectra were averaged for each run.
Data was normalised with the data collected for the buffer as a blank. The machine
units (of the collected data), θ (measured in mdeg) were converted to ∆  (units of
M−1cm−1), molar circular dichroism. This was done using the following equation;
∆ = θ
0.1×MRW
(l × c)× 3298 (2.1)
where MRW is the mean residue weight (molar mass divided by number of residues),
l is the path length (measured in cm) and c is the concentration (in units of mg/mL).
The resulting data analysed using the CDPro software (available at
http://lamar.colostate.edu/), specifically utilising the CONTINLL, CDSSTR and
SELCON3 programmes.42 The reference set, base sets 1 and 10, were suggested for
the PlcH and the SPT data respectively. The output CD data were then analysed
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by plotting the experimental data and calculated data versus the measured wave-
lengths in order to determine which programme yielded the best analysis.43, 44, 45
2.8 Bio-SAXS
Biological small-angle X-ray scattering (Bio SAXS) data on all four SPT con-
structs, at various concentrations, were collected by M. Grøftehauge on B21 at
Diamond Light Source. Data reduction was performed in DAWN by James Doutch
(automatically performed on the beamline pipeline).
2.9 Enzymatic activity
2.9.1 Establishment of an in vitro enzymatic activity assay
An assay was established in order to compare the sphingomyelinase activity of
PlcHR2 to that of Bacillus cereus sphingomyelinase (BcSMase), a well-characterised
standard for SMase activity. It was further used to screen compounds for inhibitory
effects. Experiments were conducted using the Amplex R© Red Sphingomyelinase
Assay Kit (Invitrogen Molecular ProbesTM).46, 47, 48
The overall assay reaction mechanism is shown below in Figure 2.1.
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Figure 2.1: Schematic of the Amplex R© Red Sphingomyelinase Assay reaction
mechanism. Sphingomyelin is hydrolysed by the SMase (1), resulting in phos-
phocholine and ceramide. The former is hydrolysed by alkaline phosphatase (2),
producing choline and phosphate. Choline is oxidised by choline oxidase (3), re-
sulting in betaine and two hydrogen peroxide molecules. Hydrogen peroxide reacts
with the Amplex R© Red reagent (10-acetyl-3,7-dihydroxyphenoxazine) catalysed by
horseradish peroxide (4), producing resorufin, the strongly fluorescent end product.
2.9.2 Experimental protocol for the Amplex R© Red
Sphingomyelinase Assay Kit
All stock solutions were prepared according to the user manual.46 Stock solu-
tions included 5X Reaction buffer (0.5 M Tris-HCl pH 7.4, 50 mM MgCl2), func-
tional enzyme stock solutions and substrate stock solution. The following protocol
describes the assay for a high throughput reaction, performed in 96-well black (to
reduce background signal) microplates (Perkin Elmer R©).
One assay was performed in a single well; the equivalent of one reaction. The total
reaction volume was set to 200 µL per well.
The sphingomyelinase (BcSMase or the PlcHR2 from P. aeruginosa), in storage
buffer (50 mM Tris pH 7.4, 50 mM NaCl, 0.1 mM TCEP) at a concentration of 10
mg/mL (0.1 mM), was diluted in 1X Reaction buffer to the required concentration.
A volume of 100 µL was utilised per assay (over a range of concentrations). 10 mL of
Amplex R© Red reagent working solution was prepared by mixing 100 µL Amplex R©
Red reagent stock solution (10 mM), 100 µL horseradish peroxide stock solution (2
U/mL), 100 µL choline oxidase stock solution (0.2 U/mL), 200 µL alkaline phos-
phatase stock solution (8 U/mL), 1.0 mL sphingomyelin solution (5.0 mM solution
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in 2% Triton X-100) and 8.5 mL 1X Reaction buffer. 100 µL of the enzyme solution
was added to each reaction well of the microplate. 100 µL per reaction of 1X reac-
tion buffer was used as a negative control and 100 µL of a 10 µM solution of H2O2
was employed as a positive control. To start the reaction, 100 µL of the Amplex R©
Red working solution (0.1 mM Amplex R© Red reagent, 0.02 U/mL horseradish per-
oxide, 0.002 U/mL choline oxidase, 0.16 U/mL alkaline phosphatase and 0.5 mM
sphingomyelin in 2% Triton X-100, all in 1X Reaction buffer) was added to each well
resulting in a final reaction volume of 200 µL per well. For assays involving addition
of inhibitory compounds, the compounds were added to the wells and mixed with
the protein solution before starting the reactions (details are stated in the results
section for individual experiments) The reactions were covered to keep out light and
incubated at 37 ◦C for 30 minutes. All fluorescent measurements were made using
a BioTek FLx800 microplate reader (using excitation at λ = 540 ± 17.5 nm and
fluorescence detection at λ = 600 ± 20 nm) at a 50% sensitivity. Each reaction was
carried out in triplicate unless otherwise stated.
This assay was utilised to test the SMase activity of the PlcH constructs, PlcH 2 and
PlcH 4. As a control experiment, purified, circular pOPIN F plasmid (employed as
vector for both PlcH constructs) was tested using the same experimental protocol
as for the enzymes. No SMase activity was detected (data not shown).
2.9.3 SPT activity assay with [14C]-serine
Labelled [14C]-serine was utilised with palmitoyl-CoA in activity assays to es-
tablish the activity of the SPT constructs in crude or purified form.49, 50
The protein sample was dialysed into 50 mM HEPES pH 7.6, 150 mM KCl, 0.2
mM EDTA, 5% glycerol and 25 µM PLP using a Slide-A-Lyzer dialysis cassette.
A typical assay was carried out at a 250 µL volume. The reaction consisted of 20
µM SPT (in 50 mM HEPES pH 7.6, 150 mM KCl, 0.2 mM EDTA, 5% glycerol
and 25 µM PLP), 1.6 mM palmitoyl-CoA and 20 µM [14C]-serine. The reaction was
incubated at 37 ◦C for 70 minutes whereafter the reaction was terminated by the
addition of 20 µL of 2 : 1 CHCl3 : CH3OH. The solution was thoroughly mixed
by vortexing. The organic and aqueous layers were separated by centrifuging at
10,000 × g for 5 minutes. The chloroform layer was transferred to a 1.5 mL non-
stick Eppendorf tubes and removed by vacuum centrifugation at 30 ◦C. The lipid
residue was resuspended in 15 µL (CHCl3 : CH3OH) from which approximately 8
µL were applied to a TLC plate in a 40 : 10 : 1, CHCl3 : CH3OH : NH4OH solvent
system. In reactions containing myriocin as inhibitor, 5 µL myriocin dissolved in
CH3OH was added to the reaction to a concentration of 100 µM after addition of
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palmitoyl-CoA. After the inhibitor was added, the reaction was incubated at 37 ◦C
for 20 mins before addition of serine ([14C]-labelled or un-labelled). The TLC plate
was scanned using an AR-2000 radio TLC Imaging Scanner (Bioscan).
Fluorography was used as an alternative, visual technique. The TLC plate was
sprayed with En3Hance Spray (Perkin-Elmer R©) and left to dry, twice. A photo-
graphic film was placed on the TLC plate, left at −80 ◦C and typically developed
24 hours later.
2.9.4 Activity assay and product identification by mass
spectrometry
SPT ∆158 was dialysed into suitable buffer (50 mM HEPES pH 7.6, 150 mM
KCl, 0.2 mM EDTA, 5% glycerol and 25 µM PLP) in a Slide-A-Lyzer dialysis
cassette, then transferred to a glass vessel (to avoid plastic-ware polymer contam-
ination). Palmitoyl-CoA and L-serine were added to the vessel at concentrations
of 1.6 mM and 20 mM, respectively, to a total volume 250 µL and 20 µM SPT
∆158. The reaction was incubated at 37 ◦C for 75 minutes. 1.5 mL of 2 : 1 CHCl3 :
CH3OH was added and the mixture vortexed. The aqueous and organic layers were
separated by centrifugation at 4,000 × g for 5 minutes. The chloroform layer was
removed under vacuum at 30 ◦C, leaving a lipid residue which was resuspended in
500 µL of 2 : 1 CHCl3 : CH3OH and submitted for analysis by mass spectrometry
2.9.4.1 Mass spectrometry of SPT activity assay product
Protein masses were determined using MALDI-ToF (matrix assisted laser des-
orption/ionisation time-of-flight) (Autoflex II ToF/ToF) using a linear detector.
Protein samples at approximately 2 mg/mL in 100 mM NaCl, 10 mM Tris pH 7.5
buffer were analysed on a MALDI ion source. Data were acquired and analysed
using FlexAnalysis 2.0 (Bruker Daltonik) by the Durham University, Department of
Chemistry Mass Spectrometry Open Access facility.
2.9.5 Thermal Stability Assays
Thermal stability assays were carried out for PlcH 2 and SPT ∆158, using
a fluorescent dye. SYPRO Orange dye (Invitrogen) was used as the fluorescent
dye as it exhibits a large change in fluorescence upon protein denaturation. It has
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an excitation wavelength of 492 nm51 which reduces the risk of small molecules
quenching the fluorescent intensity. The molecule is hydrophobic in nature and thus
binds to the hydrophobic protein regions once the protein starts unfolding, and the
detected fluorescence levels can be used to judge the degree of denaturation, allowing
determination of the melting temperature of proteins.
Protein samples were mixed with 5000X SYPRO Orange dye to a final concentration
of 20X. The additives and protein were loaded into a clear plastic 96-well plate,
allowing for a broad range of conditions to be tested. To each of the wells, 10 µL
additive solution and 10 µL protein-dye solution was added (final dye concentration
was 10X SYPRO Orange). Fluorescence at 610 nm was measured in 1 ◦C increments
in a temperature range from 24−95 ◦C using a 7500 FAST RT-PCR system (Applied
Biosystems). The fluorescent data were plotted against the temperature resulting
in a sigmoidal curve of fluorescence as a function of increasing temperature. The
inflection point of the curve corresponds to the melting temperature of the protein
and was determined by fitting a Boltzmann (sigmoidal) distribution to the curve
and then differentiating it, using the QtiPlot 0.9.7.10 software.52, 53, 54
2.9.6 Protein crystallisation
HTP screening was undertaken using a Screenmaker 96+8TM Xtal liquid han-
dler from Innovadyne technologies Inc. to produce sitting drops. Two sitting drops
of 100 nL reservoir solution + 100 nL protein solution and of 200 nL reservoir solu-
tion + 100 nL protein solution respectively, were set up.
For PlcH 4 trays were set up at 1.9 mg/mL using the JCSG+55 screen (Mole-
cular Dimensions). Manual hanging drop trays were set up with PlcH 2 at a con-
centration of 1.9 mg/mL with a reservoir volume of 0.5 mL and a drop ratio of 1 :
1. Optimisation screens of the promising conditions identified in initial screens for
PlcH 4 were set up using hanging drop trays at a concentration of 2.1 mg/mL with
a reservoir volume of 0.5 mL and a drop ratio of 1 : 1.
Initial HTP screens for the SPT constructs were set up with the following
screens. JCSG+55 (Molecular Dimensions), the PACT Premier55 (Molecular Dimen-
sions), the Index56 (Hampton), Morpheus57 (Molecular Dimensions), Clear Strategy
1 and 2 (Molecular Dimensions),58 Structure Screen I and II59, 60 (Molecular Dimen-
sions) and Midas61 (Molecular Dimensions). In addition, screens were set up with
100 µM myriocin using the same conditions. Additional screens were set up at
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the OPPF using the HydraTM 96 Robbins Scientific robot (Cartesian, Digilab, mi-
crosys). Two sitting drops of 100 nL reservoir solution + 100 nL protein solution
and of 200 nL reservoir solution + 100 nL protein solution respectively, were pro-
duced. These trays were set up at a concentration of 5.2 mg/mL with the JCSG+55
(Molecular Dimensions), the PACT Premier55 (Molecular Dimensions), the Index56
(Hampton), Morpheus57 (Molecular Dimensions) and the Wizard 1 and 2 screens.
Two identical screens were set up for each screen, one was kept at 4 ◦C and one at
21 ◦C. Concentrations of protein were typically between 1.2 and 5.2 mg/mL.
2.9.7 Figures
All figures of chemical structures were created with Chemdraw Std. 13.0 unless
otherwise stated.
57
Chapter 3
The
phospholipase/sphingomyelinase
PlcHR2 from Pseudomonas
aeruginosa
3.1 Introduction
Pseudomonas aeruginosa is a Gram-negative bacterium. It is an important
opportunistic pathogen which affects immuno-compromised as well as cystic fibrosis
patients severely. The pathogen produces various virulence factors aiding bacterial
invasion and infection.
In this chapter, my work on the heterodimeric haemolytic phospholipase, PlcHR2,
which represents an important virulence factor from the opportunistic pathogen
Pseudomonas aeruginosa, will be presented. Particular focus is given to the sphin-
gomyelinase activity of this enzyme. After a brief introduction of the bacterium and
its various proteins that contribute to pathogenesis, the biochemical and biophysi-
cal charaterisation of PlcHR2, and the efforts towards a structural description will
be summarised with the ultimate goal of finding novel inhibitors with therapeutic
potential.
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3.1.1 Pseudomonas aeruginosa
Bacteria are a diverse group of prokaryotic (usually unicellular) organisms which
have adapted to a wide variety of environments. Bacteria can broadly be divided
into two classes, according to the ability of the cells to stain with crystal violet com-
pound also known as pyoctanine (Gram-negative bacteria do not retain this stain
whereas Gram-positive bacteria do). Gram-positive bacteria possess a single phos-
pholipid membrane covered by a thick peptidoglycan layer whereas Gram-negative
bacteria also possess an extra layer consisting mainly of lipopolysaccharides (LPSs)
and proteins as shown schematically in Figure 3.1.
Figure 3.1: Schematic of a Gram-positive and a Gram-negative bacterium.
Pseudomonas aeruginosa is a Gram-negative bacterium. It is part of the family
Pseudomondacea and it belongs to the genus Pseudomonas, a diverse group of more
than 140 species out of which 25 are often associated with humans. Those species
linked to diseases are usually opportunistic pathogens such as P. aeruginosa and P.
maltophilia.62
P. aeruginosa was first discovered by C. Gessard in 188263 due to a distinctive blue
pigment, pyocyanine, which is produced by most strains.62 Its importance as a hu-
man pathogen was not discovered until much later. Today its involvement in human
disease and mortality is well-established and hence a lot of research has been carried
out in order to better understand the pathogen-host relationship. The complete
genome of P. aeruginosa strain PA01 consisting of approximately 6.3 million base
pairs, was thus sequenced by C. K Stover et al 64 by genome-shotgun sampling; at
the time it was the largest bacterial genome ever to have been sequenced. It was
59
chosen due to its important role as a human opportunistic pathogen, which is linked
to its resistance to most antibiotics and most disinfectants, providing scientist with
a unique understanding of the connections between gene complexity, size and ability
to adapt to its surroundings.
3.1.1.1 Physical appearance/aspects of P. aeruginosa
Pseudomonas aeruginosa is a rod-shaped aerobic bacterium which usually mea-
sures 0.5 - 0.8 by 1.5 - 3.0 µm. Most strains move by means of a single polar
flagellum,62 although some strains can possess up to three flagella. In nature it is
usually found as a unicellular organism in planktonic form where it can swim us-
ing its flagellum but can also exist attached to either a surface or a substrate as a
biofilm, depending on the specific strain (section 3.1.4.1). Clinically isolated strains
often have surface structures such as pili which are believed to enable the bacteria
to better fix at a surface and thus enhance chances of colonisation.65 Pili are also
believed to have antiphagocytic properties (section 3.1.4.1).
The presence of P. aeruginosa is often diagnosed by a fruity odour, its ability to
grow at elevated temperatures, fluorescence with exposure to UV light (sometimes
used to confirm presence in wounds) and its inability to ferment lactose. Isolates
of the bacterium can form three distinct types of colonies; small, rough colonies are
usually formed by isolates from water or soil whereas clinical samples can produce
two smooth colony types - large colonies with flat edges and an elevated appear-
ance (fried egg) or colonies with a mucoid appearance (usually from urinary tract
or respiratory secretions) due to alginate slime.66
3.1.1.2 Suitable growth environments of P. aeruginosa
P. aeruginosa is a ubiquitous bacterium which prefers moist environments. It
can be found growing in marshes, soils and coastal marine habitats but it can also
grow on surfaces of plants and occasionally on animal tissue.62, 64, 67
The bacterium is non-fermentative aerobe and thus does not acquire energy from
carbohydrate fermentation but rather from oxidation.64 Despite having an aerobic
metabolism it can grow under anaerobic conditions if NO−3 is present as a respira-
tory electron acceptor.68 Its oxidative, aerobic metabolism is supported due to the
lack of sugar transporters necessary for maintaining glycolytic pathways leading to
a dependence on various other carbon compounds.64 The bacterium’s nutritional
needs are simple as it can utilise more than 75 organic factors as carbon sources
for growth but the simplest medium in which it can grow in the laboratory consists
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of acetate and ammonium sulphate (carbon and nitrogen sources). It can even be
found growing in distilled water.62, 64 The optimum temperatures for growth are
between 25 ◦ and 37 ◦C but unlike other Pseudomonas species, P. aeruginosa can
also grow at temperatures up to 42 ◦C.
The bacterium has a remarkable tolerance for many types of environment and is
able to resist high salt and dye concentrations, weak antiseptics and many com-
monly used antibiotics (section 3.1.3.3).64
3.1.1.3 P. aeruginosa - a Gram-negative bacterium with
antibiotic resistance
The P. aeruginosa bacterium is enveloped by three layers consisting of an in-
ner cytoplasmic membrane, a thin peptidoglycan layer and an outer membrane con-
sisting mainly of lipopolysaccharide, phospholipids and outer membrane proteins
(OMPs), as shown in Figure 3.2.64, 69 In P. aeruginosa, the LPS has been found to
be less toxic than for other Gram-negative bacteria; it generally consists of hydroxy
fatty acids, heptose and 2-keto-3-deoxyoctonic acid as well as core- and side-chain
polysaccharides.62 LPS is attached to the outer membrane surface by lipid A (a hy-
drophobic lipid component of LPS) which is linked to a repeating saccharide chain
(the outermost part of LPS) via a core oligosaccharide. The side chain is a variable
O antigen which extends into the surrounding environment thus enabling cellular
interactions. The O antigen specifies the bacterial serotype specificity.65
Figure 3.2: Simplified schematic of a Gram-negative bacterium membrane.
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Many of the commonly used antibiotics show limited efficacy against P. aerug-
inosa infections as the low permeability of the outer membrane renders them resis-
tant. LPS and outer membrane proteins embedded in the outer membrane protect
the bacterium from certain chemicals as it increases the overall negative charge of
the membrane (as opposed to Gram-positive bacterial membranes, which just con-
sist of a cytoplasmic membrane and a thick peptidoglycan layer).64 Many bacteria
have evolved sophisticated systems to secrete various proteins including important
virulence factors into the surrounding medium. P. aeruginosa is found to possess,
amongst others, very efficient eﬄux systems against antibiotics70 (section 3.1.2) and
OMPs have been shown to be actively involved in antibiotic transport, secretion of
virulence factors as well as securing the structures which are involved in cell adhe-
sion and motility.65
In certain clinically isolated P. aeruginosa strains, specific overexpressed OMPs
have been linked to resistance, especially against quinolones (a family of antibacte-
rial synthetic drugs).69
3.1.2 Secretion pathways in P. aeruginosa
Gram-negative bacteria employ up to six types of protein secretion systems in
order to secrete a large variety of proteins ranging from ones used for ion uptake
to proteins for hydrocarbon hydrolysis.71, 72 These systems are extremely useful for
host invasion; they can enable colonisation and can aid in immune response evasion.
More importantly, bacteria need a channel through the outer membrane in order to
secure energy sources.
Bacteria, like other types of cells, are surrounded by a hydrophobic membrane pre-
venting toxic factors entry, but channels through this membrane allow movement of
molecules. Pathogenic bacteria require virulence factors to cross the bacterial cell
wall but also the cell plasma membrane of the host. The relevant secretion systems
important for P. aeruginosa are briefly described below.
3.1.2.1 The Sec and the Tat pathways
As the Gram-negative cell wall consists of an inner and an outer membrane
(both hydrophobic) separated by the hydrophilic periplasm, it poses a challenge for
large, hydrophilic proteins and toxins being secreted by the pathogen. The protein
can either pass from the cytoplasm to the surface of the bacterium in a one-step
mechanism or it can briefly stop in the periplasm and then cross the outer membrane
in a two-step mechanism.
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In the two-step mechanism, the proteins are generally secreted via an export pathway
utilised by periplasmic and outer membrane proteins - the most important one of
these is the Sec pathway. In order to be secreted via the Sec pathway, proteins must
have an N-terminal signal peptide which is cleaved off for the protein to be delivered
to the periplasm.72 Proteins are transported in an unfolded manner. Translocation
of proteins in folded conformation through the inner membrane can also occur via
the twin arginine translocation (Tat) system, which consists of three components -
TatABC.73, 74 It is regulated by pH changes, unlike the Sec system which utilises
ATP hydrolysis.75 Many substrates employing the Tat-system require a cofactor for
functionality that they obtain from the cytoplasm. PlcH and PlcN (sections 3.1.7.2
and 3.1.7.3) utilise the Tat system to cross the inner membrane recognised by a
specific Tat sequence, the N-terminal signal peptide. This sequence contains two
conserved arginine residues. This step is followed by the type II secretions system
(T2SS) (the extracellular secretion machinery, Xcp) to cross the outer membrane
(as do proteins that cross the inner membrane via the Sec pathway).75 Tat signal
sequences are long (35 amino acids for PlcH) and positively charged (3+ and 6+)
which distinguishes them from Sec-dependent signal sequences.
3.1.2.2 The type III secretion system
The type III secretion system (T3SS)76, 77 (also known as the T3SS nanoma-
chine, injectosome) is incredibly useful for pathogens as it enables injection of sub-
strates into the cell cytosol from the pathogen cytoplasm, so long as the two cells
are in direct physical contact with each other. P. aeruginosa uses this system to
inject certain proteins that remain in the membrane, which aid in creating a pore,
a translocon, leading from the pathogen into the eukaryotic cells, allowing for other
proteins to access the host cells. The T3SS is extremely useful for transporting vir-
ulence factors into eukaryotic cells, and thus for acute infections and cytotoxicity.72
The effectors such as ExoS (a bifunctional type III cytotoxin) and ExoU (an effector
protein, cytotoxin and broad-specificity phospholipase A) (section 3.1.6.1) passing
through the T3SS are in an unfolded state whereafter they bind to a cognate chap-
erone before being secreted.
3.1.3 The pathogenicity of P. aeruginosa
P. aeruginosa is an important human pathogen that exploits weaknesses in
host defences to cause infections and disease. It can infect almost any human tissue
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if the immune system is compromised or circumvented in any way. As an oppor-
tunistic pathogen, P. aeruginosa poses a particular threat to immuno-compromised
patients such as those undergoing chemotherapy treatment for cancer and patients
co-infected with AIDS (acquired immunodeficiency syndrome).78 Furthermore, P.
aeruginosa causes dangerous infections in patients with burns and large open wounds
where fatality rates are near 50%.
However the pathogen rarely causes disease in healthy individuals, as the host de-
fence system is generally very effective79 and human polymorphonuclear leukocyte
(PMN)-dependent killing ensures resistance.80
Bacterial infections by P. aeruginosa are of particular importance in hospitals (noso-
comical infections) where they are a significant source of septicaemia in urinary-tract
infections especially in catheterized patients and in hospital-acquired pneumonia in
patients using respirators or ventilators.64, 79, 80 During septicaemia the pathogen
often causes thrombosis and vasculitis. Dermatitis, soft tissue infections, osteochon-
dritis, endocarditis, gastrointestinal infections and a variety of systemic infections
are all a results of infection with the bacterium.64 It has been shown that P. aerug-
inosa infections are considerably more dangerous for patients infected with strains
that contain a type III secretion system and express the virulence factor, ExoU
(ventilator-associated pneumonia)81 (section 3.1.5). Suppression of the immune re-
sponse can occur when ExoU impedes the phagocytic cells from eradicating bacterial
infections of the lungs. This underlines the importance of the secretion system dis-
cussed previously.
The human host defence includes neutrophil elastase (NE), which is secreted dur-
ing inflammation by both macrophages and neutrophils, is linked to tissue damage
occurring during P. aeruginosa infection. Mice that lack NE are less likely to sup-
press a P. aeruginosa infection than wild-type mice.80 Both these results show that
NE is a part of a natural defence mechanism.82 Whilst NE can kill P. aeruginosa
bacteria, there are many defence mechanisms in place in the bacteria which prevent
easy clearance of an infection by the hosts. Examples of these are polysaccharide al-
ginate which is known to possess antiphagocytic properties and rhamnolipids which
can bring about necrotic death of PMNs. More rhamnolipids are produced in P.
aeruginosa biofilms if PMNs are present, thus encouraging biofilm formation pro-
viding protection for the pathogen.
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3.1.3.1 Cystic fibrosis patients
Probably the most important patient group severely affected by P. aeruginosa
are people suffering from the genetic condition cystic fibrosis (CF). Cystic fibrosis
(with a prevalence of 1:2000 in Caucasians) is a disorder inherited through reces-
sive genes, and often patients die young; the mean lifetime is around 35 but can
be increased to more than 50 years when treatment is available.83 It is a condition
that affects a wide range of tissues and organs. Important functions are affected
by this disease such as pancreatic function, the liver, sweat glands, small intestines
and the airways. It also results in diabetes mellitus, lowered liver function, salt loss
and more mucous production hindering the airways.83 CF sufferers carry a muta-
tion in the cftr (cystic fibrosis transmembrane regulator) gene,84 which is located
on chromosome 7.83 This encodes the CFTR, which is an ABC-type ion channel
mainly responsible for chloride (Cl−) transport across membranes. Mutations in the
cftr -gene lead to a variety of physiological defects; the mutations cause the CFTR
to be faulty, which results in less paraciliary fluid (a non-viscous fluid produced by
epithelial cells lining airways during active ion transport) in the lower part of the
respiratory tract hindering this non-inflammatory defence mechanism from clearing
microbes from the airways. Instead the inflammatory defence mechanism is trig-
gered, involving antibodies and PMNs leading to chronic respiratory inflammations
and abnormal lung functionalities.62 With respect to P. aeruginosa infections it is
remarkable that neutrophils of healthy humans secrete less NE than those of CF
patients,80 leading to further tissue damage. The most notable effects are in the
sinus and lungs with abnormal epithelial cells of the airways (usually obstructed by
thick mucous in CF patients) allowing long-term colonisation of these locations by
a number of opportunistic pathogens including P. aeruginosa. CF patients tend to
have severe tissue damage and fibrosed lungs but no worse than seen in patients
with other problems.84 The mucous-filled environment is ideal for certain mucoid
strains of P. aeruginosa that grow in biofilm.83 They have been shown to produce
more extracellular polysaccharide than other strains. The mucoid strains are often
found to produce less toxin A and elastase and in some cases lack a flagella. Most
strains isolated from CF patients have been found to contain little or no O antigen,
the long polysaccharide side chain of LPS.62
Morbidity and mortality in CF patients is mainly caused by P. aeruginosa in 90% of
cases. It can also result from infection with a Burkholderia cepacia complex which
cause respiratory failure leading to a necessity for lung transplants or death in severe
cases, or by Staphylococcus aureus, Mycobacterium and several others pathogens.
Studies of adult CF patients have shown that more than 80% are infected with P.
aeruginosa and in the past about 50% of those would die from chronic infection.
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New, intensive, pre-emptive therapies mean that fewer children contract chronic in-
fection but eventually all CF patients acquire chronic infections which can not be
eradicated.85
3.1.3.2 Effect on the cystic fibrosis transmembrane regulator
by sphingomyelinases
Recently, a link has been discovered between the CFTR and sphingomyelinases
(SMases). CFTR function is inhibited by SMases from human respiratory pathogens
as the phosphorylation of the regulatory domain required to activate the CFTR is
reduced when sphingomyelin is being hydrolysed by SMases.84 Channel activation
occurs by phosphorylation by the cAMP-dependent protein kinase A (PKA) of the
regulatory domain, which contains several phosphorylation sites. This results in ac-
tivation increasing as more sites are phosphorylated but only to a certain threshold.
SMase D (from Corynebacterium pseudotuberculosis which is associated with repi-
ratory problems) and SMase C (from either Bacillus anthtracis or Staphylococcus
aureus) hydrolyse sphingomyelin to choline and ceramide-1-phosphate or phospho-
choline and ceramide respectively. Both larger products have two long hydrophobic
chains and thus prefer to remain in the membrane and it has been suggested that
the two small components, either choline or phosphocholine, are sufficiently soluble
to dissipate after hydrolysis. Neither choline nor phosphocholine are thought to act
as inhibitors whereas the longer products, ceramide-1-phosphate or ceramide, are
thought to attach to the CFTR, causing inhibition of the Cl− channel.86
In addition, it has been suggested that the CFTR defects increase the chances of
bacterial infections in CF patients, thus worsening the chances of pathogenic ef-
fects. The CFTR current decreases as SMase C and SMase D inhibits it, causing
increased mucous production which supports bacterial colonisation and growth. Tis-
sue necrosis has been linked to SMase D activity and both ceramide-1-phosphate
and ceramide are known triggers of inflammation and cell death.2 These results
suggest that targetting bacterial virulence factors such as phospholipases and sphin-
gomyelinases are a possible way of changing the life span and quality of CF patients.
3.1.3.3 P. aeruginosa infections treatment
P. aeruginosa infections have not yet been and can not be completely eradi-
cated from CF patients’ lungs as the bacterium has multiple adaptive mechanisms;
the most important one being its ability to form a biofilm (technique also adapted
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by other bacteria) which provides further protection against antibiotics and the in-
flammatory response.
Chronic suppressive therapy entails early treatment in the form of either prophy-
laxis or therapy with antibiotics in order to hinder biofilm formation. Lung function
has been reported in clinical trials to improve after treatment with combination
of already existing antibiotics.83 Popular antibiotics used to treat CF patient lung
infections are colistin (systemic administration) and nebulised tobramycin (admin-
istered by inhalation) (Figure 3.3). Tests, both in vitro and in vivo, have shown
that combination therapies involving both oral and intravenous administration is
necessary in order to reach high enough antibiotic concentrations in all areas of the
lungs.87 Fluoroquinolones, gentamicin and imipenem (Figure 3.3) are some of the
few antibiotics that are effective against P. aeruginosa, though unfortunately only
certain strains.88 A treatment method combining the antibiotics gentamicin and car-
benicillin (Figure 3.3) is currently used (although resistant strains are emerging),89
however these infections can not be eradicated and the consequent inflammation
and tissue damage ultimately leads to pulmonary failure and death.
In spite of significant progress in the treatment of P. aeruginosa infections,
further research is desperately needed in order to identify novel treatments able to
eradicate bacterial infections, which could greatly improve the patients’ outlook on
and quality of life.
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(a)
(b)
(c)
(d)
(e)
Figure 3.3: Structures of existing drugs used against P. aeruginosa infections. a)
Colistin; b) Tobramycin; c) Gentamicin; d) Imipenem and e) Carbenicillin.
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3.1.4 Pathogen-host interactions of P. aeruginosa
Bacterial infection and colonisation consists of three distinctive invasion stages;
attachment and colonisation of the bacteria, local invasion and systemic disease.
The bacteria fix themselves to the epithelial cells of the upper respiratory tract
using their pili and then link to other cells by interference. Pili adherences90 in
combination with possible overexpression and secretion of a protease enzyme able to
degrade fibronectin make colonisation of the tract possible. Fibronectin degradation
exposes underlying pili receptors of the tract epithelial cell surface. These receptors
appear to be galactose, mannose or sialic acid receptors.66 Bacterial invasion is a
multifaceted mechanism; the most important aids to P. aeruginosa invasion and
infection are touched upon in the following sections.
3.1.4.1 Biofilm formation and antibiotic resistance
Biofilm formation is a major contributor to wide ranging antibiotic resistance
of the bacterium as the drugs are unable to reach the cell when colonies of biofilm
form on a surface.64 Certain P. aeruginosa strains produce a mucoid exopolysac-
charide91 which is a repeating polymer of glucoronic mannuronic acid also known
as alginate66 as well as extracellular DNA and proteins which forms the biofilm
matrix,92 anchoring the cells to the surface. This matrix also protects the bacteria
from host defences and these mucoid strains are less susceptible to antibiotics than
planktonic bacteria.
Biofilm is a major obstacle in treatment of antibiotic resistant CF pathogens lead-
ing to combination therapy and further resistance development, fuelling the need
for the development of new drugs and antibiotics.83 Ciprofloxacin (shown below in
Figure 3.4) has been used in combination with colistin to target biofilms where the
former kills the bacteria growing in biofilms and the latter kills the lower layers.
Furthermore, presumably due to the fact that P. aeruginosa evolved to live in vari-
ous environments in the presence of soil the bacteria have developed a resistance to
many naturally occurring antibiotics from moulds and bacili.
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Figure 3.4: Schematic of Ciprofloxacin.
3.1.5 Virulence factors expressed by the bacterium
A large variety of virulence factors are overexpressed and secreted by P. aerug-
inosa during infection, which aid the pathogen in tissue invasion. However, the
cellular and molecular mechanism by which these factors work and the nature of
the pathogen-host interactions are mostly unknown. The key virulence factors are
briefly mentioned below.
3.1.5.1 Extracellular toxins
Extracellular proteases with differing isoelectric points, pH and substrate re-
quirements are found in approximately 90% of P. aeruginosa strains.62 One example
is elastase, which breaks down many host proteins including elastin, and alkaline
protease, which interferes with fibrin formation, are both present at the pathogen
invasive stage and destroy the supporting cellular structures of the host. Some have
been linked to haemorrhagic lesion formation leading to necrosis, causing tissue de-
struction thus facilitating bacterial tissue invasion. Interestingly, LPS which forms
part of the outer membrane of the pathogen, is another important virulence factor.65
The two most studied extracellular protein toxins from P. aeruginosa are Exotoxin
A and Exoenzyme S.93 The most toxic extracellular protein is Exotoxin A,94 a cy-
totoxin to most eukaryotic cells where it acts as an inhibitor in certain susceptible
cells to protein synthesis. It causes ADP ribosylation of the eukaryotic elongation
factor 2, causing inhibition of the protein synthesis thus killing the host cell. It is
expressed by 90% of the P. aeruginosa strains and a dosage of 0.2 µg is enough to
kill a mouse host. It has been noted that patients surviving bacterial sepsis have
high levels of antitoxin A or low or no amounts of Exotoxin A were produced by
the infecting strain. Exoenzyme S is a type III secretion effector which acts as a
ADP-ribosyltransferase.95 It was first detected in blood before the bacteria and is
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usually found in bacteria growing in burnt tissue. This may contribute to worsening
the function of phagocytic cells to prepare for invasion.
3.1.5.2 Haemolysins and phospholipases
The bacterium also expresses two important haemolysins96 - lecithinase and
phospholipase - which release haemoglobin from red blood cells by destroying them.
Additionally, another non-haemolytic cytotoxin is linked to P. aeruginosa - it is a
pore-forming protein, leukocidin, which is toxic to most eukaryotic cells, neutrophils
and lymphopcytes, thus aiding bacterial invasion.97
Lecithinase is an α-toxin which possesses haemolytic poperties and is capable of
causing myonecrosis, also known as gas gangrene.98 Last but not least, several phos-
phatidyl choline phospholipases C (PC-PLCs) are secreted by the bacterium. These
include the two phospholipases PlcA and PlcB that are both members of the well-
characterised Zn-dependent phospholipase family (section 3.1.7.1). The haemolytic
phospholipase C, PlcH, is the most important PLC; it is the focus of this chapter
and will be described in section 3.1.7.2
3.1.6 Phospholipases
Phospholipases belong to a class of enzymes that degrade a large variety of
phospholipids; they are involved in a number of important processes in eukaryotes
such as inflammation and oncogenesis, whereas they are involved in microbial vir-
ulence in prokaryotes.99 Phospholipases can be divided into defined classes each
containing sub-groups depending on substrate and cofactor preferences.
Phospholipases are classified according to the position of cleavage site of the
phospholipid. These include PLA1, PLA2 and PLB that cleave ester bonds and
PLC and PLD which cleave the phosphoester bonds (Figure 3.5). They are further
divided according to their enzymatic mechanism and evolutionary relationship.
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Figure 3.5: Schematic showing the structure of diacyl, a glycerophospholipid, and
the cleavage sites for the phospholipases PLA1, PLA2, PLB, PLC and PLD.
3.1.6.1 Phospholipase A and ExoU
PLAs are a diverse group of phoshpolipases with functions spanning from lipid
signalling molecule production to playing a role in the structure and function of
membranes in eukaryotes. They can be divided into two subclasses, PLA1 and
PLA2. The virulence factor ExoU from P. aeruginosa possesses phospholipase ac-
tivity which was discovered as inhibition of its cytotoxicity was linked to eukaryotic
PLA2 inhibitors thus proving that is possesses PLA activity. The notion was fur-
ther supported when it was shown to contain an N-terminal domain which aligns
with a domain of patatins, a group of proteins contained in the PLA2 subclass, as
well as calcium independent PLA2s.100 ExoU has been shown to play a role in a
number of human infections, in particular hospital acquired pneumonias. Its role
in pathogenicity is further supported by the fact that approximately 30% of highly
pathogenic P. aeruginosa strains produce ExoU.99
3.1.6.2 Phospholipase D
Phospholipases D (PLDs) are not frequently produced in prokaryotes but are
very common in eukaryotes.99 PLD produces phosphatidic acid and choline by hy-
drolysing phosphatidylcholine (PC) or phosphatidylinositol (PI). PLDs belong to
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the class PLD Superfamily due to a conserved motif at the active site. The two sub-
classes of the family consist of plant and bacterial PLDs versus the animal and fungal
PLDs. PLDs identified in bacteria are commonly linked to virulence,101 but little is
known about bacterial PLDs. The best studied example of a bacterial PLD is the
one from Y. pestis, commonly referred to as murine toxin.102 Cardiolipin synthase is
another member of the PLD Superfamily; it forms cardiolipin, a phospholipid that
is part of prokaryotic cell membranes and is thus formed in both Gram-positive and
-negative bacteria by transfer of a phosphatidyl group from one phosphatidylglyc-
erol (PG) to another. PLDA is an example of a PLD from P. aeruginosa and it is
located in the periplasm. It prefers PC as substrate, which led to the discovery of
the ability of the bacterium to synthesise PC; moreover it is suggested that PLDA
is involved in phospholipid signalling events within the bacterium and chronic pul-
monary infection.
3.1.7 Phospholipases C from P. aeruginosa
PLC activity was first discovered in α-toxin from Clostridium perfringens, in
1941 by Macfalane and Knight,103 and has been observed in many other pathogenic
bacteria since. However, the specific role of PLCs in pathogenicity was not discov-
ered until later.
3.1.7.1 The bacterial Zn-dependent PLCs
Zn-dependent enzymes are characterised by three Zn2+ ions in the active site
that are necessary for catalytic activity. Bacterial PLCs include the important viru-
lence factors α-toxin of Clostridium perfringens and PlcB of Listeria monocytogenes.
They play different roles in pathogenesis. For example the C. perfringens α-toxin
is cytotoxic to eukaryotic cells and contributes to the severe myonecrosis (gas tissue
produced in gangrene). PlcB is vital for the escape of the intracellular pathogen
from phagocytic vacuoles into the cytoplasm of macrophages or other cell types
infected with the L. monocytogenes bacteria.98
73
3.1.7.2 Haemolytic phospholipase C
The haemolytic phospholipase C, PlcH from P. aeruginosa, is the founding
member of a growing family of phospholipases C, PLCs. These are found in many
bacterial and fungal pathogens,86, 104 including proteins from Bordatella spp,
Mycobacterium tuberculosis, Burkholderia pseudomallei and Francisella tularensis.86
The first extracellular PLC from P. aeruginosa was discovered by Liu105 in 1966,
who noticed its heat-labile haemolytic activity. In the 1980s, PlcH (haemolytic phos-
pholipase C) was found to have phospholipase C and haemolytic activities, and its
sequence revealed it as a founding member of a novel class of prokaryotic PLCs.86, 106
This PLC, PlcH, shares no sequence similarity with the previously discovered PLCs
and it is not associated with zinc as a cofactor either. PLC from L. monocytogenes
and C. perfringens both possess the same enzymatic activities, but PlcH is approx-
imately twice as large as the Cf α-toxin (78 and 48 kDa repectively) and other
Zn-dependent PLC enzymes, which may be due to the fact that is is functional as a
heterodimer. The importance of PlcH is supported by the fact that it is expressed
by 70% of all clinical strains of P. aeruginosa.62
PLC enzymes have a high cytotoxicity to E. coli thus making investigations
into related human diseases extremely difficult, however, the full length protein is
successfully expressed in its natural host, P. aeruginosa.
PlcH has both phospholipase and sphingomyelinase (SMase) activity according to
the amount of ceramide present, but it also possesses sphingomyelin synthase (SMS)
activity (as shown by Luberto et al)107 where ceramide receives a phosphate head-
group from phosphatidylcholine (PC), producing sphingomyelin (SM) and diacyl-
glycerol (DAG).
Phosphatidylcholine phospholipases hydrolyse PC to give DAG and phospholcholine,
but SMase activity hydrolyses SM resulting in ceramide and phosphocholine. Ce-
ramide and DAG are involved in apoptosis, cell differentiation, stress response in
eukaryotes and growth regulation and DAG is involved in inflammation, transfor-
mation and proliferation. Often increased levels of DAG is used as a diagnostic for
mammalian PC-PLC activity.
3.1.7.3 Non-haemolytic PLC
The haemolytic phospholipase C, PlcH, is expressed by Pseudomonas aerugi-
nosa alongside a non-haemolytic orthologue, PlcN108 (section 3.1.7.3). They share
a 60% sequence similarity and more than 40% identity; however they have dis-
tinctly different functions in infection and disease but are both secreted to the
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environment.86, 104 Only PlcH possesses distinct pathogenic properties such as its
haemolytic properties whereas PlcN is non-haemolytic. It is noteworthy that both
PlcH and PlcN (as well as PLA and PLB)99 are expressed by all P. aeruginosa
strains as they are encoded by genes which are connected to more stable parts
of the core chromosome. PlcN is expressed when P. aeruginosa is grown under
Pi-limiting conditions.109 It is 73 kDa enzyme which is very similar to PlcH with
respect to substrate preference. PlcN displays phospholipase C activity and activity
on phosphatidylserine (PS) but no evidence is seen for SMase activity.110 Experi-
ments suggest that PlcH and PlcN consist of distinct domains. PlcN has not been
as well characterised as PlcH as no obvious link has been noted with regards to its
role in pathogenesis. It has been suggested that PlcN can hydrolyse PS which is
exposed during apoptosis of eukaryotic cells (the cytoplasmic facing membrane rich
in PS flips to the extra cytoplasmic side). Another suggestion is that it may be
involved in P. aeruginosa phospholipid biosynthesis alongside PlcH.
3.1.8 The importance of the PlcH family
More than 50 PlcH-homologues have been identified in the Zn-independent
phosphoesterase superfamily.88 To cleave the phosphodiester bond the Zn-dependent
and Zn-independent bacterial PLCs employ a different catalytic mechanism sup-
ported by a number of biochemical and biomedicinal results as listed below.
Divalent zinc and nickel both inhibit the activity in the PlcH family, whilst the
usual inhibitors that work on Zn-dependent enzymes have no effect on this novel
class.86 D609, tricyclodecan-9-ylxanthate, is a popular inhibitor for Bacillus cereus
PLC but this does not affect the activity of either PlcH or its homologues from M.
tuberculosis.86
Calcium can be bound by PlcH; it affects the haemolytic effect of the complex but
no change is seen to the enzymatic activity. It is not clear if any cofactor is required
for enzymatic activity.
3.1.9 The PlcHR2 complex
PlcH (78412 Da) is co-expressed with an ancillary protein, PlcR2 (17 kDa),
forming the heterodimeric complex, PlcHR2. The structural gene coding for PlcHR,
plcH and plcR1 and plcR2, two overlapping, in-phase genes, make up the plcHR three
gene operon from P. aeruginosa.88, 111At 3 to plcH, the plcR1,2 genes are situated
and they are expressed from in-phase overlapping genes and have both been shown
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to be crucial in the PlcH secretion process. The PlcR1 is synthesized with a Sec-
dependent signal sequence and the plcR2 starts at an initiation codon internal to
plcR1 (see Figure 3.6)
Figure 3.6: The plcHR three gene operon showing the overlapping in-phase genes,
plcR1 and plcR2, positioned at 3’ to plcH. ATG marks the initiation codons.
When PlcH is expressed in P. aeruginosa under low phosphate conditions, it
is associated with a 17 kDa protein when purified but this complex disassociates
leaving a single protein of 78 kDa, PlcH. Only the individual protein PlcH is inhib-
ited by tetradecyltrimethylammonium (TDTMA). This suggests that the chaperone
protein is not only required for secretion but also offers protection from inhibition
and may be involved in the folding of the protein.
The plcH gene is expressed without the plcR gene in choline media, but is expressed
as plcHR, which contains a PlcR chaperone protein. PlcH is expressed at high
phosphate (Pi) conditions if either choline, carnitine, betaine or dimethylglycine are
present or, at low Pi concentrations.88 PlcR1 and PlcR2 were originally thought
to be regulatory proteins but are actually two calcium binding chaperone proteins
needed for extracellular PlcH secretion (via the Tat secretion system) and PlcR2 is
vital for the haemolytic activity of PlcH.88
PlcR2 is a specific chaperone that stays associated with PlcH, forming the het-
erodimeric complex, PlcHR2. The complex composition has been verified by liquid
chromatography electrospray mass spectrometry, showing that the two proteins are
at a 1 : 1 stoichiometry.112 PlcR1 consists of 207 amino acids whereas PlcR2 is
smaller and only consists of 151 amino acids; the difference is accounted for by a
signal sequence only possessed by PlcR1.
111 Without the signal sequence (20 amino
acids), the difference is only 36 amino acids, of which 10 are prolines and 15 are
various hydrophobic amino acids (such as as Val, Phe, Ile or Ala). When expressed
in E. coli, PlcR1 is found in the periplasm whereas PlcR2 is in the cytoplasm. Both
PlcRs may possess further functions which are still to be elucidated.
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3.1.9.1 Sequence analysis of the PlcHR2 components
The sequence of amino acids in PlcH show a multi-domain structure (Figure 3.7)
beginning with an N-terminal Tat secretion signal followed by a catalytic domain
of about 500 residues. The first 38 amino acids in the 730 amino acid sequence
for PlcH are a signal peptide coding for the Tat-signal. The Tat-signal sequence is
necessary for PlcH secretion through the inner membrane in P. aeruginosa.75 It is a
leader sequence recognised by the export machinery from the cell and can therefore
not be part of the active enzyme as it needs to be accessible. This suggests that it
is not part of the structural core and that it may not even be folded. The signal
sequence is usually hydrophobic and may even be cleaved in vivo. There are also
two C-terminal domains whose function is unknown. It has been suggested that
these domains contain four Ca2+-binding domains (found using structure prediction
programmes such as I-TASSER)113 but their biological role remains yet to be de-
termined (they may be involved in the ability of the enzyme to interact with the
cell membrane in order to access substrates).75 When aligning the sequence of PlcH
and the homologues, there is a unique region with 24 amino acids, and this region
and the RGD (Arg-Gly-Asp) motif are believed to take part in the interaction with
PlcR1,2.
86 Residue Thr178 is important for activity and studies have shown that an
active site mutant, Thr178Ala, resulted in a significant reduction in activity.30
Figure 3.7: The PlcH multi-domain structure highlighting the Tat-signal, the RGD
motif, Thr17 and the unique region.
3.1.10 PlcHR2 and its role in pathogenicity
The PlcHR2 is an important enzyme due to its proven biological role in pathogen-
host interactions as detailed below.
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3.1.10.1 Cytotoxicity of PlcH
PlcHR2 has been shown to be cytotoxic to macrophages and neutrophils.
30 It
exhibits haemolytic activity to sheep and human erythrocytes.112 This effect has
been studied on blood agar plates with bacteria expressing both the plcH and the
plcR genes in a T7 expression system in E. coli both together and separately, re-
vealing more about their individual roles in haemolysis.111
Figure 3.8: Blood agar plate used to demonstrate the haemolytic activity of plcH
and plcR expressed both together and separately in E. coli BL21 (DE3) in a pGEM
vector under the T7 promoter. A) Expression without the plcH and plcR genes
in the pGEM; B) expression of plcR; C) expression of plcH and D) expression of
plcHR. Reprinted with permission from Figure 1, Cota-Gomez et al.111
The haemolytic area observed on the blood agar plate is much larger than the
area of bacterial growth when both the plcH and the plcR genes are on the same
plasmid under the T7 promoter and are being expressed by E. coli BL21(3DE) cells.
However, when plcH is expressed alone, under the same conditions and from the
same system, the haemolytic area is much smaller and only just extends beyond the
bacterial growth area. No evidence of haemolysis is seen when plcR is expressed
alone under the same conditions and from the same system. It was suggested that
this either meant that less PlcH was expressed or was unable to be secreted in cells
without the plcR gene. The former suggestion was discarded as the expression was
controlled by the T7 promoter in all cases.111 PlcH is affected by PlcR posttrans-
lationally, as they form a heterodimeric complex, and so PlcH secretion is not as
efficient when lacking the plcR gene, even though no effect is seen on expression
levels.
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3.1.10.2 Membrane vesicles
Membrane vesicles (MVs) are structures shed from P. aeruginosa bacteria that
contain LPS; they appear during the logarithmic growth and more are produced
when small amounts of antibiotics such as gentamicin are present.114 Active en-
zymes are present in the MVs, amongst these PLC, and it has been suggested that
MVs may be used to deliver virulence factors. Studies with wildtype and knock-
out mutant, PAO1WT and PAO1∆R, show different amounts of PLC activity in the
corresponding MVs which may indicate that plcR is useful in the correct localisation
of PlcH within the MVs.
3.1.10.3 Sphingomyelinase activity of PlcHR2
Recent studies have shown that PlcH functions as a sphingomyelinase (SMase)30
and that the SMase activity of PlcH may be more critical to pathogenesis than its
phosphatidylcholine phospholipase C (PC-PLC) activity,86, 112 since the cytotoxoc-
ity of PlcH is linked to its SMase activity.115 The catalytic mechanism has not been
elucidated but a proposed mechanism shown below in Figure 3.9 is based on the acid
phosphatase, F. tularensis novicida AcpA (section 3.1.7.2). One of the active site
residues of FtAcpA, Ser196, corresponds to Thr178 in PlcH. In the proposed cat-
alytic mechanism, Thr178 is deprotonated, then activated by an unknown divalent
metal ion. A nucleophilic attack by the oxygen atom on Thr178 on the substrate
phosphate group leads to an intermediate which remains bound at the active site
and the release of ceramide (when the substrate is sphingomyelin), whereafter it
is hydrolysed resulting in the formation of phosphocholine (when the substrate is
sphingomyelin). Thr178 is believed to be involved in the enzymatic SMase activity,
as site directed mutagenesis of this residue results in the loss of SMase activity.30
PC-PLCs hydrolyse phosphatidylcholine (PC) and produce diacylglycerol (DAG)
and phosphocholine. SMases hydrolyse sphingomyelin (SM) and produce ceramide
and phosphocholine. Ceramide and DAG are important components of eukary-
otic cell membranes and they can often act as antagonists towards each other in
mammalian systems.86 They are involved in various processes such as apoptosis,
regulation of growth and differentiation. The latter is affected by ceramide levels
whereas DAG has been observed to be involved in inflammation, transformation
and proliferation.28, 116 The bacterial PlcHR2 produces this eukaryotic secondary
messenger which may be the reason for its cytotoxic effects.
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Figure 3.9: Proposed catalytic mechanism of PaPlcH. Thr178 in the active site is
deprotonated and then activated by and unknown divalent metal ion. The Thr178
oxygen atom performs a nucleophilic attack on the sphingomyelin phosphate group,
forming an intermediate bound to the enzyme and the release of ceramide. The
intermediate is then hydrolysed and phosphocholine is released.
3.1.11 Chapter objectives
This section describes the work towards biophysical characterisation of PlcH
from P. aeruginosa as well as attempts at crystallisation. PlcH is part of a het-
erodimeric complex, PlcHR2, which has previously been crystallised,
117 however,
the structure has not yet been solved. In order to better investigate the structure
of PlcHR2, twelve DNA constructs for PlcH were designed, cloned and subsequently
tested in expression trials, to aid the identification of the domain structure and
produce the minimal catalytic domain for subsequent crystallisation trials. Several
biophysical characterisation experiments were conducted with the expressed and pu-
rified proteins. In parallel, a commercially available sphingomyelinase activity assay
kit suitable for high throughput screening was established for identification of new
potential inhibitors of the SMase activity of the wild-type PlcHR2 complex.
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3.2 Results
This section describes the work towards a crystal structure determination of
PlcH from P. aeruginosa, from cloning and expression to a detailed biochemical and
biophysical characterisation of the protein.
3.2.1 Cloning and small-scale expression trials at the OPPF
3.2.1.1 PlcH construct design
In order to determine the domain boundaries of PlcH, the sequence was com-
pared to that of a known structure. The haemolytic phospholipase C, PlcHR2,
and acid phosphatase, AcpA (respiratory burst inhibiting acid phosphatase), from
F. tularensis novicida 118 (an intracellular bacterium) share a sequence identity of
just under 20% but a number of active sites and residues are conserved. The two
enzymes are remotely related, as AcpA is part of a superfamily containing many
bacterial enzymes, amongst these, phospholipases C (PLCs). A sequence alignment
(Figure 3.10) of AcpA and the significant region of PlcH (residues number 1 to 481),
was carried out in Clustal Omega.119, 120 Based on the domain prediction following
sequence alignment, the starting points of 12 constructs were determined in order to
try and include as many of the essential structural features as possible. The cleav-
age sites in the sequence were determined by the amino acid sequence as hydrophilic
groups may enhance protein solubility.
The sequence alignment highlights the residues which are highly conserved within
the superfamily containing AcpA and PlcH. In the crystal structure of AcpA, a
vanadate or another metal ion is held in the active site by ten residues which are
conserved in enzyme homologues within the superfamily and in PlcH, five of these
are conserved.118 The residues concerned are Glu64, Asn65, His127, His371 and
Asp407 (numbers correspond to sequence alignment in Figure 3.10). Despite the
low identity between the two sequences overall, the identity within the active site
is significantly higher. As well as the five residues mentioned above, further four
residues are of importance. Thr178 and Glu358 of PlcH align with Ser196 (a nu-
cleophile) and Asp408 (involved in metal binding) of AcpA, respectively. Another
important ion pair are Asp364 and Arg401 which are equivalent to Asp414 and
Arg435 of AcpA. The conservation of these nine key residues suggest that the octa-
hedral metal-binding site as well as the hydroxyl nucleophile of AcpA are conserved
in PlcH.
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Figure 3.10: Sequence alignment of the F. tularensis AcpA sequence and the
first 481 residues of P. aeruginosa PlcH produced in ESPript 3121 (available at
http://espript.ibcp.fr) with secondary structure overlay of AcpA. Residues enclosed
in a red box are identical, residues enclosed in a blue frame with red letters are of
similar type and the rest have a low identity score. α denotes α-helices, β denotes
β-sheets, TT denotes strict β-turns and η denotes 310-helices. The vertical arrows
highlight the five conserved active site residues and four further important residues.
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The constructs decided upon based on the sequence alignment and specific
residues are described in Table 3.1 and shown schematically in Figure 3.11.
Construct aaN aaC pOPIN Tag PCR product MW/ Plasmid
label vector size kDa name
1 2 730 E C-His 2214 82.54 pPlcH-1
2 2 730 F N-His 2214 82.54 pPlcH-2
3 40 686 E C-His 1968 73.54 pPlcH-3
4 40 686 F N-His 1968 73.54 pPlcH-4
5 40 699 E C-His 2007 74.92 pPlcH-5
6 40 699 F N-His 2007 74.92 pPlcH-6
7 40 730 E C-His 2100 78.27 pPlcH-7
8 40 730 F N-His 2100 78.27 pPlcH-8
9 40 712 E C-His 2022 76.42 pPlcH-9
10 40 712 F N-His 2022 76.42 pPlcH-10
11 48 473 E C-His 1305 48.64 pPlcH-11
12 48 473 F N-His 1305 48.64 pPlcH-12
Table 3.1: Summary of the 12 PlcH constructs, including construct label, N- and
C-terminal, pOPIN vector employed, construct size, molecular weight and plasmid
label. The molecular weight represents the protein without the His6 tag. All proteins
contain a 3C cleavage site.
These constructs were all expressed from a pOPINE (C-terminal tag) or pOPINF
(N-terminal tag) vector and contain a His6 tag at the specified terminal. The hexa-
histidine enables IMAC purification.
Figure 3.11: Schematic of full length PlcH and two relevant constructs, PlcH 2 and
PlcH 4. This is compared to the F. tularensis AcpA (shown in purple). Start and
end residues are labelled.
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Three PCR experiments were carried out before successfully cloning all con-
structs and all PCR products were analysed by agarose gel. The products from the
third and final PCR experiment are shown below in Figure 3.12.
Figure 3.12: 1.25% agarose gel of PCR products, constructs 1 to 12. Product sizes
are estimated relative to a Bioline Ltd. HyperladderTM I.
Figure 3.12 shows that that constructs 1 and 2 (C- and N-His6 tags) are slightly
larger than 2000 bps and the two shortest, 11 and 12 (C- and N-His6 tagged) are
less than 1500 bps. This is consistent with the expected sizes (see Table 3.2.1.1),
2214 and 1305 bps, respectively. The bands representing constructs 9 and 10 (C-
and N-His tagged) on the gel are not as strong as for the other PCR products but
they are still present at the expected size. The agarose gel confirms that the PCR
resulted in the correct size products.
The purified, linearised expression inserts were inserted into the appropriate
pOPIN vector (Table 3.1) via an InFusion reaction. The InFusion reaction products
were transformed into OmniMaxII cells (section 2.2.4). Following the transforma-
tion of the InFusion reaction products, the cells were plated out and a Blue/White
screening (section 2.2.6) was performed. Two white colonies (in white colonies, the
vector contains the correct gene) were picked for each construct (1 - 12), resulting
in two clones (Clone 1 and Clone 2) of each construct. The plasmid DNA for the
two clones of each of the 12 constructs was purified by mini-prep.
Mini-preps were performed for all 2 x 12 clones followed by verification PCR ex-
periments in order to establish that the correct plasmids had been obtained (as
described in section 2.2.9, Table 3.1) and the products obtained were analysed by
agarose gel (section 2.2.2). The gel is shown below in Figure 3.13.
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Figure 3.13: 1.25% agarose gel of PCR verification products, constructs 1 to 12.
Product sizes are estimated relative to a Bioline Ltd. HyperladderTM I.
Both clones were derived from cells containing the same construct and thus the
bands corresponding to the same construct should be in identical positions for the
two clones on the agarose gel. Figure 3.13 clearly shows the PlcH constructs (1 -
12, see Table 3.1), one of each of the clones is closer to the correct plasmid size than
the other. The band seen on the gel may also vary in strength between the two
clones. Only the best clone for the 12 constructs was taken forward for small-scale
expression trials ie. the clone with the correct molecular weight was chosen and if
both clones yielded the same results, the one with the strongest band was chosen.
For constructs 1, 2, 3, 4, 6, 7 and 8, clone 2 was chosen and for constructs 5 9, 10,
11 and 12, clone 1 was chosen as the most successful clone resulting in the correct
plasmid size.
Based on the results obtained from the verification PCR (section 2.2.9) and the
chosen clone (1 or 2) for each of the 12 purified constructs (1 - 12), the 12 chosen
plasmids were transformed into different E. coli strains expressed under different
conditions.
Two strains of chemically competent E. coli cells were used for transformation
and expression trials of the 12 PlcH constructs; B834 (DE3) and Rosetta I (DE3)
pLysS cells. Colonies from each strain were picked for all 12 constructs, and each was
expressed using different methods of induction; IPTG medium (IPTG induction) and
Overnight ExpressTM Instant TB medium (autoinduction). The expressed cultures
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were centrifuged and the supernatant was analysed using a 12% SDS PAGE. The
results are shown in Figure 3.14 below.
(a)
(b)
Figure 3.14: 12% SDS PAGE of 5 µL of resolved, purified protein (for constructs
PlcH 1 to PlcH 12). Proteins were expressed from two E. coli strains; B834 (left
side of gels) and Rosetta I (DE3)pLysS. Expression was carried out using IPTG
induction medium (Figure (a)) and OvernightExpressTM Instant TB autoinduction
medium (Figure (b)). Proteins were stained with Instant Blue (Expedeon) dye
and protein size was estimated relative to a Wide Range SigmaMarkerTM . Arrows
indicate strong bands at the expected size.
Figure 3.14 (a) and 3.14 (b) provide information on the extent of protein ex-
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pression under different conditions. No particularly strong bands were visible at the
correct molecular weights for the 12 PlcH constructs expressed using IPTG induc-
tion as seen in Figure 3.14(a).
In Figure 3.14(b) however, four strong bands are present at the expected molecu-
lar weight (see Table 3.1) for the PlcH constructs expressed in the autoinductive
medium (see Figure 3.14(a)). The strong bands were seen for constructs PlcH 4
(B834 cells) PlcH 8 (B834 cells), PlcH 2 (Rosetta I (DE3)pLysS cells) and PlcH 4
(Rosetta I (DE3)pLysS cells) all expressed in the OvernightExpressTM Instant TB
autoinduction medium. The respective molecular weights are 73.5, 78.3, 82.5 (full
length construct) and 73.5 kDa. In general, the PlcH constructs expressed in Rosetta
I (DE3) pLysS cells gave rise to stronger bands than those expressed in B834 cells,
thus more protein was expressed by Rosetta I (DE3)pLysS cells. Furthermore,
larger constructs (higher molecular weight) gave rise to stronger bands (PlcH 2 and
PlcH 4). Those constructs with N-His tags also gave stronger bands (better expres-
sion) compared to those with C-His tags.
The highest levels of expression were seen for the two N-His tagged proteins, PlcH 2
and PlcH 4, in Rosetta I (DE3) pLysS cells employing the autoinduction method.
3.2.2 Large-scale expression and purification
Transformation of the plasmids of constructs PlcH 2 and PlcH 4 into a range
of strains of E. coli (BL21, BL21 (DE3), BL21 (DE3) Rosetta II, Tunetta and
Rosetta II (DE3) pLysS) was attempted but transformation was only possible into
BL21 (DE3) cells. Expression levels were below detection levels. Glycerol stocks of
Rosetta I (DE3) pLysS and Rosetta II (DE3) pLysS cells containing all the relevant
PlcH construct plasmids (obtained from the OPPF) were employed instead. Only
overnight cultures from Rosetta I (DE3) pLysS yielded growth.
3.2.2.1 Initial expression assay
An initial expression assay was carried out to test for leaky expression (protein
secretion during expression). A small-scale expression was carried out (section 2.4.2)
in autoinduction media (TBonex) and YT media (without addition of IPTG). Cell
lysate and media was analysed on a 12% SDS-PAGE gel (section 2.5.6). The result-
ing gels are shown below in Figure 3.15.
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(a) (b)
(c) (d)
Figure 3.15: 12% SDS PAGE of 10 µL of resolved sample for construct a) PlcH 1,
82 kDa; b) PlcH 2, 82 kDa; c) PlcH 3, 73 kDa and d) PlcH 4, 73 kDa. A) Insoluble
fraction (after cell lysis) from expression in TBonex. B) Supernatant containing
soluble protein after expression in TBonex. C) TBonex medium kept after expression
and pelleting. D) Insoluble fraction from expression without induction in YT. E)
Supernatant after expression in YT. F) YT medium kept after expression and cell
pelleting. All gels were stained with Instant Blue (Expedeon) dye and protein size
was estimated relative to a Precision Plus Dual colour Marker.
As verified by Figure 3.15, none of the PlcH constructs (PlcH 1 - PlcH 4: two
different construct lengths (82 and 73 kDa), N- and C-His tagged ((PlcH 2 and
PlcH 4) and (PlcH 1 and PlcH 3) respectively) (Table 3.1) show protein secretion
into the medium but all remain inside the cells they are expressed in, as no bands
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are visible at the corresponding molecular weights for the media fraction. No protein
of the desired size was found in media concentrated 8 times either (results omitted
for clarity). Thus, expressing PlcH in E. coli prevents release of a potentially toxic
enzyme in an uncontrolled manner and no PlcH is secreted from E. coli unlike the
native protein, PlcHR2, expressed by P. aeruginosa.
3.2.2.2 Large-scale expression and purification
Large-scale expression (in multiples of 500 mL) of constructs PlcH 2 and PlcH 4
in Rosetta I (DE3)pLysS cells was carried out as described in section 2.4.3.
Purification strategies outlined in 2.5 were followed (proteins were purified us-
ing an IMAC column (section 2.5.2) followed by overnight dialysis, anion exchange
MonoQ 5/50 column purification (section 2.5.3) followed by gel filtration using a
Superdex200 16/60 column (section 2.5.4). Protein was identified as peaks in the
absorbance at 280 nm and relevant fractions were collected and analysed by SDS-
PAGE.
Amount of pure, uncleaved protein usually obtained for PlcH 2 was 2 mg of pro-
tein/L culture and for PlcH 4 was 0.5 mg/L culture.
(a) (b)
Figure 3.16: 12% SDS PAGE of a peak fraction after an optimal expression
and purification with gel filtration as the final step. Proteins were stained with
Instant Blue (Expedeon). (a) PlcH 2; size estimated relative to Wide Range
SigmaMarkerTM (Sigma-Aldrich) and (b) PlcH 4; size estimated relative to a Wide
Range SigmaMarkerTM (Sigma-Aldrich). The proteins remain uncleaved.
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Figure 3.16 (a) and (b) show a single peak fraction after gel purification (fi-
nal purification step) from an optimal purification of uncleaved PlcH 2 and PlcH 4.
Strong bands are seen at the correct molecular weights for PlcH 2 and PlcH 4 (Ta-
ble 3.1) with a few fainter bands at approximately 15 kDa in Figure 3.16 (b). The
results clearly indicate expression of the desired recombinant proteins albeit with
some impurities.
3.2.2.3 pOPINF protein expression and purification
To rule out activity from the prepared protein samples being caused by anything
other than the PlcH constructs the pOPINF vector was obtained from the OPPF.
It was transformed into Rosetta II (DE3) pLysS cells and expressed and purified as
PlcH 2 and PlcH 4. No bands were detectable on a 12% SDS-PAGE containing all
the corresponding fractions after applying the samples to a gel filtration column.
No SMase activity was detected using the Amplex R© Red Sphingomyelinase Assay
Kit (section 2.9). Data not shown.
3.2.3 Mass spectrometric analysis
A trypsin digest of cleaved PlcH 4 was performed as described in 2.6.1. The
sample was analysed by mass spectrometry. MALDI-ToF (Matrix Assisted Laser
Desorption/Ionisation Time of flight) was used in order to verify that the protein
being expressed and purified was the one desired (see Appendix B, Figure B.1 for
spectrum).
A Mascot search (available at http://www.matrixscience.com/) was conducted using
the specific amino acid sequence of PlcH 4. Eight of the peaks seen in the spectrum
were easily identifiable from the list of possible sequence fragments (m/z : 861.8;
969.3; 1040.3; 1550.3; 1675.4; 1986.4; 2082.6 and 3549.6). 23% of the PlcH sequence
was covered by peptides identified in the data providing strong evidence that the
protein is PlcH 4.
The protein bands on an SDS-PAGE gel of PlcH 2 and PlcH 4 were analysed by
tryptic digest followed by mass spectrometry (School of Biological and Biomedical
Sciences, Durham University). Analysis showed that the purified protein sample is
contaminated with Hfq from Shigella flexneri. S. flexneri Hfq shares 100% identity
with Hfq from E. coli leading to the conclusion that the contamination in the PlcH
protein samples is E. coli Hfq.
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3.2.4 CD spectroscopy on PlcH constructs
In order to verify that the expressed and purified PlcH constructs were properly
folded, CD spectra were recorded and analysed as described in section 2.7.
The experimental, processed data spectra are shown in Figure 3.17.
Figure 3.17: Experimental CD data, molar circular dichroism, plotted against wave-
length (nm) for PlcH 2 and PlcH 4 (58 and 119 nM respectively), measured at
21 ◦C.
Figure 3.17 shows the experimental spectra, ∆ , plotted against the wave-
length. Qualitatively, the two spectra possess features characteristic of spectra for
folded proteins with representative structures.43, 44 The spectra do not look similar,
despite construct PlcH 4 making up the core of PlcH 2. The spectrum for PlcH 2
suggests that this construct mostly consists of β-sheets and the spectrum for PlcH 4
suggests that this construct may be disordered.
The data were further analysed using three different programmes - CONTINLL,
CDSSTR and SELCON3 - in order to estimate the secondary structure. The analysis
yielded molar circular dichroism, ∆ , calculated by each programme (using the same
basis set of proteins) which was then compared to the experimentally measured ∆ 
values (Appendix B, Figures B.2 and B.3). For both PlcH constructs, the CDSSTR
programme analysis most closely matched the experimental data.
The percentages of secondary structure elements as calculated by the CDSSTR
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programme is shown in Table 3.2.
Construct α-helices (%) β-sheets (%) Turns (%) Unordered (%)
PlcH 2 36 33 15 16
PlcH 4 58 18 18 6
Table 3.2: Calculated secondary structure elements for the two PlcH constructs.
CDSSTR analysis showed for PlcH 2 and PlcH 4.
A more quantitative analysis performed by the CDSSTR programme calculated
the distribution of secondary structure elements of the two PlcH constructs which
is summarised in Table 3.2. PlcH 2 is folded evenly in α-helices, β-sheets and
turns whereas PlcH 4 has a larger proportion of α-helices but fewer β-sheets. The
amount of turns in the PlcH 4 construct corresponds to the first 39 residues missing
compared for PlcH 2. The discrepancy between the two structures may be linked
to sample quality.
The CD data shows that the expressed and purified PlcH constructs are likely to be
properly folded proteins as the experimental spectra do not show the features of a
denatured sample.
3.2.5 Thermal stability assay on PlcH
Various techniques exist for screening compound libraries and their effect on
soluble protein; one of the simpler methods is thermal stability assays (TSAs).
Techniques involving measurements of changes in fluorescence are also known as
Differential Scanning Fluorimetry (DSF)122 or Thermofluor assays (TFAs). For the
following experiments a fluorescent probe, SYPRO Orange was added to the protein
solution; it possesses high fluorescence when in non-polar or hydrophobic environ-
ments whereas it possesses low fluorescence in polar or hydrophilic environments.53
The samples are slowly heated whilst the fluorescence is monitored; the change oc-
curs as the protein unfolds as the temperature rises, leading to an exposure of the
hydrophobic regions and thus an increase in fluorescence, allowing for the identifi-
cation of the protein melting temperature.
The melting temperature of the protein studied can be altered, by affecting the
protein stability by the addition of various additives causing changes in the protein
environment. Factors usually screened for include changes in pH, salt concentrations,
ionic strength and potential inhibitor compounds. This technique thus enables the
identification of potential additives and buffer conditions which may enhance crys-
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tallisation conditions for the protein in question.
Protein stability and solubility is dependent on its free energy of unfolding which cor-
relates with its melting temperature. The free energy of unfolding, ∆GU , decreases
as the temperature increases and equlibrium is reached when the concentration of
folded and unfolded protein are the same, resulting in ∆GU = 0. This is the param-
eter affected by varying the protein environment.
Plotting fluorescence measurements against temperature results in sigmoidal curves
(ideal behaviour). The inflection point of this curve occurs at the temperature at
which ∆GU = 0, corresponding to the melting temperature of the protein under the
associated condition Figure 3.18, Figure 3.19 and Table 3.3 show the representative
curves and a summary of the melting points respectively.
Conditions tested included a range of additives and salts commonly employed in
protein buffers (Table 3.3) to span solutions with as large a range of ionic strengths
and combinations as possible with the amount of PlcH 2 protein available. Fur-
thermore, miltefosine was chosen as an additive and tested based on a paper by M.
J. Wargo et al,123 showing that this small molecule has an inhibitory effect on the
sphingomyelinase (SMase) activity of PlcHR2. D-erythro sphingosine was chosen as
it is a ceramide analogue and thus resembles the PlcHR2 substrate, sphingomyelin.
Both were tested at various ratios relative to the protein.
Fluorescent data of a protein solution containing the additives was collected at
1 ◦C intervals, recording the fluorescence. The fluorescent data for the conditions
resulting in most extreme changes in melting temperatures of PlcH 2 are shown in
Figure 3.18 and Figure 3.19. The data for all conditions screened is summarised in
Table 3.3.
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Figure 3.18: Sigmoidal curves of fluorescent TSA data. A summary of the emission
of SYPRO orange mixed with PlcH2 at 610 nm as a function of temperature (24−
95 ◦C). The additives are shown to be stabilising or destabilising compared to the
control (no additive), PlcH 2 and SYPRO orange. Results are based on a single
measurement. a) Control; b) 10 mM NiCl2; c) 1 M (NH4)2SO4; d) 10 mM ZnCl2.
PlcH 2 was at a constant concentration 5 ×10−6 M.
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Figure 3.19: Sigmoidal curves of fluorescent TSA data. A summary of the emission
of SYPRO orange mixed with PlcH 26 at 610 nm as a function of temperature
(24− 95 ◦C). The additives are shown to be stabilising or destabilising compared to
the control (no additive), PlcH 2 and SYPRO orange. Results are based on a single
measurement. a) Control and b) 1 mM D-erythro sphingosine.
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Compound Concentration/M Tmelt/
◦C ∆Tmelt/ ◦C Ionic strength/M
Control 51 0
NaCl 1 53 2 1
0.4 52 1 0.4
(NH4)2SO4 1 60 9 3
0.4 54 3 1.2
NH4Cl 0.4 51 0 0.4
Na2SO4 0.4 55 4 1.2
MgSO4 0.4 50 -1 1.6
0.01 50 -1 0.04
CaCl2 0.01 50 -1 0.3
MnCl2 0.01 55 4 0.3
ZnCl2 0.01 66 15 0.3
NiCl2 0.01 40 -11 0.3
Li2SO4 0.4 53 2 0.84
NaCHO2 0.4 54 3 0.4
NaCH3CO2 0.4 53 2 0.4
Miltefosine 0.0001 48 -3
0.00001 49 -2
0.000005 × [protein] 50 -1
0.0000025 50 -1
D-erythro sphingosine 0.001 38 -13
0.0001 43 -9
0.00001 51 0
0.000005 50 -1
0.0000025 51 0
Table 3.3: Summary of the additives tested, their concentration, effect on melting
temperature of PlcH 2, at a constant concentration of 5 ×10−6 M.
In general, most of the additives tested did not appear to have a large effect
on the stability of PlcH 2, based on the single measurements performed, however a
few stood out.
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Amongst the salts tested, most had very little effect on thermal stability. NaCHO2
(sodium formate) had a very small influence but increased melting point by 3 ◦C.
Na2SO4 at 0.4 M and MnCl2 at 10 mM both stabilised PlcH 2 by 4
◦C each. The
biggest stabilising effect was seen by (NH4)2SO4 which stabilised the protein by
3 ◦C and 9 ◦C at 1 and 0.4 M respectively, and ZnCl2 which at 10 mM increases the
melting temperature by 15 ◦C. A large destabilising effect of 11 ◦C is seen fo 0.01 M
of NiCl2 which may be due to the fact that PlcH 2 contains a His6-tag. The data
collected for the specific binding molecules shows that miltefosine does not appear
to have much impact on the thermal stability of PlcH 2. D-erythro sphingosine on
the other hand has a destabilising effect on PlcH 2 which increases with higher con-
centrations of the compound; the melting temperature for PlcH 2 decreases by 9 ◦C
at concentrations of 100 µM D-erythro sphingosine and by 13 ◦C at 1 mM. Small
concentration in the range of the protein concentration appear to have very little or
no effect on thermal stability.
Overall the compounds tested did not succeed in stabilising PlcH 2 significantly,
other than ZnCl2 and (NH4)2SO4. Interestingly, miltefosine which inhibits native
PlcHR2, does not appear to have a stabilising effect on PlcH 2.
3.2.6 Crystallisation trials of PlcH constructs
Crystallisation screens were set up for the two PlcH constructs, PlcH 2 and
PlcH 4 (section 2.9.6).
3.2.6.1 PlcH 2 crystallisation
For PlcH 2, crystallisation trays were set up with the JCSG+ screen and none
of the conditions tested yielded any crystals. The vast majority of crystallisation
experiments showed amorphous precipitate within weeks. None of the conditions
displayed any degree of crystallinity that suggested follow-up crystallisation experi-
ments.
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3.2.6.2 PlcH 4 crystallisation
For PlcH 4, crystallisation trays were set up with the JCSG+ screen.55 Crystals
were found under many conditions in the JCSG+ screen set up with PlcH 4 at 0.44
mg/mL after approximately 5 months.
Several optimisation trays were set up around conditions G9 and G11 in the JCSG+
screen, and resulted in similar crystals.
(a) (b) (c)
Figure 3.20: Pictures of crystals found in trays set up with PlcH 4 with the JCSG+
screen. (a) JCSG+ F10: 1.1 M sodium malonate, 0.1 M HEPES pH 7.0, 0.5% V/V
Jeffamine ED-2001 (in loop); (b)JCSG+ G9: 0.1 M potassium thiocyanate, 30%
w/V PEG 2k MME and (c) JCSG+ G11: 0.1 M Bis Tris pH 5.5, 2 M ammonium
sulphate.
Several conditions in the JCSG+ screen yielded crystals of various shapes; nee-
dles (150 µm), jagged rectangles (200 µm × 50 µm), rods (200 µm) and flat hexagons
(60 - 100 µm × 60 - 100 µm).
3.2.6.3 Data collection and structural analysis
Datasets were collected at Diamond Light Source (DLS) on beamline I03 for the
crystals harvested from JCSG+ screen set up with PlcH 4. Crystals from various
conditions diffracted but full datasets were only collected for crystals from conditions
F10, G9 and G11 in the JCSG+ screen (1.1 M sodium malonate, 0.1 M HEPES pH
7.0, 0.5% V/V Jeffamine ED-2001; 0.1 M potassium thiocyanate, 30% w/V PEG
2k MME; 0.1 M Bis Tris pH 5.5, 2 M ammonium sulphate). The crystals from
conditions G9 and G11 are shown in Figure 3.20.
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Initial indexing of the dataset collected for the hexagonal crystals from condition
F10 was undertaken using iMosflm124 which yielded the space group and unit cell
dimensions described in Table 3.4. The cell dimensions were noted as being small
considering the molecular weight of 73.5 kDa of protein and a search against the
known structures contained in the Protein Data Bank (PDB) showed that the di-
mensions were near identical to those of the Hfq protein from E. coli 125 (PDB code
1HK9), indicating that the diffracting protein was not PlcH 4. Molecular replace-
ment (MR) was carried out in Phaser126 using E. coli Hfq. One round of rigid body
refinement was carried out yielding the R-values listed below in Table 3.4.
Dataset
Beamline DLS I03
Wavelength (A˚) 0.9795
Lattice Hexagonal
Space group P61
a (A˚) 61.33
b (A˚) 61.33
c (A˚) 167.34
α, β, γ ( ◦) 90.0, 90.0, 120.0
Resolution range (A˚) 52.40 - 1.86
R (%) 24.26
Rfree (%) (based on 5% of data) 27.37
Table 3.4: Data collection and refinement statistics for the crystals harvested from
JCSG+ screen set up with PlcH 4.
This established that the space groups of the collected data were identical to
that of E. coli Hfq. No further refinement was undertaken as the R values clearly
show that the structure had been solved as being identical to the Hfq protein from
E. coli (containing 102 amino acids with a molecular weight of 11166.3 Da) and not
PlcH 4.
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3.2.7 Activity assay probing the SMase activity of PlcHR2
The Amplex R© Red Sphingomyelinase Assay Kit (Invitrogen, Molecular ProbesTM)
was used to investigate the sphingomyelinase (SMase) activity and kinetic param-
eters of PlcHR2 and the PlcH constructs PlcH 2 and PlcH 4 (section 2.9). Ini-
tial experiments allowed for the derivation of relevant assay parameters necessary
for screening a library of ceramide analogues127 and various commercially available
compounds such as potential inhibitors of the SMase activity of PlcHR2.
All experiments in this section were carried out above the critical micelle concen-
tration (CMC) of Triton X-100.128
3.2.7.1 Resorufin as fluorescent standard
Assay readings were output in arbitrary fluorescent units (AFU), thus in order
to express measured values in terms of enzyme activity, a calibration curve of a
fluorescent dye standard of known concentration was constructed using the same
instrumentation. Resorufin (Figure 3.21) is the obvious choice since it is the final
product in the assay reaction. Measurements over a range of resorufin concentra-
tions were made to construct a standard curve shown below in Figure 3.22
Figure 3.21: Structure of resorufin.
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Figure 3.22: Standard fluorescent curve of resorufin at concentrations between 0
and 20 µM. The insert shows the initial, linear region. Error bars indicate standard
deviations based on one set of triplicate measurements.
* Arbitrary Fluorescent Units.
A linear response was seen for resorufin concentrations between 0 and 0.8 µM
as demonstrated in the insert in Figure 3.22, representing the data collected at
low concentrations of resorufin. The experimental data were fitted with a linear
regression curve later used to convert measured fluorescence values using the assay
kit to the more commonly used unit, U.
The katal is the standardised unit (SI unit) for enzymatic catalytic activity and
is defined as the enzymatic activity required for a rate of reaction with one mol of
product per second under specific assay conditions (1 kat = 1 mol(product)/s).129
The katal can not be used to express the rate of reaction, but is used to express a
property of a specific enzyme. A unit (U) is used as a measure of rate of reaction;
it is the amount of protein required to produce 1 µmol of product per minute of
reaction (µmol min−1) and so 1 U is the equivalent of 16.67 nkat. For practical
reasons, one unit of enzymatic activity has been defined as the amount of enzyme
required for hydrolysis of 1 picomol of sphingomyelin per minute (1 U = 1 pmol
substrate/minute) under the assay conditions stated in section 2.9.
100
3.2.7.2 Saturation curve of the B. cereus SMase
In order to optimise the assay parameters Bacillus cereus SMase (BcSMase),
a standard sphingomyelinase, was used in an initial experiment. This was done to
ascertain the effects of varying the BcSMase concentration, between 0 and 18 nM,
on the level of fluorescence detected (Figure 3.23).
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Figure 3.23: Saturation curve of the enzymatic activity of BcSMase, represented by
amount of SM hydrolysed, as a function of enzyme concentration. Substrate con-
centrations were kept constant at 0.25 mM. Error bars indicate standard deviations
based on one set of triplicate measurements. Background fluorescence was corrected
for by subtracting the average background (based on negative control measurements)
from all measurements before averaging. Insert of initial rate region showing a linear
increase.
Figure 3.23 shows a characteristic enzymatic saturation curve where the en-
zyme concentration is related to the rate of reaction. The curve shows an initial
rate region at low concentrations where the level of enzymatic activity, and hence
product formation, increase linearly with enzyme concentration. At higher enzyme
concentrations, the level of specific activity rises asymptotically with increasing en-
zyme concentration (it approaches the theoretical maximum value).
The concentration of BcSMase assayed was between 0 and 18 nM and the linear,
initial rate region was determined to be between 0 and 0.57 nM (see insert in Fig-
ure 3.23). Specific activity was calculated based on the linear region of the resorufin
standard curve by relating the fluorescence to resorufin concentration (the amount of
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product being formed and thus the amount of substrate being hydrolysed). 0.15 nM
is the molar equivalent of 1 U (1 pmol of SM hydrolysed per minute) for BcSMase.
3.2.7.3 Saturation curve of the P. aeruginosa SMase, PlcHR2
A similar experiment was conducted with PlcHR2 in order to calculate the
specific SMase activity.
All experiments and data processing were performed in an identical way to the one
described for BcSMase (section 3.2.7.2). The assay was conducted with PlcHR2
concentrations ranging from 0 to 100 nM. The measured values give rise to a similar
saturation curve (see Figure 3.24) as for BcSMase.
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Figure 3.24: Saturation curve of the enzymatic activity of P. aeruginosa SMase,
PlcHR2. Activity measured as picomol of SM being hydrolysed per minute is plot-
ted as a function of PlcHR2 concentration. Substrate (SM) concentrations were kept
constant at 0.25 mM. Background fluorescence was corrected for by subtracting the
average background (based on negative control measurements) from all measure-
ments before averaging. Insert of initial rate region showing a linear increase. Error
bars indicate standard deviations based on two sets of triplicate measurements.
The linear calibration curve measured for resorufin was used to determine the
enzymatic activity measured for PlcHR2. A linear region was identified as the initial
rate region, at PlcHR2 concentrations between 0 and 0.78 nM.
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This experiment establishes the relationship between protein concentration (mol/L)
and enzymatic activity (U). From the initial rate region of the enzymatic saturation
curve, the molar concentration of the enzyme per unit of enzymatic activity is easily
deduced, employing the equation for the regression line fitted to the linear region
of data (insert in Figure 3.24). 0.26 nM PlcHR2 is equivalent to 1 U of enzymatic
activity for the SMase, PlcHR2, under the given reaction conditions.
These results were employed to determine the initial rate region, in order to
ensure that all other experiment were carried out at concentrations at which the
rate remains constant. The value of 0.78 nM was chosen for further experiments as
it falls in the linear region where the rate of reaction remains constant.
3.2.7.4 Investigating the activity of recombinant PlcH proteins.
The PlcH constructs expressed in E. coli, PlcH 2 and PlcH 4, were tested under
similar conditions to PlcHR2 in order to assess the impact of a PlcR deletion and of
the Tat-signalling sequence on SMase activity.
All experiments and data processing were performed in an identical manner to the
one described for BcSMase (section 3.2.7.2). The assay was conducted with PlcH 2
and PlcH 4 concentrations ranging from 0 - 100 nM for both proteins.
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Figure 3.25: Saturation curve of the enzymatic activity of PlcH 2. Activity mea-
sured as picomol of SM being hydrolysed per minute is plotted as a function of
PlcHR 2 concentration. Substrate (SM) concentrations were kept constant at 0.25
mM. Background fluorescence was corrected for by subtracting the average back-
ground (based on negative control measurements) from all measurements before
averaging. Error bars indicate standard deviations based on two sets of triplicate
measurements.
Figure 3.25 shows enzymatic activity of PlcH 2 as a function of its concentra-
tion. A clear SMase response is seen at high concentrations of the enzyme (at 100
nM) but at low concentrations (<25 nM) the measured fluorescent response was not
discernible from the background fluorescence.
The experiment demonstrated that PlcH 2 is active as a SMase and hydrolyses SM
at concentrations above 25 nM.
In experiments conducted with PlcH 4 no SMase activity was detected (data
not shown). Even at enzyme concentrations of 100 nM, no activity was detectable
leading to the conclusion that the loss of both the PlcR monomer and the Tat-
signalling sequence as well as a C-terminal truncation result in PlcH 4 not being
active as an SMase.
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3.2.7.5 Enzyme kinetics of PlcHR2
Many enzymes follow simple Michaelis-Menten kinetics which is based on a two-
step mechanism where the enzyme first binds the substrate in a reversible reaction.
The complex between enzyme and substrate is then converted into the enzyme and
the product. A characteristic feature of Michaelis-Menten kinetics is that the rate
of reaction approaches a maximum rate asymptotically.
In order to investigate the kinetics of PlcHR2, the enzyme was kept constant at 0.78
nM whilst the sphingomyelin concentration was varied between 0 and 250 µM (0 -
13.4 mol %). The data are summarised in Figure 3.26.
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Figure 3.26: Enzymatic activity plotted against the SM mol % at a constant PlcHR2
concentration of 0.78 nM. Data shown for triplicate measurement. Error bars omit-
ted for clarity.
Furthermore, plotting the inverse rate versus the inverse substrate concentra-
tion (1/V versus 1/[SM]), a Lineweaver-Burk plot, does not result in a straight
line, further underlining the fact that the enzyme does not follow Michaelis-Menten
kinetics under the complex assay conditions presumably due to the fact that the
substrate is presented in the form of a mixed micelle.
The Amplex R© Red Sphingomyelinase assay kit is a continuous assay, resulting
in the reaction carrying on until all the Amplex R© Red reagent has reacted with
hydrogenperoxide to form resorufin.
A timed assay was conducted at a range of PlcHR2 concentrations to monitor the
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substrate usage at specific times after enzyme addition in order to decipher more
about the protein kinetics under the specified conditions in order to represent the
reaction as progress curves until the reaction reaches an equilibrium.
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Figure 3.27: Enzymatic activity plotted against time of fluorescent measurement at
enzyme concentrations of a: 2.3 nM, b: 1.6 nM, c: 0.78 nM and d: 0.29 nM. Data
shown for a single triplicate measurement. Error bars omitted for clarity. Data
shown for triplicate measurement.
The data from the timed assay, shown in Figure 3.27, shows a trend where the
activity starts to approach a plateau at high PlcHR2 concentrations as the time
of the experiment progresses. This maximum rate of reaction (where the activity
plateaus) is approached more rapidly the higher the protein concentration.
3.2.8 Substrate and product analogues as inhibitors of PlcHR2
Having validated the assay parameters, the inhibitory effect of several substrate
and product analogues was investigated as a first step towards a substrate-based
structure-activity relationship (SAR).
With suitable parameters identified, the effect of these compounds on the sphin-
gomyelinase activity of PlcHR2 was investigated using the Amplex
R© Red Sphin-
gomyelinase assay kit.
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3.2.8.1 Ceramide analogues
Three commercially available ceramide analogues were chosen for initial inhi-
bition assays; sphingosine (C18H37NO2), acetylsphingosine (C20H39NO3) and C17-
ceramide (C35H69NO3), shown in Figure 3.28.
(a)
(b)
(c)
Figure 3.28: The chemical structures of the three commercially available ceramide
analogues: a) sphingosine; b) acetylsphingosine and c) C17-ceramide.
The PlcHR2 concentration was kept constant at 0.78 nM and the SM con-
centration was constant at 50 µM. These parameters are based on the results in
section 3.2.7.3, where the protein concentration is within the linear, initial rate re-
gion with a high enough signal (sensitivity) to ensure reproducible measurements.
The inhibitors were added directly to the microplate wells to final concentrations of
0.625, 1.25, 2.5, 5 and 10 µM.
The inhibitory effect of the compounds was determined by comparing the ratio
of fluorescence detected when the sample contained the potential inhibitor, protein
and other reagents to a sample containing only protein and other reagents (defined
as 100% activity). The ratio was then multiplied by 100 in order to express the
achieved fluorescence as a percentage activity detected when specific inhibitors were
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added to the reaction mixture.
The results obtained are summarised in Figure 3.29.
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Figure 3.29: Bar chart showing the percentage activity measured for PlcHR2 in the
presence of 0.625, 1.25, 2.5, 5 or 10 µM of commercially available ceramide analogue
(at constant protein and substrate concentrations of [PlcHR2] = 0.78 nM and [SM]
= 50 µM respectively). Values are averaged over two triplicate measurements. Error
bars are based on standard deviations.
The results in Figure 3.29 show that none of the three commercially available
analogues assayed have any significant inhibitory effect on the SMase activity of
PlcHR2 at concentrations between 0.625 and 10 µM. However, the data collected
for C17-ceramide suggests inhibition at higher compound concentration based on
the small inhibitory effect, 17.9% inhibition with standard deviations of 15.9 and
14.7% recorded for compound concentrations of 5 and 10 µM respectively, suggest
that higher concentrations of C17-ceramide could give rise to inhibition of the SMase
activity of PlcHR2.
108
3.2.8.2 Ceramide analogue library
A library of 97 ceramide analogues (structures and numbers assigned in Ap-
pendix B, Figure B.5) was synthesised and characterised by Dr J. Mina during the
course of his Ph.D.,127 providing an opportunity to screen these compounds for po-
tential inhibitory effect of the SMase activity of PlcHR2.
Experiments were conducted as described in section 2.9. The PlcHR2 concentration
was kept constant at 0.78 nM and the SM concentration was constant at 50 µM.
The inhibitors were added directly to the microplate wells to final concentrations of
10 µM.
The results, calculated as above, are shown graphically in Figure 3.31 and numeri-
cally in Table 3.5. The results in Figure 3.31 and in Table 3.5 only summarise the five
most promising inhibitor and five most promising activator compounds. The limit
was set for activities <70% and for activities >150% respectively. Only compounds
meeting this requirement and with a standard deviation of <20% were included.
All data are shown below in Figure 3.30 and in a 3-dimensional representation in
Appendix B; Figure B.4.
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Figure 3.31: Bar chart showing the percentage activity measured for PlcHR2 in
the presence of 10 µM of ceramide analogue (at constant protein and substrate
concentrations of [PlcHR2] = 0.78 nM and [SM] = 50 µM respectively). The numbers
under each bar corresponds to the the assigned compound (Appendix B, Figure B.5).
Values are averaged from 3 independent measurements. Error bars are based on
standard deviations.
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Compound number % activity Standard devation Structure
23 64.7 6.0
24 60.0 4.4
25 65.2 3.4
26 65.3 13.4
32 68.4 9.3
66 159.2 5.2
67 159.7 5.5
68 153.4 11.8
69 157.4 18.9
71 152.4 10.2
Table 3.5: Summary of the compound number, % activity detected when compound
is present, standard deviation and the chemical structure of the five strongest in-
hibitors and five strongest activators.
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The results summarised in Figure 3.31 and in Table 3.5 show that compounds
number 23, 24, 24, 26 and 32 have an inhibitory effect on the enzymatic activity of
PlcHR2 and they reduce the measured activity to between 60 and 68% compared to
the control reactions not containing any ceramide analogue. Three of these (numbers
24, 25 and 26) contain a large, flexible carbon chain (C13H27) out of which one (24)
contains a small amine group (NH2) and the other two (25 and 26) a larger amine
group (NHCOMe and NHCOCH2Ph). However, the chiral centre retains the same
configuration for all five compounds. Furthermore, none of these compounds contain
a phenyl ring located close to the chiral centre.
Compounds number 66, 67, 68, 69 and 71 have an activating effect on the enzymatic
activity of PlcHR2 and increase the measured activity to between 152 to 160%
compared to the control. Two of these, 69 and 71, contain a phenyl ring close to
the chiral centre. Compounds 66, 67, 69 and 71 all have large substituted amines.
Out of the 97 tested compounds, five showed moderate inhibitory effects and five
gave rise to significant activation of the enzymatic activity of PlcHR2.
3.2.8.3 Inhibitors of sphingolipid synthesis enzymes
Miltefosine (C21H46NO4P) is a commercially available compounds which pos-
sesses structural similarities to the two choline-containing lipids, PC and SM, and
has been identified as an inhibitor to cleavage of these lipids123 in vivo. It is currently
the only orally administered drug available to treat Leishmaniasis. Miltefosine and
two other commercially available analogues, perifosine (C25H52NO4P) and edelfos-
ine (C27H58NO6P) (structures shown in Figure 3.32), were thus assayed in a similar
manner to above.
(a)
(b)
(c)
Figure 3.32: The chemical structures of a) miltefosine; b) perifosine and c) edelfosine.
113
Experiments were conducted as described in section 2.9. The PlcHR2 concen-
tration was kept constant at 0.78 nM and the SM concentration was constant at 50
µM. The inhibitors were added directly to the microplate wells to final concentra-
tions of 1.25, 2.5, 5, 10 and 20 µM.
The results, calculated as above, are shown graphically in Figure 3.33.
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Figure 3.33: Bar chart showing the percentage activity measured for PlcHR2 in
the presence of 1.25, 2.5, 5, 10 or 20 µM of miltefosine (blue), perifosine (red) or
edelfosine (green) (at constant protein and substrate concentrations of [PlcHR2] =
0.78 nM and [SM] = 50µM respectively). Values are averaged over two triplicate
measurements. Error bars are based on standard deviations.
The results in Figure 3.33 show that both miltefosine and edelfosine have no
inhibitory effect on the SMase activity of PlcHR2 at concentrations between 1.25
and 20 µM under the assay conditions but instead have an activating effect. The
addition of miltefosine resulted in measured activities between 153% and 123% at
concentration of 2.5 and 10 µM respectively and the addition of edelfosine resulted
in measured activities between 134% and 173% at concentrations between 2.5 and
20 µM resepectively. In terms of structure, the two compounds are very similar;
edelfosine has a longer carbon chain and contains two ether groups.
Perifosine has a small inhibitory effect on the activity of PlcHR2 under the described
conditions (the activity was measured to be 83%, 83%, 82% and 91% at concentra-
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tions between 1.25 and 10 µM). The difference in structure between perifosine and
the other two compounds is a cyclohexane ring after the phosphate headgroup con-
taining a di-methylated nitrogen. This deviation from the typical phosphocholine
headgroup may affect the inhibitory effects of this compound.
The experiments provided no evidence for inhibition of the SMase activity of PlcHR2
under the conditions assayed for miltefosine and edelfosine. Perifosine showed some
inhibitory effect on PlcHR2 under the conditions assayed.
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3.3 Discussion and future work
3.3.1 PlcH expression and purification
Small-scale expression performed at the OPPF showed that the best results ex-
pressing the highest amount of pure protein were obtained using Rosetta I (DE3)pLysS
cells and the autoinduction method. All the cells tested at the OPPF, B834 and
Rosetta I(DE3) pLysS, are derivatives of BL21 cells often employed for protein ex-
pression.
The first problems encountered with the PlcH constructs was attempting transfor-
mation into various cells out of which only into BL21(DE3) cells was successful.
However, expression levels from those cells were below the levels of detection.
Large-scale expression was subsequently carried out with glycerol stocks of the con-
structs in Rosetta I (DE3) pLysS cells from the OPPF of the two most promising
constructs, PlcH 2 and PlcH 4. This proved to be challenging as expression levels of
PlcH 2 and PlcH 4 in both BL21(DE3) and Rosetta I (DE3) pLysS cells remained
limited at approximately 1 mg/L of expression medium, which may be due to the
toxic nature of the PlcH protein. Autoinduction was proved to be better for expres-
sion of PlcH than induction by IPTG addition. Utilising autoinduction media often
results in a higher yield of soluble protein than when using IPTG induction due to
the tight control of induction by the media composition.
An alternative to BL21 cells would be C41(DE3) or C43(DE3)130, 131 cells which
are a derivative of the E. coli BL21(DE3) strain; plasmids that were difficult to
transform into other BL21(DE3) strains due to high toxicity, have been shown to
transform into C41(DE3) cells and they have proved to stabilise the plasmids during
expression of toxic recombinant proteins, making these ideal for expression of recom-
binant PlcH. ArcticExpress(DE3)132 cells grow at lower temperature thus slowing
protein expression down, which can lead to expression of more active and soluble
protein, overcoming issues with inclusion bodies.
The last obvious route to explore would be to try and express the PlcH constructs in
Pseudomonas aeruginosa bacteria, as the levels of expression are likely to be higher
in originating organism, and thus toxicity levels would not be an issue. Problems
could potentially arise from purification as the constructs lack plcR and would there-
fore not be secreted from the bacteria, requiring cell lysis. It should be noted P.
aeruginosa is a human pathogen and thus expression from this bacterium requires
a biosafety level 2 laboratory which the laboratory the work was conducted in is
currently not certified for.
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3.3.2 Hfq contamination
Protein expression and purification was problematic due to the high levels of
contamination by the E. coli Hfq protein found in most samples of purified protein,
as verified by mass spectrometry of SDS-PAGE gel bands containing the PlcH con-
structs as well as crystallisation of the contaminant. The reasons for co-expression
and purification of this protein with the PlcH constructs is unknown but may be
due to the 24 histidine residues at the C-termini of the Hfq hexamer, allowing for
co-purification on IMAC columns. Hfq is a well-known, frequently found contami-
nant in protein samples purified from E. coli and the suggested method for removal
is to utilise several different purification methods.133 However, even though three
purification steps were carried out for all protein samples, the Hfq protein must
have been strongly bound to the PlcH constructs, as it was not even removed after
a size exclusion column. In order to minimise contamination, further purification
steps could be carried out or an hfq gene deficient strain of E. coli could be used for
protein expression.
3.3.3 Biophysical characterisation
In order to verify protein identity, a trypsin digest was carried out on the PlcH 4
construct. The data provided evidence that despite Hfq contamintaion, the protein
was indeed PlcH 4 as 23% of the sequence was covered by the peptides identified in
the data.
Analysis of the CD spectroscopy data revealed that the longest PlcH construct,
PlcH 2, consists of 36% α-helices and 33% β-sheets, whereas the shorter construct,
PlcH 4, consists of 58% α-helices and 18% β-sheets. These calculated values and the
experimental spectra suggest that PlcH 2 is correctly folded. PlcH 4, on the other
hand, does not seem to follow the same folding pattern as PlcH 2, as it appears to
consist of more α-helices, despite missing the Tat-sequence as well as 43 residues at
the C-terminal. The experimental spectrum also suggests that this construct may
not be entirely correctly folded, but more disordered than the calculated parameters
suggest.
The secondary structure elements were calculated by the three programmes; CON-
TINLL, CDSSTR and SELCON3, which utilise the chosen reference set to calculate
values of molecular circular dichroism based on the data input into them. The data
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shown for the secondary structure elements of the two PlcH constructs were calcu-
lated by CDSSTR; this was chosen by comparing the experimentally measured
∆  with the calculated ∆  by each of the programmes. The calculated data showing
the best overlap with the experimentally measured values was used to predict the
percentage of secondary structure elements. Even though the calculated percentages
only give an approximation to the structure of the proteins, the discrepancy between
the values calculated for the constructs in conjunction with the experimental spectra
reveals useful information.
The protein targets, the PlcH constructs, were thus verified both by mass spectrom-
etry and CD spectroscopy verified that the constructs were folded proteins.
3.3.4 Stabilising and destabilising conditions for PlcH con-
structs
Based on the results obtained when studying the thermal stability of PlcH 2
under different conditions, a few trends become apparent.
(NH4)2SO4 and NaCl were both tested as additives at concentrations of 1 and 0.4
M; the former was found to have a stabilising effect on PlcH 2 whereas no statisti-
cally significant effect on the protein melting temperature was seen for the latter.
(NH4)2SO4 is commonly used to salt out proteins. Polyvalent anions enable salting
out proteins from solution whereas polyvalent cations counteract this. Utilising a
salt consisting of a univalent cation and a multivalent anion will thus increase the
salting out effect. The Hofmeister series of anions is useful for predicting which
salts will be effective for salting out proteins; the earlier on in this series the anion
appears, the better it is at solubilising proteins. Citrate and sulphate are first in
the series and thus (NH4)2SO4 is very effective at stabilising proteins, which also
explains why NaCl and NH4Cl have very little effect on protein stability. This was
further shown by Na2SO4 which was only tested at 0.4 M concentration but had a
similar effect as (NH4)2SO4 at 0.4 M on the protein stability whereas MgSO4 had
no statistically significant effect on the melting temperature.
Another important factor in protein stability is the ability of the cation to bind
to the protein either via an active site or a non-biologically relevant site. CaCl2,
MnCl2, NiCl2 and ZnCl2 were all used as additives at a 0.01 M concentration (ionic
strength 0.3); CaCl2 has no effect on stability and MnCl2 only has a small effect
(Table 3.3). NiCl2has a destabilising effect which may be linked to the His6-tag on
PlcH 2. ZnCl2 had a very stabilising effect on PlcH 2 which may be linked to its
frequent use in crystallisations; Zn+2 may play a structural role as it is found bound
both in active and non-biologically active sites in many proteins.
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Miltefosine, a known inhibitor of PlcHR2, was not seen to have any effect on the
thermal stability of PlcH 2, whilst D-erythro sphingosine, a sphingomyelin deriva-
tive, destabilises the same protein significantly at high concentrations (0.1 and 1
mM) compared to the protein concentration (5 µM).
Further experiments should be undertaken including a wider range of concentrations
of the already tested additives. Moreover, a buffer screen should also be carried out
in order to further optimise the purification conditions of the PlcH constructs.
3.3.5 Discussion of crystallisation of PlcH
The crystallisation experiments coupled with tryptic digests of SDS-PAGE
bands and subsequent mass spectrometry of those bands revealed Hfq protein from
E. coli contamination. The contamination was not apparent in purifications and was
only suspected after solving datasets. Combined with the mass spectrometry results,
it has become evident that Hfq protein co-purifies with the PlcH constructs under
the chosen conditions. Despite testing different purification methods and buffers,
the contaminant is present in purified protein samples. The Hfq protein has been
observed to aggregate into a hexamer (observed with RNA binding) and contains
24 histidine residues. Only the purest fractions after purifying on a size exclusion
column were utilised for crystallisation trays suggesting that Hfq interacts with the
PlcH constructs.
In order to attempt to overcome this problem, expression of PlcH constructs
should be carried out in E. coli∆ with the hfq gene deleted. Another possibility is
further purification on different types of columns such as a cation exchange column
or a heparin column, for example.
3.3.6 Amplex R© Red SMase assay
The Amplex R© Red Sphingomyelinase assay kit was chosen as a suitable assay
as it had been employed successfully to determine the sphingomyelinase activity of
the neutral SMase from Trypanosoma brucei.134 In order to establish the same as-
say for the heterodimeric SMase, PlcHR2, from P. aeruginosa, various assays were
carried out.
In order to gain a better understanding of the assay conditions, the theory of surface
dilution kinetics is briefly discussed below.
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3.3.7 Surface dilution kinetics
PlcHR2 is a water-soluble enzyme which displays sphingomyelinase activity.
This enables it to participate in lipid signalling pathways which include enzymes that
degrade lipids (as a function of SMase activity) or participate in lipid biosynthesis (as
a SMS) as well as enzymes requiring lipid activators or cofactors.135 The environment
surrounding a lipid dependent enzyme allows for different interactions to occur;
three-dimensional bulk interactions and two-dimensional surface interactions. Thus,
the lipid concentration in the bulk and on the surface contribute to the kinetic
parameters. A kinetic model has been developed to describe the interactions at play
between enzymes and lipids - ’surface dilution kinetics’, by R. A. Deems et al.136
The following model was developed by R. A. Deems et al 136, 135 and explains
the reaction of a phospholipase A2 from cobra venom (PlLA2) on a mixed micelle
of phosphatidylcholine and Triton X-100, a non-ionic detergent (known as a neutral
dilutor as it does not have an effect on the enzyme).137, 138 Equation 3.1 represents
the bulk step and Equation 3.2 represents the surface step occurring during reaction.
E+A
k1−−⇀↽−
k−1
EA (3.1)
EA+B
k2−−⇀↽−
k−2
EAB
k3−−⇀↽−
k−3
EA+Q (3.2)
where E is the soluble enzyme, which the associates with the mixed micelle, A
(usually consisting of the relevant lipid substrate and Triton X-100), and forming a
mixed micelle complex between the lipid, Triton X-100 and the enzyme (EA). This
step is dependent on the bulk concentrations of both E and A. [A] is the sum of
molar concentrations of the lipid substrate and Triton X-100, if the enzyme binds
to the surface of the micelle in a non-specific way (described by the ”surface bind-
ing model”). However, [A] is the molar concentration of the lipid substrate, if the
enzyme during the first step binds specifically to a lipid substrate molecule in the
micelle surface (described by the ”phospholipid binding model”). After association
with the micelle, the enzyme binds a single lipid substrate molecule, B, in its active
site, thus forming another complex, EAB. This step is a function of the surface
concentrations of both EA and B, as the complex is formed at the surface of the mi-
celle. The catalysis reaction forms Q, the product, and the enzyme-micelle complex
is regenerated.
The equation for the surface dilutions scheme is shown below in Equation 3.3.
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V =
Vmax[A][B]
KAsK
B
m +K
B
m[A] + [A][B]
(3.3)
In Equation 3.3, KAs = k−1/k1, K
B
m = (k−2 + k3)/k2 where the former is the
dissociation constant (in bulk concentration terms) and the latter is the interfacial
Michaelis constant (in surface concentration units). Vmax is the true maximum
rate which occurs at an infinite bulk concentration and an infinite mole fraction
of phospholipid substrate. It is assumed that the average surface area of the lipid
substrate and the Triton X-100 molecules is identical; that the the surface area for
each enzyme binding site on the micellar surface is constant, even if the bulk or
surface substrate concentration changes; that the aggregation number and size of
the mixed micelles remains constant in the concentration range utilised even when
the bulk or surface substrate concentration is varied and that the enzyme has access
to the entire lipid pool.135
Enzyme kinetics are important when attempting to understand how a specific
enzyme functions.139 Kinetics have been used to describe various enzyme reactions,
mainly in solution. However, since many soluble enzymes react with aggregates
of substrate (such as lipid membranes or structures consisting of proteins and nu-
cleotides) or are membrane bound themselves, the kinetic theories are evolving to
include more complex systems.
3.3.7.1 Substrate micellar structures
Several parameters are involved in the kinetics describing systems of e.g. a
phospholipase and phospholipids. Firstly, the form that the substrate takes in the
reaction solution is important, as rates of reactions are often dependent on the shape
of aggregates the enzyme interacts with. Structures with differing morphology are
formed when amphiphatic (most contain a polar headgroup and a hydrophobic tail
group) molecules are dispersed in water. The aggregate structure formed is influ-
enced by many factors including other amphiphatic molecules in the mixture, the
headgroup structure and chain length, temperature, salt concentration as well as
the way in which dispersion occurred. As an example, most phospholipases have
been found to have preferences for specific structures and hydrolysis reactions will
occur faster for certain shapes of aggregates. However, similar enzymes do not nec-
essarily have a preference for the same type of aggregate.139, 128 Aggregates form
to hide the hydrophobic tails within the structure whilst exposing the hydrophilic
head groups to the water. Several studies have been carried out in order to try to
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predict the aggregate shape specific substrates will form under certain conditions,
employing techniques such as differential scanning calorimetry, Fourier transform
infrared spectroscopy, NMR (nuclear magnetic resonance) techniques, X-ray and
neutron scattering and electromagnetic microscopy (EM), making it a non-trivial
issue.
Generally, amphiphatic molecules containing one hydrophilic headgroup and
two hydrophobic tailgroups form structures containing bilayers such as bicelles and
vesicles when in water, whereas those with only one tailgroup form micelles without
a bilayer structure. If both types of compound are present in solution, both micellar
and vesicle structures can form. When detergents such as Triton X-100, that usu-
ally form micelles in solution, are added to vesicles of phospholipids with long fatty
acid chains, it results in the formation of mixed micelles. The detergent molecules
become integrated into the vesicle lipid bilayer, which when the concentration in-
creases eventually distorts the bilayer structure, transforming the structure to a
mixed micelle. The lipid to detergent ratio necessary for forming mixed micelles is
dependent on the individual lipids (differing head- and tailgroups) and detergents.
The critical micelle concentration (CMC - the concentration of detergent monomer
where a significant amount of micellar aggregates appear) of the detergent must be
subtracted from the detergent concentration when calculating the ratio of detergent
to lipid. In this case, the CMC represents the concentration where the amount of
detergent molecules are available as monomers in solution and thus not at the mi-
cellar surface (0.22 - 0.24 mM for Triton X-100).128
In interfacial kinetics, mixed micelles are an important tool which allows the in-
troduction of lipids into a system whilst mostly maintaining a similar environment,
and they allow for easy manipulation of the surface concentration (via regulation
of detergent and lipid ratios). It is important to note that the phospholipids are
orientated along a surface (not a bilayer) with higher curvature compared to normal
membranes.
The structure containing the phospholipids can have a strong influence on the en-
zyme affinity for the surface, and studies on PLA2s has revealed mixed micelles,
micelles and SUVs as the most common structures.
3.3.7.2 Interfacial catalysis
Interfacial catalysis has been defined as a reaction occurring involving at least
one component which is present at an interface and is catalysed by an enzyme which
can exist freely in solution or be associated with the aggregate.
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There are several differences between soluble kinetics and interfacial kinetics, adding
several factors into the kinetic considerations. The kinetics are influenced by the
enzymes ability to attach to the aggregate surface, the substrate concentration at
the surface and the environment in which the substrate is located; the two latter
factors both affect the enzymatic activity.139
The manner in which the enzyme binds at the aggregate surface, whether it binds
reversibly to the substrate molecules or any other molecules present at the surface,
is irrelevant as long as the enzyme remains at the surface so that interfacial catalysis
can occur. It is also possible for the enzyme to interact non-specifically with both
hydrophilic interfacial regions or the hydrophobic core, or can simply be tethered ie.
the enzyme is bound covalently to a moiety in or at the surface. It is important to
note that the catalytic site must not interact during the binding step as the enzyme
would otherwise bind to the substrate immediately and thus the kinetics would no
longer be dependent on the surface concentration of the substrate. For integral
membrane proteins the binding step is not included in the kinetic considerations as
they are lodged within the membrane/phospholipid bilayer, and therefore do not
depend on the substrate surface concentration.
In order to determine kinetic parameters for this kind of system, it is vital to un-
derstand the mechanism with which the enzyme is held at the aggregate surface.
Both the enzyme and the substrate bulk concentrations must be known and whilst
the bulk enzyme concentration is easily obtained, the bulk concentration of the sub-
strate can be difficult to verify.
The enzymatic activity is a function of the bulk and the surface concentrations of
the substrate. The interaction occurring between the enzyme and the surface needs
to be determined to establish whether to include the bulk concentration of the sub-
strate only or the bulk concentration of the detergent in the equation as well. The
surface concentrations of the surface components (measured in mol/cm2) define the
reaction as the second step in the catalysis reaction occur in two dimensions only.
This is obtained by dividing the moles of enzyme and substrate present at the inter-
face by the total interfacial surface area, which is simplified as a mole fraction when
assuming all molecules at the interface occupy a similar volume which is invariable
under the conditions of the assay.
In the mixed micelle, the substrate becomes fixed at the micellar surface which af-
fects the kinetics of the enzyme in multiple ways; the substrate can be fixed in a
specific conformation which either reduces or increases interactions with the protein
depending on the environmental steric interactions. This means that depending on
the environment and the micellar shapes, the enzymatic activity can change drasti-
cally.
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3.3.8 Sphingomyelinase activity of native PlcHR2 and PlcH
constructs
Native PlcHR2 shows the expected enzymatic saturation curve and sphin-
gomyelinase activity. It was shown to be slightly less active than BcSMase, a stan-
dard SMase. The native PlcHR2 is also approximately an order of magnitude more
active than the full length PlcH 2 construct, where the latter has lost most of its
activity and only shows signs of SMase activity at concentrations above 25 nM. The
reasons for the loss of activity may be due to the loss of PlcR2 which has been
shown to contribute directly to enzymatic activity. Furthermore, PlcH 2 is folded
as shown by CD spectroscopy, however some crucial parts may be flexible without
PlcR2, reducing enzymatic activity. PlcH 4 showed no detectable SMase activity
and CD spectroscopy indicated a higher degree of unfolding.
3.3.9 PlcHR2 kinetics
An assay was conducted varying the sphingomyelin substrate concentration in
order to investigate native PlcHR2 kinetics. As shown, the enzyme does not follow
simple Michaelis-Menten kinetics under the assay conditions, as plotting the data
as a Lineweaver-Burke plot does not result in a straight line. However, to estab-
lish whether an enzyme follows interfacial kinetics, employing the surface dilution
model, extensive measurements must be made at various surface concentrations of
the substrate and utilising various enzyme concentrations in order to determine the
enzymatic activity. Due to limited materials, this experiment was only performed
at a single enzyme concentration. The kinetics of the system are very complex and
more data are needed in order to determine the enzyme kinetics.
A timed assay was also performed in order to study the progress curves until the
reaction reached an equilibrium. This particular assay was not ideal for this study as
the levels of fluorescence recorded were lower than expected after the usual 30 min-
utes of incubation, at the various concentrations, as the assay plate was constantly
moved between 37 ◦C, incubation temperature, and Troom, thus slowing down reac-
tion times. Furthermore, the platereader fluorescent detector was saturated quickly
and thus unable to read the levels of fluorescence achieved at the point of equilibrium
of the reaction.
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3.3.10 PlcHR2 ligands
When a potential inhibitor is added to to the reaction mixture, the interfacial
catalysis steps are affected. The inhibitor may enhance the enzyme binding to the
surface, thus displaying activating properties. To determine whether a compound is
a competitive inhibitor, the surface concentration of inhibitor is used when studying
the inhibition dependence.139 When analysing the results obtained for the effect of
various compounds on the SMase activity of PlcHR2, some of the tested compounds
stood out as being activators. According to the above description, this is likely
linked to the structure of the compounds and their subsequent enzyme binding at
the mixed micelle surface.
The commercially available compounds screened for inhibitory effect on the SMase
activity of PlcHR2 were chosen due to their structural similarity to the substrate,
sphingomyelin. These compounds were shown to have little or no effect on the
PlcHR2 SMase activity.
The library of 97 ceramide analogues showed five compounds with an inhibitory
effect and five compounds with an activating effect on the PlcHR2 SMase activity.
Three of the inhibiting compounds contain a long, flexible alkyl chain. Four of the
activating compounds contain a phenyl ring at the end of show carbon chains and
the fifth compound only contains a short carbon chain. The side groups all vary in
size. This shows that there is no clear trend and not enough examples to develop a
structure activity relationship.
Experiments with miltefosine, perifosine and edelfosine showed a small inhibitory
effect for perifosine. However, during the course of the experiment there was an indi-
cation that miltefosine had a delayed inhibitory effect (data not shown). Due to the
fact that the assay is continuous with fluorescence increasing over time, the detector
was saturated when attempting to obtain a quantitative result. Pre-incubating the
enzyme with the compounds did not give rise to any change in results. In order
to quantify the effect, one would therefore have to utilise a system that monitors
the assay over a set time period with a detector possessing a high enough dynamic
range that allows detection of the high fluorescent rates achieved by the system.
3.3.11 Chapter conclusions
The work in this chapter demonstrated a biophysical and biochemical analysis
of the native PlcH2 and the PlcH constructs from P. aeruginosa, drawing on multi-
ple techniques.
For the first time, successful cloning and small-scale expression using the autoinduc-
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tion method of twelve PlcH constructs leading to expression and purification of two
constructs, PlcH 2 and PlcH 4 (Table 3.1), was achieved. Expression and purifica-
tion proved challenging and expression levels were between 0.5 and 2 mg per litre of
expression medium. The protein folding was examined using CD spectroscopy; the
spectrum for PlcH 2 showed characteristics of folded protein whereas the spectrum
for PlcH 4 suggested a partially unfolded sample.
Crystallisation trials for the two PlcH constructs did not result in any diffracting
PlcH crystals. However, crystallisation trays set up with PlcH 4 resulted in diffract-
ing E. coli Hfq protein crystals (a common contaminant of samples expressed in E.
coli and purified by Ni-NTA columns). This was further supported by mass spec-
trometry analysis of an SDS-PAGE gel band of both PlcH constructs.
The enzymatic SMase activity of PlcHR2 was tested using a commercially available
assay kit. Once the assay had been developed, several commercially available ce-
ramide analogues as well as an in-house library of 97 compounds were screened for
their effect on the SMase activity of PlcHR2. The in-house library contained five
compounds with an activating effect and five compounds with an inhibitory effect on
PlcHR2. The SMase activity of the two expressed and purified PlcH constructs was
tested under similar conditions. PlcH 4 did not appear to possess SMase activity
but PlcH 2, the full length construct, showed SMase activity, albeit considerably
lower than the native PlcHR2. This shows that the PlcR2 chaperone is required for
full activity and the full length PlcH is required for activity.
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Chapter 4
The Toxoplasma gondii Serine
Palmitoyltransferase
4.1 Introduction
Toxoplasma gondii is a protozoan zoonotic parasite. It is an important agricul-
tural as well as human pathogen, and thus incurs a significant cost to the economy
and human health. The parasite causes toxoplasmosis and can infect any warm-
blooded animal including humans.140 In fact, T. gondii has been suggested to be
the most common parasitic infection globally.
The infection is usually symptomless in healthy individuals; however, congenital
toxoplasmosis is extremely serious as it can lead to severe birth defects such as blind-
ness and intellectual disabilities. In addition, acute toxoplasmosis affects immuno-
compromised patients where it often causes encephalitis or infection of various or-
gans. It is also a large contributor to mortality rates of AIDS patients. The agri-
cultural sector is also affected by toxoplasmosis. The food industry demands safe
and high quality food and pigs are known to be a source of foodborne toxoplasmosis
making farm management a priority to prevent infection.141 Toxoplasmosis is also
a large contributor to sheep miscarriages.142 Although a number of drugs including
pyrimethamine and sulfadiazine are available for treatment, the parasite can remain
in the host body in its inactive form until the host’s immune system is compromised
for example by a primary infection. The limited efficacy of current drug treatments
calls for a renewed effort to identify new potential targets.
The enzyme serine palmitoyltransferase (SPT) catalyses the condensation of L-serine
and palmitoyl-CoA to form 3-ketodihydrosphingosine (KDS); the first step in the
biosynthesis of sphingolipids which is essential for T. gondii proliferation, thus any
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disruption of this pathway would slow down parasitic growth in vivo, making this
metabolic pathway an ideal target.
4.1.1 Toxoplasma gondii
Toxoplasma gondii is an intracellular protozoan parasite belonging to the phy-
lum Apicomplexa.143 This includes many important members such as Eimeria,
Leishmania and Cryptosporidium species, both containing enteric pathogens which
can thrive in the digestive tract. Another important member is Plasmodium falci-
parum, which causes malaria and is linked to approximately 700,000 deaths (Fact-
sheet on the World Malaria Report 2013, WHO)144 every year. T. gondii is therefore
the crucial model apicomplexan parasite, the advantage being that it is more easily
manipulated genetically and sustains stable transfection.143
T. gondii is a promiscuous parasite with felidae as the definitive host.145 T.
gondii can infect nearly any mammalian cell as well as fish and insect cell lines
in vitro.141, 145, 146 From an evolutionary point of view it is interesting to note that
infections in new world monkeys and marsupials is often acute and lethal, as they
have not involved in the same environment as cats and hence have very limited im-
munity.147
T. gondii was discovered in 1908 independently by two groups of scientists
(Nicole and Manceaux; and Splendore) studying the protozoan pathogen Leishma-
nia.148, 149 The first case of congenital toxoplasmosis was observed in 1923150 but
not established until 1938 when an infant was born who had contracted congeni-
tal toxoplasmosis and died a month later; the parasite was identified in the infant
by pathologists. Congenital infection by transmission was then discovered in many
other warm blooded animals (including goats, sheep and rodents).148 The human
case of congenital toxoplasmosis was linked to ingestion of undercooked meat by
the mother during pregnancy by Weinman and Chandler in 1954. Extensive infec-
tion of herbivores and vegetarians was not explained through meat ingestion and
congenital transmission alone, leading to the discovery of infection through contact
with cat faeces. In 1970 the coccidian lifecycle150 and the parasitic sexual stage was
found in the small intestines of the cat151 and thus characterised biologically and
morphologically.
The T. gondii parasite is found all over the world and has the widest range of hosts,
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warm-blooded animals (mammals and birds) and humans, of any parasite.148, 150
Most hosts do not display any symptoms whereas a few contract clinical toxoplas-
mosis; however, the reason why certain seemingly healthy individuals develop severe
symptoms is unknown.
4.1.2 The complex life cycle of T. gondii
The parasite life cycle is complex and consists of both sexual and asexual repro-
duction. T. gondii is a polyxenous and heteroxenous parasite which is transmitted
between the various host-species via many pathways. In the 1960s the heteroxenous
lifecycle was discovered. The T. gondii life cycle represents a number of stages in-
cluding both a sexual and an asexual reproduction path (Figure 4.1). The sexual
stages occur in the intestine of the primary host (carnivorous) whereas the asexual
stages are mainly associated with a variety of intermediate hosts, ranging from most
livestock animals to humans (omnivores and herbivores).
The three infectious stages of T. gondii are linked in a life cycle; the stages consist
of tachyzoites (form aggregates of multiple tachyzoites known as clonal groups) and
bradyzoites (found in tissue cysts), both in intermediate hosts, and the sporozoites
(found in oocysts that are zygotes surrounded by a thick cyst wall) linked to a re-
sistant stage which takes place externally to the hosts.152
The life cycle is summarised below in Figure 4.1 and explained in detail in the
following sections, 4.1.2.1 and 4.1.2.2.
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Figure 4.1: Diagram of the T. gondii life cycle adapted from Figure 1 in M. W.
Black et al.145 The diagram shows how the sexual cycle is activated in felidae only.
This is followed by how the infection is spread via the environment to mammals and
birds.
4.1.2.1 Asexual stages of T. gondii
During the acute infection in mammals and birds, T. gondii appears in the form
of tachyzoites which are capable of rapid growth and asexual reproduction. Tachy-
zoites are short, crescent shaped cells with one elongated anterior and a rounded
posterior (Figure 4.2), generally measuring 2 by 6 µm, containing a centrally po-
sitioned nucleus.152 Cell movement is achieved by gliding, rotating or flexing as
no physical means such as flagella or cilia are present to facilitate motion. This
type of motility has been observed for certain bacteria but is more prevalent for
apicomplexa.153
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Figure 4.2: Schematic of the organelles in the T. gondii asexual tachyzoite stage.
Reprinted from Figure 2 in M. W. Black et al.145
The tachyzoite form of the parasite can enter the host cells by phagocytosis or
by penetrating through the plasmalemma where they assume an ovoid shape and
become encased in a parasitophorous vacuole (PV).154 The tachyzoite cells rapidly
undergo asexual division which occurs by endodyogeny148 within tissue cysts (PVs);
the parent cell gets devoured by two progeny cells that have formed within it. This
carries on until the host cell can no longer support the continued growth, at which
point it bursts, thus the invasion rate is controlled by the host type. In this man-
ner, the parasite is released around the whole host system. The parasites take this
form during the acute toxoplasmosis phase145 and tachyzoite replication only takes
between 6 to 8 hours (tested in vitro) (Figure 4.1(5)); this is repeated until they
leave the cell to cause further infection which usually involves 64 to 128 parasites
aggregating in a single cell. Thereafter they differentiate and become bradyzoites
(Figure 4.1(6)) which are usually found 7 to 10 days after initial infection.145 The
change can be induced in vitro 155 by stimuli including cyclic nucleotide kinase in-
hibitors or sodium nitroprusside as well as changes in pH to more alkaline conditions.
Exogenous stress has been noted as an important factor for tachyzoite to bradyzoite
differentiation156, 157 and may be linked to an onset of protective immunity.156 Stress
can be caused by changes in signalling pathways such as nutrient starvation or cyclic
nucelotides.155
Bradyzoites (1.5 by 7 µm), also known as cystozoites,148 are structurally very similar
to tachyzoites; they are narrower and possess a nucleus located near the posterior
end of the cell. These cells also divide by endodyogeny. They are found in tissue
cysts which are most commonly found in the central nervous system (CNS) or in
muscular tissues such as cardiac and skeletal muscles as well as eyes and brain, but
can also emerge in other organs such as the liver, kidneys or lungs of infected species.
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Cysts can contain a few or hundreds of bradyzoites and thus vary significantly in
size; those found in the brain tend to be smaller than the intramuscular ones which
can be up to 100 µm long - many times the size of the surrounding cells. Tissue
cysts are not harmful to the host152 and hence do not generally cause an immune
response. The bradyzoites are associated with chronic parasitic infections. The
parasites are believed to cross158 the blood-brain barrier (BBB) inside leukocytes
(Trojan horse mechanism) by affecting the gene expression of the endothelial cells
of the brain. This has been identified for cells expressing the antigen CD11b with
or without the CD11c antigen159 and is believed to be responsible for 60% of the
cells successful in crossing the BBB.158 The asexual stage is fulfilled once the cysts
are ingested (Figure 4.1(7)). Bradyzoites are released as the cysts pass through the
digestive tract, where the tissue cyst walls are dissolved by proteolytic enzymes such
as pepsin or trypsin,148 but the bradyzoites released are able to survive and cause
host infection. In the digestive tract the cells infect the intestinal lumen epithelia
where differentiation back to tachyzoites (undergo rapid division, ready for distri-
bution within the host) occurs, thus allowing the parasite to persist within the host
indefinitely, thus continuing the cycle.
Spontaneous reactivation from bradyzoites into tachyzoites can occur; in healthy
hosts, the immune system prevents distribution of the tachyzoites within the host
however, immuno-compromised hosts may be unable to control this reactivation
process, leading to a fatal outcome for the host.145
4.1.2.2 Sexual stage of T. gondii
Felidae are the primary host for the T. gondii parasite.149 When a cat ingests a
tissue cyst (Figure 4.1(7)), the cysts wall is dissolved in the stomach and the small
intestine, releasing bradyzoites152 which penetrate the small intestine epithelial cells;
between the brush border and the nucleus within the PVs where they commence T.
gondii development. The asexual developmental stages are labelled A to E (these
stages are separate from generations as each T. gondii type consists of several gen-
erations), labelling fives stages of differing morphologies. The sexual cycle does not
start until two days after tissue cyst ingestion and after 3 to 15 days, gamonts can
be found in the ileum and the small intestine. The oocyst wall forms to contain the
parasite whereupon the infected epithelial cells burst and the oocysts can then infect
the lumen of the intestine.149 The sexual stage involves several division stages start-
ing two days after ingestion of a tissue cyst.152 For 3 to 15 days after inoculation,
gamonts are present in the ileum and small intestine; microgametogenesis causes
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the microgamont to divide resulting in up to 21 nuclei (Figure 4.1(1)). This sexual
differentiation results in the formation of microgametes which swim and fertilise
the mature macrogametes by utilising their flagella, forming zygotes, whereafter the
oocyst wall is formed (Figure 4.1(2)). The zygotes move through the digestive tract
and are shed in faeces after rupturing from the enterocyte (Figure 4.1(3)). Sexual
reproduction generally occurs by self-fertilisation.
Cats, and other felidae, can become infected through all three infectious T. gondii
stages - tachyzoites, bradyzoites and sporozoites (found in oocysts) - which influ-
ences the rate of shedding. Oocysts and tachyzoite ingestion only lead to shedding
50% of the time whereas tissue cyst ingestion results in shedding in nearly all cats.
The time between initial infection and shedding, the pre-patent period, depends on
the T. gondii stage ingested; this period is between 3 to 10 days for tissue cysts but
can take up to 18 days after ingestion of oocysts.149 If this time period is 11 to 17
days, the ingested form is believed to be at a transitional stage somewhere between
tachyzoites and bradyzoites.148 Dubey et al 149 also provides evidence for bradyzoites
being capable of early (after three days) development during infection (observed in
cell cultures not containing any antibodies) and that conversion directly between
oocysts and bradyzoites can occur.149, 152
The only hosts excreting oocysts, the only stage that is environmentally sta-
ble, are felidae, making them the definitive host for T. gondii.160 Oocysts isolated
from cat faeces can be stored in normal tap water for one year and still cause tox-
oplasmosis in mice, in contrast to tachyzoites and bradyzoites that are killed upon
contact with water.149 They can survive storage at temperatures of 4 ◦C for up to a
year and a half, but are killed above 60 ◦C, can survive at −21 ◦C for 28 days160 or
−10 ◦C for at least 106 days under laboratory conditions.150 Oocysts have proved
to be resistant to disinfectants due to their impermeable outer shell. The fact that
oocysts are so resilient against environmental factors makes them almost impossible
to eradicate.150, 152
4.1.3 Infection routes of T. gondii
4.1.3.1 Transmission of T. gondii to animals
As mentioned above, cats are the definitive hosts of the T. gondii parasite as
they are the only host that shed oocysts149 which have the ability to survive in the
environment under harsh conditions.140 Cats can be infected via both vertical and
horizontal transmission.150 Ingestion of a single tissue cysts or bradyzoite can lead
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to a cat shedding millions of sporulated oocysts in a time-period that only tends
to last 1 - 2 weeks. It has been estimated that 1% of the cat population is usually
shedding at one time.140 Infection of felidae can also occur through ingestion of
oocysts. Several hundred sporulated oocysts are required to infect a cat as they are
fairly non-pathogenic,150 whereas other animals such as pigs, mice and sheep can
get infected by ingestion of a single oocyst.149 In these intermediate hosts, a few
oocysts can be lethal. Some species are remarkably resistant, for example, ingestion
of 100 bradyzoites will not infect a mouse.
The reason contamination is so widespread in a population is due to the number
of shed oocysts and their ability to survive in the environment. Domestic cats and
other felidae members shed oocysts which are further spread by invertebrates such
as cockroaches, earthworms and flies from the soil and even larger animals. Black
bears, white-tailed deer and raccoons are all scavengers and thus a good indicator
for oocyst contamination in specific areas, whereas animals used for food can be
infected for years due to environmental contamination.140
The above examples show that nature is a ubiquitous reservoir for potential infec-
tions that can never be completely controlled or eradicated.
4.1.3.2 Transmission of T. gondii to humans
The most common transmission of T. gondii to humans occurs through contact
with domestic cats and cat faeces.140, 150
Foodborne toxoplasmosis is another route for human infection. These infections are
very common and are often associated with hospitalisations and death. Toxoplas-
mosis has been verified as the second most frequent foodborne disease in the USA
in 2012 and the fourth most frequent cause of hospitalisations linked to foodborne
illness, amounting to 327 deaths and 4428 hospitalisations per annum.160 The in-
gestion of T. gondii in food through tissue cysts in undercooked meat is a major
source for T. gondii infection and it has has been linked to clinical toxoplasmosis.
Ingestion of tissue cysts is a common transmission route to humans through inges-
tion of raw or undercooked meat. T. gondii infections are strongly affected by the
cultural habits for eating raw meat and drinking unpasteurised goat milk. Thus the
range of infections depend on geographical location with significantly more people
infected in countries like France, where it is more common to eat raw, dried or cured
meat compared to in the UK.140, 150, 160 Ingestion of raw fruit and vegetables that
have not been properly washed can cause T. gondii infection. Interestingly organic
food has a higher chance of causing infection as the environment is not controlled
and secured against oocyst contamination. For example, studies show that no pigs
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were seropositive if kept indoors. Outdoors, free-range pigs showed that 2.9% of
the ones in the study were seropositive. Infection can occur in chicken but chicken
meat is often chilled or injected with enhancing solutions which mostly kills tissue
cysts. Undercooked sheep-meat poses a high risk and goats-cheese from raw milk
could be a contributor to toxoplasmosis. Horse meat has been the cause of severe
human toxoplasmosis, especially in France.161
A third route of infection with T. gondii is via blood transfusion and organ trans-
plant. During the latter, this can either occur through transplant from an infected
donor of bone marrow or an organ into an immuno-compromised patient without
immunity or be triggered in an immuno-compromised recipient patient with a la-
tent infection. Drugs administered to lessen chances of rejection, often used in organ
transplants, are both immunosuppressive and cytotoxic and can therefore trigger in-
duction of the disease.
Generally, humans infected with oocysts as opposed to the other T. gondii life cy-
cle stages display more intense symptoms and generalised disease, suggesting that
oocyst may be more pathogenic.149 Infection by tachyzoites is less important for
humans,150 however it is impossible to determine which of the other two routes
is most prevalent. Due to the numerous infection routes, control of and complete
eradication of infection with T. gondii is difficult.
4.1.4 Cell invasion by T. gondii
For cell invasion to occur, contact between the host cell outer membrane, con-
taining a negative surface charge, and the parasite cell (tachyzoites; this is linked
to step 5 in Figure 4.1) surface, also negatively charged, must occur.145 Despite the
parasite’s ability to infect a wide range of animals, the mechanism for invasion is
still not characterised. It is however believed to be due to a machinery associated
with a host receptor, by insertion of the parasite receptor into the host cell mem-
brane or by utilising one or more host cell receptors. The invasion consists of several
steps starting with establishing physical contact between the host and the parasite
(regulated by antigens on the parasite surface). The surface of T. gondii contains
many proteins,145 most of which are members of a family related to SAG1, a surface
antigen, and seem to be involved in initial contact and attachment to the surface of
the host cell. This step is followed by attachment occuring due to release of adhesin
proteins released by certain secretory organelles called micronemes,146 parasite glid-
ing motility (this movement is acto-myosin dependent) on the host cell surface and
penetration. The penetration is believed to be enabled by proteins known as rhop-
tries which are secreted by a secondary organelle; RON2, RON4, RON5 and RON8
135
are in a pre-formed complex which binds to the microneme protein, AMA1, to make
up the moving junction complex. This junction becomes the opening to the host
cell plasma membrane for the parasite. A parasitophorous vacuole is formed around
the parasite where it stays whilst within the host. For tachyzoites, the microtubule
cytoskeleton of the host functions by enabling cargo transport into the host cell
from its periphery and movement of the rhoptry proteins which are secreted into
the host.146 It was found that by disrupting the microtubules, invasion levels are
reduced if this happens soon after parasite stimulation but not if this happens at
later times after invasion.
4.1.5 T. gondii infection
4.1.5.1 Infection in humans
Toxoplasmosis can occur in many different ways as described above. When
acquired postnatally, the most common symptoms are swollen lymph nodes and
occassionally flu-like symptoms (muscle aches, tiredness, sore throat, fever and
headaches); this does not pose a threat to healthy humans but diagnosis is vital
for pregnant women for the sake of the fetus.140 The most dangerous infection, con-
genital toxoplasmosis, occurs when a pregnant women becomes infected. The most
dangerous infections occur during the first trimester of the pregnancy and the ef-
fects on the fetus are more serious than if infection occurs during the second or
third trimester. In most cases the infection hardly affects the pregnant woman, but
the parasite within her can have devastating effect on the fetus. The starting point
is a general infection, which localises in the CNS.140 Symptoms vary across a spec-
trum and the manifestations vary greatly, although ocular disease frequently occurs.
Mild symptoms include minor eye problems such as a decline in vision. The scale
ranges to very severe problems such as retinochoroiditis, intracerebral calcification,
convulsions and hydrocephalus (a build-up of fluid on the brain occurs, the least
common effect).140 Testing of all pregnant women for T. gondii infection is routine
in some European countries, including France, Denmark, Norway, Belgium, Italy
and Austria.161 The cost-benefit of such mass screening is being debated in many
other countries however, it can be beneficial to the fetus as drugs can be adminis-
tered (section 4.1.5.4) to counteract potential effects.
Immuno-compromised people infected with T. gondii generally develop en-
cephalitis. Often, patients undergoing treatment where immunosuppresive agents
are administered, are likely to be infected with T. gondii. Symptoms of infection
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are convulsions, drowsiness, headaches, disorientation, amongst others and many
patients can become comatose. Toxoplasmosis can often be fatal to AIDS patients
and even though any organ can become infected, the brain is the most commonly
infected organ.140 The majority of AIDS patients, simultaneously suffering from tox-
oplasmosis often experience persistent and acute headaches that can not be treated
efficiently with analgesics. Headaches are usually replaced by lethargy, confusion,
ataxia or even coma, during more advanced stages of toxoplasmosis. Brain lesions
occur where the most predominant is necrosis.
4.1.5.2 Behavioural effect of T. gondii infection
Over the last decades there have been a number of reports indicating specific
behavioural effects of T. gondii infections. For example, a recent study162 of elec-
tronic health records found a link between cat bites and diagnosed depression in
patients where 41.3% of patients admitted to hospital for treatment of cat bites also
suffered from depression. Cat bites are not necessarily linked to T. gondii trans-
mission but shedding is, thus cat owners are more likely to be infected with the
parasite. Interestingly, the parasite has also been linked to several disorders such as
obsessive compulsive disorder (OCD) and schizophrenia amongst others. Changes
in personality have also been linked to infection and prenatal depression. T. gondii
cysts are predominantly located in neural tissues, leading to the belief that it is
perfectly placed to utilise its ability to thereby alter host behaviour. However, the
fact that more patients with cat bites displayed signs of depression may just be an
indicator of different personality types having a specific preference for pets. Whilst
this is not conclusive evidence for depression being linked to cat ownership, it is
interesting when considering existing studies of T. gondii and psychiatric disorders.
A study on infected mice showed they had higher activity levels and spent
more time exploring unknown, more open areas, than the healthy mouse counter-
parts, leading to the conclusion that infected mice behave differently in unknown
situations than uninfected ones. Studies on rats have shown that even though learn-
ing abilities may be decreased in infected individuals, it was not as pronounced as for
infected mice; this was linked to the higher infection rates found in the mouse brains
during latent toxoplasmosis.163 Mice were also found to have higher mortality rates
during acute infection. Due to the better health of rats, they were chosen as better
models for infection. Rats are neophobic and their response to a novel situation is
avoidance; a comparative study of infected and uninfected rats (both wild and lab-
oratory rats) exposed to novel stimuli was conducted. T. gondii infected rats were
less neophobic than uninfected rats. Further studies were made to determine the
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effect of infection on the rats’ recognition of the danger of cats. Rats tend to have
a strong aversion to cat odour but infected rats, rather than avoiding cat-scented
areas, were partial to areas with cat odour. This unnatural behaviour could, in
nature, lead to higher risk for predation by cats, and thus a continued proliferation
of the parasite.
This hypothesis has however been disputed by some A. R. Worth et al 164 who sug-
gested that the interpretation of these findings was inaccurate. They argue that
the parasite may not necessarily need to undergo the sexual cycle and that the
evidence seen for enhanced predation caused by behavioural alterations is not con-
sistent across all studies on the subject matter. Studies on the parasite Eimeria
vermiformis have shown similar behavioural changes in infected mice, even though
the parasite does not need the predatory stage for life cycle completion, suggesting
that the behavioural change observed for T. gondii is not necessary for parasitic
survival. The relative fearlessness is believed to be a side effect that has arisen due
to an overall reduction of neophobia. This theory is still questioned by scientists.
In summary there is some evidence that infection with T. gondii can affect host
behaviour, but more studies are clearly needed.
4.1.5.3 Socio-economic costs of T. gondii infection linked to agriculture
Various sources of infection exist on farms such as cats that shed oocysts which
contaminate water and soil that the animals are in contact with as well as consump-
tion of animal tissues, including birds and rodents, by pigs.141, 160 The incentives for
avoiding animal infection are high and involve excellent farm management to keep
infection pathways blocked by better cat and especially rodent control. There are
also large economic costs associated with livestock infections by T. gondii and 1.5
- 2 million animal deaths a year could be avoided (associated with sheep and goat
miscarriages).147
A study of migrant agricultural workers in Mexico indicated that the seropreva-
lence of anti-Toxoplasma IgG and IgM antibodies, was higher in workers living in
rural areas compared to more urban locations. Poor workers were more likely to
be infected with T. gondii, as their living conditions including clean water supply,
sanitation conditions and healthcare services were substandard.165 Although most
healthy adults are not affected by toxoplasmosis, some display symptomatic toxo-
plasmosis such as dizziness, memory problems and reflex impairment, which are all
contributing factors to lowered performance at work as well as related accidents.
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4.1.5.4 Diagnosis, treatment and prevention of toxoplasmosis
Infection with T. gondii can be reliably diagnosed using various methods;
the most common ones are the Sabin-Feldman dye test (a very sensitive serologic
method), the direct agglutination test (DAT) (for serological diagnosis) and the
detection of IgM antibodies (for detection of congenital toxoplasmosis).148 Other
examples include an indirect hemagglutination assay and an indirect fluorescent an-
tibody (IFA) assay. However, no tests are available yet that can distinguish which
infection route the host was infected through.140
Treatment of toxoplasmosis in humans has been treated with sulfonamides such as
sulfadiazine.140
Pyrimethamine and spiramycin (Figure 4.3) has been utilised for pregnant women
to lessen the transmission to the fetus, as these compounds are known not to cross
the placenta.148, 166
(a) (b)
(c)
(d)
Figure 4.3: Structures of existing drugs used against toxoplasmosis. (a) Sulfonamide;
(b) Sulfadiazine; (c) Pyrimethamine and d) Spiramycin.
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Successful vaccinations have so far only been developed for some animals. An-
imals infected with T. gondii develop immunity against further infection, so the
vaccinations currently available are live vaccines.147 One example of a vaccine pro-
tecting against sheep and goat congenital toxoplasmosis and abortion for up to 18
months is the S48 strain Toxovax R© vaccine. The strain utilised is unable to dif-
ferentiate into bradyzoites which disables it from establishing a persistent infection
in the host. Moreover, the sexual life cycle which usually takes place in cats, can
not be initialised thereby shutting down the oocyst production route. Another oral
live vaccine has been developed to prevent oocyst shedding by cats, however the
downside of this vaccinations is the short shelf life and high cost associated with
it.160
4.1.6 T. gondii drug targets
Apicomplexa are a type of pathogen which cause a wide range of diseases that
are usually difficult to treat. They are commonly treated with chemotherapy, how-
ever new drugs targeting pathways in the parasites’ metabolism such as the digestion
of haemoglobin and the fatty-acid biosynthetic pathway, are emerging.4 Often, the
drug may only work against a specific parasitic life stage, complicating treatment.
Another problem that presents itself is the emergence of drug resistance leading to
a constant need for new drugs, treatments and drug targets.
Drug treatment of intracellular eukaryotic pathogens is challenging due to the patho-
gen placement coupled with the similarity between pathogen and host biology.167
Parasitic drug targets usually consist of a specific function or component which,
when inhibited, will either be lethal to the parasite or will impair its ability to
function and cause infection. The target is usually a metabolic pathway, a dynamic
process or a specific enzyme which does not exist within the host or differs enough to
ensure that the drug will not affect the host adversely. Certain lipids are present in
apicomplexa which are not found in the mammalian hosts making the apicomplexan
lipid synthetic pathway a viable drug target.
The sphingolipid synthetic pathway of T. gondii differs sufficiently from that of the
host to make it an attractive drug target.4
4.1.6.1 Sphingolipids in T. gondii
De novo sphingolipid synthesis occurs in many organisms but was reported for
T. gondii tachyzoites by Azzouz et al,168 who described de novo glycosphingolipid
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synthesis by labelling the parasites with tritiated serine and galactose. As described
in (section 1.1.2.2), de novo sphingolipid biosynthesis commences with the condensa-
tion between L-serine and palmitoyl-CoA to form 3-ketodihydrosphingosine (KDS),
catalysed by the enzyme serine palmitoyltransferase (SPT) - a step common to all
species.
More than 20 different types of sphingolipids, with both saturated and unsaturated
fatty acids, can be found in T. gondii. It contains higher levels of sphingolipids with
phosphate, with ceramide phosphoethanolamine being the most frequent one, how-
ever levels of sphingomyelin are low, all relative to the usual levels in mammalian
cells. T. gondii also differs from mammalian cells in that the levels of free ceramides
are higher, especially mono-, di- and trihexosylceramides. In order to survive and
proliferate, apicomplexan parasites rely on complex lipid metabolic pathways, many
of which have been identified as ideal drug targets.
Intracellular parasites can utilise a second route for sphingolipid biosynthesis,
namely scavenging from the host cell to acquire lipids which are then employed
to form the parasitophorous vacuole membrane usually constructed during invasion
of host cells from components synthesised by the parasite or obtained from the
host.24, 169 , 170, 171
Aureobasidin A is an antibiotic172 which, without affecting changes to the
host cell, inhibits complex sphingolipid synthesis and thus reduces the parasite’s
replication process, however the specific target has not been identified. 1-phenyl-
2-palmitoylamino-3-morpholino-1-propanol (PPMP) and L-cycloserine (LCS) also
reduce parasitic levels of ceramide synthesis.
6In plants, yeast and certain protozoa, the equivalent is inositol phosphorylceramide
(IPC) produced via IPC synthase as the evolutionary equivalent.173 This latter en-
zyme is not present in mammalian cells and has thus been the focus of drug targeting,
both as anti-protozoals as well as anti-fungals.
4.1.7 Serine palmitoyltransferase, SPT
Serine palmitoyltransferase belongs to the PLP (pyridoxal-5-phosphate) (Fig-
ure 4.4) dependent superfamily enzymes, including the small family of α-oxoamine
synthases (AOS).50 The enzymes belonging to the AOSs catalyse the condensation
reaction between acyl-CoA thioester substrates and particular amino acids, releas-
ing CO2 and forming an α-oxoamine.
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Figure 4.4: Schematic of pyridoxal-5-phosphate, PLP.
Eukaryotic SPT exists as a heterodimer consisting of long chain base 1 and
2 (LCB1 and LCB2),174, 175 which are heterologous subunit monomers. They are
commonly referred to as SPT1 and SPT2 and are both vital for functional activity
of the heterodimeric SPT.50 A third SPT gene has been identified which codes for
SPT350, 176 Mammalian SPT forms a heterodimer of either SPT1-SPT2 or SPT1-
SPT3. The two subunits are membrane-associated making characterisation and
crystallisation a challenging task. The monomers are structurally very similar but
their functionality differs significantly. Both SPT2 and SPT3 subunits contain a
lysine residue in the active site which is required for binding PLP by forming a
Schiff base.176 SPT1 does not contain the conserved lysine residue as well as other
important conserved residues, but instead of a catalytic role it is believed to possess
a regulatory role within the SPT dimer. However, a single site mutation within
a conserved region of SPT1, of a cysteine and a valine, leads to the SPT activity
being down-regulated. This has been linked to hereditary sensory and autonomic
neuropathy type I (HSAN1), which causes nerve abnormalities.
SPT is an important enzyme in the sphingolipid synthetic pathway as it catal-
yses the first and rate-limiting step for the pathway in all the organisms studied to
date. 3-ketodihydrosphingosine (KDS) is sphingolipid precursor product of a decar-
boxylative Claisen condensation of L-serine and palmitoyl-CoA (a 16 carbon chain
fatty acid). The overall reaction is shown schematically in Figure 4.5 below and
described in further detail in section 4.1.8.
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Figure 4.5: The condensation reaction catalysed by SPT.
The condensation reaction between L-serine and palmitoyl-CoA is generally
used as a standard experiment to verify SPT activity (section 4.2.7).
4.1.7.1 PLP-binding site in SPT
Due to the eukaryotic SPT containing two membrane-associated monomers,
isolation of the protein has been challenging, making mechanistic studies difficult.
Despite the challenges posed for isolating eukaryotic SPT, small quantities have
been purified from yeast and from mammalian cells. Prokaryotic SPT, on the other
hand, is soluble and most mechanistic information has therefore been obtained from
studies of prokaryotic SPTs. Furthermore, the active site residues are conserved
from the bacterial SPTs in SPT2 and SPT3.177 Recently, the structures of SPT
from S. paucimobilis 50 and S. multivorum,176 both homodimers, have been solved
and the active site and PLP-binding residues have been identified. For SpSPT the
active site has been determined in the external aldimine form50 and for SmSPT,
the L-serine complexed form has been determined.176 The difference between the
two structures is the active site lysine residue (Lys244), which with the L-serine
forms an external aldimine, in the SmSPT structure. All other active site residues
overlap almost perfectly.176 The active site asparagine residue (Asn52) is conserved
in several POAS members.
The T. gondii SPT is evolutionarily closer to the bacterial SPTs (P. W. Denny, per-
sonal communication) and hence, it has been hypothesized to exist as a homodimer
as opposed to its eukaryotic homologues.
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In the SmSPT 176 structure the active site consists of resides from both monomers,
creating a binding pocket for the substrate. The pockets are linked to the surface
via long hydrophobic channels usually occupied by the long chain fatty acid part
of the substrates. In the active site, the Lys244 side chain is not linked covalently
to the PLP but points away from it and forms hydrogen bonds with Ser243 and
Thr241 instead. The PLP pyridinium ring is stabilised by the hydrophobic interac-
tions occurring due to the pi stacking with the His138 and the Ala212. The His138
imidazole ring is positioned at the PLP re face. N1 in PLP is positively charged
and therefore forms a hydrogen bond with the Asp210 side chain. Several hydro-
gen bond interactions occur between a PLP oxygen atom and His213 which then
interacts with the hydroxyl group of Tyr54. The phosphate head group of PLP is
stabilised by polar interactions with the residues of the active site. These include
the Phe114 and the Ala274* N atoms as well as the Ser243 and the Ser273* side
chains (where * denotes residues located on the other monomer). The PLP phos-
phate group forms hydrogen bonds with the L-serine hydroxyl group which forms
an interaction with Ser243 via a water molecule. It also interacts indirectly with
other residues through water molecules and it is tilted 80 ◦ against the pyridinium
ring of PLP due to His138 interactions. This is shown in Figure 4.6.
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Figure 4.6: Schematic of the active site in SmSPT showing the hydrogen bond net-
work, the external aldimine between PLP and L-serine and the active site residues.
Water molecules are included. Residues denoted with a * are situated on the second
monomer. Schematic made in Chemdraw Std. 13.0 based on Figure 5 C from H.
Ikushiro et al.176
In the crystal structure of SpSPT50 PLP is bound at the active site. It forms an
internal aldimine, also known as a Schiff base, with the active site lysine (Lys265).
The side chains of Asn138, Asp231, His234 and Thr262 as well as the Gly134 and
the Tyr135 main chains form polar contacts with the cofactor. The His159 imidazole
ring stacks with the PLP pyridinium ring. The histidine is part of a three residue
conserved motif, in this case His159, Ala160 and Ser161, which is conserved in the
AOS family.
It is clear from Figure 4.6 that the PLP cofactor is bound by several residues in
the active site which are vital for the catalysis reaction to occur. Sequence homology
studies of SPTs from various organisms clearly show that these residues are highly
conserved in the SPTs,178 even though the binding sites may differ depending on
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the surrounding enzyme.
4.1.8 The mechanism of action of SPT
The reaction mechanism of SPT is shown in a simplified schematic representa-
tion in Figure 4.7.
Figure 4.7: The SPT reaction mechanism. Drawn based on scheme 1 from Y.
Shiraiwa et al.179
The PLP forms an internal aldimine at the active site lysine (Figure 4.7, I)
which undergoes a transaldimination reaction upon addition of L-serine. This re-
sults in the PLP-L-serine aldimine, the external aldimine (II) which releases PLP
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from the lysine. The external aldimine is held in the active site by polar interactions
and salt bridges. The re face of the PLP molecule is stabilised by the conserved
histidine residue which also interacts with the serine carboxyl group, which in turn
prevents unwanted side reactions from occurring. This is due to the Cα-H bond
with the serine being forced into an almost planar orientation in relation to the
PLP pyridinium ring, which does not favour dissociation. Palmitoyl-CoA enters the
hydrophobic pocket where the histidine interactions with the carboxylate are inter-
rupted. A hydrogen bond is formed between the histidine and the acyl carbonyl O
(the thioester O).180 The L-serine carboxyl group interacts with the arginine residue
which allows for the Cα-H bond to move into a more favourable, perpendicular posi-
tion relative to the PLP pyridinium ring. This allows for α-deprotonation resulting
in the formation of a quinoid intermediate (III). A Claisen-type condensation oc-
curs as the palmitoyl-CoA is attacked by the Cα carbanion where the histidine
residue and the fatty thioester act as an acid catalyst. This generates an interme-
diate (IV) whereupon the acyl-serine conjugate is decarboxylated to form a second
quinoid intermediate (V). The second quinoid Cα is protonated resulting in the
PLP-KDS external aldimine (VI), which releases KDS to regenerate the original
internal aldimine (I).
4.1.8.1 SPT inhibition
A number of SPT inhibitors have been identified.181 The two cycloserine enan-
tiomers are irreversible inhibitors of a lot of PLP-dependent transaminases,182 as
they are cyclic serine/alanine analogues. D-cycloserine (DCS) is a naturally occur-
ring compound (found in Streptomyces bacteria) whereas L-cycloserine (LCS) is a
synthetic compound (both shown in Figure 4.8). The former is often employed in
combination therapy for tuberculosis infections but only as a second-line drug as it
has severe side effects. Cyclo-serine acts in an irreversible manner due to its ability
to form an adduct with PLP in the the various AOS enzymes which utilise PLP as
cofactor. Experiments by J. Lowther et al 182 have shown that 79% and 83% of the
original activity of DCS and LCS treated enzyme respectively, can be restored when
dialysing inhibited SPT against a buffer containing 25 µM PLP, clearly showing that
these compounds bind to the PLP cofactor but do not otherwise affect the enzymes.
The compounds undergo an aromatisation mechanism whereby the PLP cofactor
in a holo-enzyme forms an external aldimine with the cycloserine. The aldimine
is deprotonated resulting in 3-hydroxyisoxazole-PMP adduct which is stable. This
reaction occurs faster with DCS than LCS, which may be the reason why the former
functions better as an antibiotic.
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The most commonly employed inhibitor of SPT activity, however, is myriocin (also
known as ISP-1 and thermozymocidin ((2S,3R,4R,6E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-
14-oxo-6-eicosenoic acid) (Figure 4.8).183
(a) (b)
(c)
Figure 4.8: Schematic of (a) D-cycloserine; (b) L-cycloserine and (c) myriocin.
It is a natural product which has been isolated from Mycelia sterilia and Myri-
ococcum albomyces ;184 it has been used as an antibiotic and as an antifungal agent.
Myriocin is a sphingosine analogue and its inhibition of SPT has been shown to
be non-competitive.183 It is the only commercially available SPT inhibitor resem-
bling sphingosine.185 Inhibition of SPT with myriocin is generally thought to be
non-competitive however L-serine binding to SmSPT can be competitively inhib-
ited with myriocin. Myriocin has a higher affinity than LCS and binds tightly as
the chain is believed to interact with the site for palmitoyl-CoA binding. Myriocin
is analogous to KDS with the differences of keto groups, the reduction of the β-keto
group, a hydroxyl and an unsaturated bond which is situated at the aliphatic side
chain.185
SpSPT was employed as the model enzyme to elucidate the mechanism of in-
hibition of SPT by myriocin. J. M. Wadsworth et al 184 suggest that myriocin acts
as a compound possessing dual mode inhibition of SPT.
Myriocin binds by forming an external aldimine with SPT containing a PLP co-
factor (holo-SPT) (confirmed by mass spectrometry and spectroscopy experiments).
Full inhibition of SPT was not recorded and is believed to be due to myriocin being
very insoluble and so high enough concentrations to saturate the binding site can
not be reached (although this is believed to be linked to the in vitro nature of the
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experiments). PLP usually forms a Schiff base external aldimine with the myriocin
molecule and normal SPT activity can be re-established with addition of PLP. How-
ever, if myriocin is incubated with the holo-SPT enzyme for a longer time-period,
this is no longer reversible. Experiments have identified the conserved active site
lysine as being crucial to the breakdown mechanism which can occur where the
external aldimine is transformed into a C18 imine adduct of this specific residue
(via a retro-aldol degradation resulting in a C18 aldehyde), causing the inhibition
to become irreversible.
Crystal structure determination has revealed that myriocin is decarboxylated result-
ing in a PLP-decarboxymyriocin aldimine.
4.1.9 Chapter objectives
The project objectives were to determine the smallest catalytically active do-
main of SPT1 from T. gondii, achieved via different constructs. 48 constructs of
various sizes and in different expression systems of TgSPT were designed in order
to optimise expression levels of the protein whilst also spanning a wide size range
in order to identify the catalytic ability of the enzyme. The focus of the project
was to express, purify and characterise the most promising constructs with the ulti-
mate aim being crystallisation of one or more of them. After optimising expression
and purification, the nature of the enzymes was determined using mass spectrom-
etry and protein folding was investigated using CD spectroscopy. Bio-SAXS was
employed to estimate the approximate size of the various constructs. Enzymatic
activity was determined using a well-established assay utilising [C14]-labelled serine
and palmitoyl-CoA. Finally, various conditions of pH, buffer systems and salts were
tested with using a thermal stability assay followed by crystallisation trials.
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4.2 Results - Identification and characterisation
of the putative SPT from T. gondii
This section describes the work towards a crystal structure determination of
SPT from T. gondii ; from cloning and expression to a detailed biochemical and
biophysical characterisation of the protein.
4.2.1 Bioinformatical analysis of the predicted spt gene
In order to identify the conserved catalytic domain of the T. gondii SPT, the
full-length sequence was analysed using a range of available bioinformatical tools. A
sequence comparison using BLAST186 (Basic Local Alignment Search Tool) revealed
that the protein consists of three distinct domains. These are a transmembrane heli-
cal domain, a pyridoxal-5’-phosphate binding pocket (an aminotransferase domain)
and a functional domain containing the active site.
The 47 amino acids at the N-terminus contain a transmembrane helix as identified
with TMbase.187 This helix is presumably responsible for anchoring the enzyme in
the membrane. Residues 48 - 181 are not well characterised but have been identified
as mainly helical using secondary structure prediction algorithms such as JPred3.188
This part of the sequence shows no significant identity with any other functionally
characterised sequence. The remaining residues 181 - 571 show significant sequence
identity with a wide range of PLP dependent amino transferases.
Based on our sequence analysis shorter constructs were chosen to improve expres-
sion and prioritised in order to identify the shortest functionally active domain. The
different starting points for the four constructs discussed in this chapter (Table 4.1)
were based on the secondary structure predictions which indicated a number of he-
lices. Each starting point was hence chosen to be in the random coil regions between
predicted helix regions.
4.2.2 Homology modelling of the TgSPT structure
TgSPT shares between 20 and 30% sequence identity with a number of bac-
terial orthologues, some of which have been structurally characterised by X-ray
crystallography.50, 176 TgSPT and SmSPT (pdb entry 3A2B),176 the closest ortho-
logue, share a 27.8% (score given in ClustalW)189 identity. A sequence alignment
of the two homologues was constructed in ClustalW.189 The sequence alignment
was utilised to generate a homology model of the 3D structure of TgSPT based on
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the already known one of SmSPT176 using the MODELLER software190 (available
on http://salilab.org/modeller/). The SmSPT monomer was used as a template to
model the TgSPT as a monomer without the N-terminal residues (SmSPT consists
of 399 amino acids compared to TgSPT consisting of 571 amino acids).
A dimer was generated in Coot191 based on the known crystal structure and a PLP
molecule was added to each monomer at the modelled active site.
PLP was built into the structural model in Coot191 where distances to the sur-
rounding residues were characterised in order to verify that the predicted residues
(determined through sequence alignment) were in the correct conformation for hy-
drogen bonding to occur with the PLP molecule. The full sequence of both SPTs
is shown aligned with the secondary structural elements of SmSPT overlaid in Fig-
ure 4.9. It is clear that the N-terminal domain of TgSPT can not be modelled as
conserved residues between the two sequences are further toward the C-terminal end
of TgSPT. The functionally active domain and the C-terminal domain show how
well conserved the residues are.
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Figure 4.9: Sequence alignment of the full TgSPT and SmSPT sequences made
in ClustalW189 and ESPript 3121 (available at http://espript.ibcp.fr) with overlying
secondary structural elements based on the crystal structure of SmSPT.176 Residues
enclosed in a red block are identical, residues enclosed in blue frames with red letters
are of similar type and the rest have a low identity score. α denotes α-helices, β
denotes β-sheets, TT denotes strict β-turns and η denotes 310-helices.
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The 3D structural model was generated for the conserved catalytic domain of
TgSPT (residues 156 to 563). In Figure 4.10, the structure of the homology model
monomer containing a PLP molecule in the binding site is shown. The fold is mainly
α-helical with a binding cleft for substrate binding.
Figure 4.10: Overall structure of the homology model of TgSPT as a holo-monomer
with PLP bound in the active site. The PLP cofactor is shown as a grey stick
model. The monomer is coloured with the central catalytic domain (residues 215 -
449) shown in pale green and the N-terminal domain and an α/β structure which
contains a six-stranded β-sheet twisted in a spiral manner surrounded by three α-
helices (residues 156 - 178, 178 - 214 and 450 - 548) in dark green. Figure was
prepared using PyMOL.192
The monomer consists of three domains (only two are shown in the Figure 4.10
as the N-terminal has not been modelled). However, in the SmSPT monomer the
first 23 residues make up the N-terminal domain (equivalent to residue number 178
for TgSPT) which contains two small α-helices. The residues from 24 to 59 (179 -
214 in TgSPT) and 295 to 393 (450 - 548 in TgSPT) make up two small parts of the
sequence which form a small domain; the structure is an α/β structure containing
a six-stranded β-sheet which is twisted in a spiral manner, and surrounded by three
α-helices from the small domain outer surface side. The remaining residues make up
the largest domain which assumes an α/β structure where a seven-stranded β-sheet
and ten α-helices are twisted to form a large and open structure. The β-sheet is a
characteristic of the PLP-enzymes belonging to the type I fold; six of the strands are
parallel (strands number 3, 8, 7, 6, 4 and 5) with β9 being anti-parallel, positioned
between β3 and β8.176
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PLP was built into the homology model and a close-up of the resulting pre-
dicted PLP binding site is shown below in Figure 4.11.
Figure 4.11: Close up of the active site of the homology model of TgSPT with PLP
bound in the active site. The PLP cofactor is shown as a grey stick model. The
N-terminal and central catalytic domain are shown in pale green and the active
site residues involved in binding the PLP cofactor are shown in teal and labelled.
Relevant hydrogen bonds are shown with distances measured in A˚. Residues Tyr209
and Ser399 as well as Ser429* and Ala430* have been omitted for clarity. * Denote
the residues located on the other monomer. Figure was prepared using PyMOL.192
Figure 4.11 shows that the residues, Gly268, Phe269, His293, Lys400, Asp366
and His369 are all forming hydrogen bonds with the PLP molecule contained in the
active site. The active site lysine, residue number 400, is also conserved for TgSPT.
The active site residues are positioned near the end of the β-sheet consisting of
seven strands.176 The PLP cofactor is positioned in the active site but is held in
place by hydrogen bonds and hydrophobic interactions. Also, there is no covalent
bond between the cofactor and the active site lysine (evidence from electron density
for SmSPT). The Lys400 side chain is not directed towards the C4 of PLP.
The PLP pyridinium ring is sandwiched between the His293 side chain and the
Ala368 side chain stabilised by hydrophobic interactions and a hydrogen bond with
Asp366 side chain to the N atom which has a δ+ charge. The His293 imidazole ring
lies parallel to the PLP pyridinium ring enabling the oxygen atom on the ring to
form a hydrogen bond with N2 on His369.
Meanwhile, the phosphate headgroup of PLP is connected to the active site residues
with polar interactions with the N atoms of the main chain in F269.
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The N-terminal domain contains the transmembrane helix responsible for membrane
anchoring plus a domain of unknown structure and function. Based on the homology
model this domain is not involved in the enzymatic reaction.
As the bacterial orthologues all function as homodimers a similar homodimer
was generated using Coot.191 As shown in Figure 4.12 the homology model clearly
allows a compact dimeric structure with residues from both subunits contributing
to the active site in the other subunit.
Figure 4.12: Homology model of the holo TgSPT dimer. One monomer is coloured
with the N-terminal and central catalytic domain in pale green and the C-terminal
domain in dark green. The second subunit is coloured similarly in brown and red.
The PLP cofactors are shown as grey spheres (with O atoms in red, N atoms in blue
and P atoms in orange). Figure was prepared using PyMOL.192
The homodimer shows the two monomers interacting in a manner in which the
active site is supplemented by residues from the opposite monomer resulting in better
binding of the substrates.176 The substrate binding pocket is located where the PLP
molecule binds; this is situated between the two monomers and residues from the
opposite monomer aid in securing the cofactor molecule in the opposing monomer.
Residues from both subunits complement the active site suggesting that the en-
zyme is active as a dimer with a surface interface of 4701.8 A˚2 (calculated using the
’Protein interfaces, surfaces and assemblies’ service PISA at the European Bioinfor-
matics Institute, available at http://www.ebi.ac.uk/pdbe/prot int/pistart.html).193
155
4.2.3 Cloning and small-scale expression trials at the OPPF
The initial cloning and small-scale expression experiments described in this
section were undertaken by I. R. Williamson at the OPPF. Based on the initial
results (Figure 4.14) the following four constructs (of the original 48) that showed
the highest expression levels of soluble protein were selected for further analysis
(Table 4.1).
Construct aaN aaC pOPIN Tag MW/ Plasmid
label vector kDa name
∆143 144 571 S3C N-His-SUMO3C 47.91 pSPT-E6
∆158 159 571 S3C N-His-SUMO3C 45.98 pSPT-F6
∆176 177 571 S3C N-His-SUMO3C 43.86 pSPT-G6
∆180 181 571 S3C N-His-SUMO3C 43.29 pSPT-H6
Table 4.1: Summary of the four SPT constructs, including construct label, N- and
C-terminal, pOPIN vector employed, construct size, molecular weight and plasmid
label. The molecular weight represents the proteins without the tags. The His6-
SUMO tag has a mass of 13213 Da. All proteins contain a 3C cleavage site.
These constructs were all expressed from a pOPINS3C vector and contain an
N-terminal His6-SUMO tag. The hexa-histidine part enables IMAC purification and
the SUMO (Small Ubiquitin-like Modifier) is mainly employed for solubility reasons.
Figure 4.13: Schematic diagram showing the full length TgSPT and the four con-
structs compared to the SmSPT. The light green (TgSPT) and dark green (SmSPT)
domains are the conserved domains of the SPTs and the orange (TgSPT) and pur-
ple (SmSPT) N-terminal domains which is membrane associated for TgSPT. The
numbers mark the relevant residue numbers.
Figure 4.13 shows a schematic representation of the constructs of TgSPT cho-
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sen for expression experiments compared to SmSPT. The constructs employed in
this chapter get sequentially shorter by removal of N-terminal residues. It is clear
from the diagram that the shorter constructs possess none of the membrane associ-
ated domain of TgSPT. Common to all constructs is the conserved domain which
resembles the bacterial orthologues.
Small-scale expression trials performed at the OPPF (similar strategy was em-
ployed for the PlcH constructs, see 2.2.10) were carried out using B834 and Rosetta
I (DE3)pLysS cells both using IPTG medium (IPTG induction) and Overnight
ExpressTM Instant TB medium (autoinduction). The induced cultures were cen-
trifuged and the supernatant analysed on a 12% SDS-PAGE gel. The results for
the constructs showing over-expression of soluble protein are shown in Figure 4.14
(partial results from data obtained at the OPPF by I. R. Williamson (I. Williamson,
M. Phil thesis, Durham University, 2012)).
(a) (b)
Figure 4.14: 12% SDS PAGE of 5 µL of resolved, purified protein (for constructs
SPT ∆143, SPT ∆158, SPT ∆176 and SPT ∆180). Proteins were expressed from
two E. coli strains; B834 (left side of gels) and Rosetta I (DE3)pLysS. Expression
was carried out using IPTG induction medium (a) and OvernightExpressTM Instant
TB autoinduction medium (b). Proteins were stained with Instant Blue (Expedeon)
dye and protein size was estimated relative to a Precision Plus ProteinTM Standard
(BioRad). These are extracts of figures of four gels obtained at the OPPF (I.
Williamson, M. Phil thesis, Durham University, 2012).
Figure 4.14 shows increased bands for the four SPT constructs ∆143, ∆158,
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∆176 and ∆180 from both B834 cells and Rosetta I (DE3)pLysS cells when induced
by IPTG as well as by autoinduction. More protein is expressed from Rosetta I
(DE3)pLysS cells and when using autoinduction rather than IPTG induction.
Based on the positive results achieved at the OPPF, these four constructs were put
forward to large-scale expression and purification described below in section 4.2.4.
4.2.4 Optimising protein expression of TgSPT
Large-scale expression of the constructs SPT ∆143, SPT ∆158, SPT ∆176 and
SPT ∆180 in Rosetta II (DE3)pLysS cells (Novagen) was carried out as described
in section 2.4.3. The pure proteins were analysed on a 12% SDS-PAGE gel as shown
in Figure 4.15.
Figure 4.15: 12% SDS PAGE of ∼25 µmol of resolved, purified, cleaved protein in
lanes labelled 1 - 4; SPT ∆143, SPT ∆158, SPT ∆176 and SPT ∆180 respectively.
Proteins were stained with Instant Blue (Expedeon) dye and protein size was es-
timated relative to a Spectra Multicolour Broad Range Protein Ladder (Thermo
Scientific).
The SDS-PAGE gel in Figure 4.15 shows large amounts of pure, cleaved protein
for constructs SPT ∆143, ∆158, ∆176 and ∆180; it is clear from the bands that the
proteins appear at the correct molecular mass (see Table 4.1) and that ∆143 is the
largest construct and ∆180 the shortest.
The gel is overloaded with protein but this provides useful information. Bands
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are present at twice the mass for each protein indicating that the SPT constructs
form homo-dimers. The pure protein had a distinct yellow colour which was noticed
during initial purifications, indicative of PLP being bound. Thus, PLP was added to
all purification buffers and sample brightness increased upon increased availability
of the PLP cofactor.
Although high expression levels were achieved, protein stability for the two shortest
constructs remained low (ie. storage at 4 ◦C overnight for further purification and
concentrating often resulted in protein precipitation by aggregation, especially for
SPT ∆180). The lane containing SPT ∆143 also reveals more impurities than the
other constructs. Typical yields were reported as 3 mg/L expression medium for
∆143, 32 mg/L expression medium for ∆158, 14 mg/L expression medium for ∆176
and 22 mg/L expression medium for ∆180. Sample purity was highest for the largest
constructs, SPT ∆143 and SPT ∆158.
In addition, samples of SPT ∆158 (45.98 kDa) and SPT ∆180 (43.29 kDa) were
applied to a native gel (section 2.5.7) to avoid denaturing the proteins and perform
a preliminary investigation into potential dimerisation.
Figure 4.16: Native gel of purifed, cleaved protein in lanes 1: SPT ∆158 and 2: SPT
∆180. Proteins were stained with Instant Blue (Expedeon) dye and protein size was
estimated relative to a Spectra Multicolour Broad Range Protein Ladder (Thermo
Scientific).
The native gel in Figure 4.16 shows no bands for SPT ∆158 and only shows
a single band at approximately 43 kDa for SPT ∆180. This suggests SPT ∆180
exists in a monomeric form under the conditions of the gel. SPT ∆158 may not
have entered the gel which could be a result of precipitation. The results for SPT
∆158 are inconclusive, thus more experimental data are needed.
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4.2.5 Protein mass spectrometry
The protein sample of SPT ∆158 was analysed by mass spectrometry (sec-
tion 2.6.2). The data are shown below in Figure 4.17. The accurate, calculated
mass of SPT ∆158 is 45980.8 Da (413 residues) and the M+ peak in the spectrum
collected on the QToF Premier is at 46132 Da ± 2, corresponding to a difference
in mass of 150.2 Da. The tag was cleaved off the protein employing the HRV 3C
protease (a cysteine protease) which recognises the specific cleavage site Leu-Glu-
Val-Leu-Phe-Gln*Gly-Pro, leaving a glycine and a proline residue at the N-terminal
of the protein. The two additional amino acids results in a total mass of 46134.9 Da,
which is within the experimental error of the [M+] peak. The 2×[M+] peak is found
at a mass of 92264 Da. This is a strong peak confirming the notion that TgSPT
does, at least partially, exist as a homo-dimer, as suggested by the bioinformatical
information and the Bio-SAXS experiments (section 4.2.5.1).
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The data shows unambiguously that the correct protein, SPT ∆158, is ex-
pressed and that there are no undesireable post-translational modifications such as
oxidations present in the protein. In addition, there is strong evidence that TgSPT
is expressed and purified as a homodimer. There is no evidence for binding of the
PLP cofactor, even though the yellow colour of pure protein strongly suggests that
the cofactor is bound. However as the protein is transformed to the gas phase, the
cofactor can easily be lost as it is not tightly bound.
4.2.5.1 Small angle X-ray scattering experiments
Small angle X-ray scattering experiments were performed in order to determine
the overall shape of the putative SPT homodimer. A representative plot of I *
s2 versus s (Kratky plot) and log(I) versus s (log-lin plot) are shown for the data
collected for SPT ∆158 at a concentration of 3.8 mg/mL are shown below in Fig-
ures 4.18 and 4.19 respectively. In the figures, I is the scattered intensity and s is
the momentum transfer.
Figure 4.18: Kratky plot of SPT ∆158 at 3.80 mg/mL showing I * s2 versus s (I is
the intensity, s is the momentum transfer). Figure generated in SASPLOT from the
ATSAS programme package.
The representative Kratky plot in Figure 4.18 of SPT ∆158 at 3.80 mg/mL has
a scattering profile which indicates that the protein is folded. This is verified by the
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decay profile, as the intensity usually decays as 1/s4 for folded proteins. A peak is
usually present at low angles in the Kratky plot for folded, globular proteins.194
Figure 4.19: SAXS curve of SPT ∆158 at 3.84 mg/mL showing log (I(s)) versus s (I
is the intensity, s is the momentum transfer). Figure generated in SASPLOT from
the ATSAS programme package.
Figure 4.19 shows the log of the intensity plotted versus s. The shape of the
curve fits with that expected for a folded protein in solution. At the very lowest
angles there is a dip in intensity and this data were not included in further data
analysis. The curves for all four SPT constructs were representative of homogeneous
protein samples. Further analysis provided the approximate MW.
The analysed Bio-SAXS data are shown in Tables 4.2, 4.3, 4.4 and 4.5 for SPT
∆143, SPT ∆158, SPT ∆176 and SPT ∆180 respectively. Porod volumes were
calculated in Primus from the ATSAS package and the Porod MW was calculated.
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Concentration/ mg mL−1 Porod Volume/ A˚−3 Porod MW/kDa Expected MW/kDA
1.50 209161 130.7 47.9
1.20 186516 116.6 47.9
0.75 198277 123.9 47.9
0.15 184332 115.2 47.9
1.50 181724 113.6 47.9
1.20 209570 131.0 47.9
0.75 188557 117.8 47.9
0.15 197805 123.6 47.9
Table 4.2: Experimental and analysed Bio-SAXS data showing the sample concen-
tration, the measured Porod volume, the estimated Porod molecular weight and the
expected molecular weight for SPT ∆143.
Table 4.2 shows the data for SPT ∆143. Despite the data being close to the
values expected for an SPT ∆143 dimer, the estimated values for the molecular
weight do not correlate well with the expected values and are not consistent between
measurements at different protein concentrations and different data collections. The
data may indicate that SPT ∆143 aggregates in solution causing the discrepancy
between the measured values and the predicted molecular weights.
Concentration/ mg mL−1 Porod Volume/ A˚−3 Porod MW/kDa Expected MW/kDA
4.80 145232 90.8 46.0
3.84 143570 89.7 46.0
2.40 137332 85.8 46.0
2.40 135714 84.8 46.0
4.80 141760 88.6 46.0
3.84 141862 88.7 46.0
2.40 136186 85.1 46.0
2.40 125169 78.2 46.0
Table 4.3: Experimental and analysed Bio-SAXS data showing the sample concen-
tration, the measured Porod volume, the estimated Porod molecular weight and the
expected molecular weight for SPT ∆158.
Table 4.3 shows the data for SPT ∆158. The numerical data shows excellent
correlation between the estimated molecular weight based on the SAXS data and the
expected molecular weight of the protein, especially at higher protein concentrations.
The data are consistent with SPT ∆158 forming homodimers in solution.
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Concentration/ mg mL−1 Porod Volume/ A˚−3 Porod MW/kDa Expected MW/kDA
4.60 137310 85.8 43.9
3.68 131613 82.3 43.9
2.30 125499 78.4 43.9
0.46 122996 76.9 43.9
4.60 132375 82.7 43.9
3.68 129764 81.1 43.9
2.30 125197 78.2 43.9
0.46 133333 83.3 43.9
Table 4.4: Experimental and analysed Bio-SAXS data showing the sample concen-
tration, the measured Porod volume, the estimated Porod molecular weight and the
expected molecular weight for SPT ∆176.
Table 4.4 shows the data for SPT ∆176. As for SPT ∆158, the numerical
data shows excellent correlation between the estimated molecular weight based on
the SAXS data and the expected molecular weight of the protein, especially at
higher protein concentrations. The data are consistent with SPT ∆176 forming
homodimers in solution.
Concentration/ mg mL−1 Porod Volume/ A˚−3 Porod MW/kDa Expected MW/kDA
2.16 112464 70.3 43.3
1.73 111622 69.8 43.3
1.08 111353 69.6 43.3
0.22 121630 76.0 43.3
2.16 112537 70.3 43.3
1.73 111390 69.6 43.3
1.08 113194 70.7 43.3
0.22 124426 77.8 43.3
Table 4.5: Experimental and analysed Bio-SAXS data showing the sample concen-
tration, the measured Porod volume, the estimated Porod molecular weight and the
expected molecular weight for SPT ∆180.
Table 4.5 shows the data for SPT ∆180. Despite the data being close to the val-
ues expected for an SPT ∆180 dimer, the estimated values for the molecular weight
do not correlate well with the expected values. They are not consistent between
measurements at different protein concentrations, especially lower protein concen-
trations. The data may indicate that SPT ∆180 is transient between a monomer
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and a homodimer in solution causing the discrepancy between the measured values
and the predicted molecular weights.
Overall, the data clearly indicate that the SPT ∆158 and ∆176 construct form
homodimers in solution. The two other constructs, SPT ∆143 and SPT ∆180,
probably also form homodimers, however, conditions may have caused them to either
aggregate or adapt a transient state between monomer and dimer in solution.
In order to reach a clear conclusion, further analysis needs to be performed to
calculate a molecular envelope in order to ascertain whether all the SPT constructs
form homodimers in solution.
4.2.6 CD spectroscopy on SPT constructs
In order to verify the correct folding of all protein constructs, CD spectra were
recorded as described in section 2.7.
The experimental, analysed spectra are shown in Figure 4.20.
Figure 4.20: Experimental CD data, molar circular dichroism, plotted against wave-
length (nm) for the three shortest SPT constructs; SPT ∆158, SPT ∆176 and SPT
∆180 (0.18 - 0.25 µM) measured at 21 ◦C.
Figure 4.20 shows the experimental spectra, ∆  plotted against the wavelength.
Qualitatively, all three spectra show the characteristic shape of a folded protein with
a significant proportion of α-helices.
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The data were analysed using three different programmes - CONTINLL, CDSSTR
and SELCON3 - in order to estimate the secondary structure. The analysis yielded
molar circular dichroism, ∆ , calculated by each programme (using the same ba-
sis set of proteins) which was then compared to the experimentally measured ∆ 
values (Appendix C, Figures C.1, C.2 and C.3). For the three constructs, SPT
∆158, SPT ∆176 and SPT ∆180, the CONTINLL programme analysis calculating
an experimental CD spectrum most closely matched the measured, experimental
data, closely followed by the CDSSTR programme. The percentages of secondary
structure elements as calculated by the programmes is shown in Table 4.6.
Construct α-helices (%) β-sheets (%) Turns (%) Unordered (%)
∆158 55 8 14 23
∆176 33 19 24 24
∆180 53 9 14 24
Table 4.6: Calculated secondary structure elements for three SPT constructs. Data
from a CONTINLL analysis showed for SPTs ∆158, ∆176 and ∆180.
The more quantitative analysis was performed by the CONTINLL, CDSSTR
and SELCON3 programmes calculated the distribution of secondary structure el-
ements of the three SPT constructs which is summarised in Table 4.6. The three
SPT constructs all consist mainly of α-helices; the percentage of α-helices decreases
as the construct size does. The percentage of turns increases as the construct size
decreases. SPT ∆176 does contains a larger number of turns which may be due to
poorer sample quality as a result of freezing.
The CD spectroscopy data shows that all the expressed and purified constructs for
TgSPT are properly folded proteins as the spectra display features characteristic of
folded proteins consisting mainly of α-helices.
4.2.7 [C14]-serine activity assay on TgSPT constructs
Once the protein constructs were shown to be correctly folded, the enzymatic
activities were determined.
The activity of the four SPT constructs was tested using an in vitro assay; [C14]-
serine and palmitoyl-CoA were employed as substrates to test for SPT functionality
as described in 2.9.3. The results of the fluorographic analysis are shown below in
Figure 4.21.
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Figure 4.21: Fluorographic imaging of TLC plate blotted with 8 µL of product from
SPT condensation of [C14]-serine and palmitoyl-CoA for the four SPT constructs.
The product KDS is found at an Rf value of ∼ 0.6. The control was the assay
performed without the addition of SPT.
As seen in Figure 4.21 a major spot is detectable at an Rf value of ∼ 0.6; as the
SPT constructs get shorter, the spots get fainter, indicating that longer constructs
possess a higher enzymatic activity. The strong bands seen at Rf values of ∼ 0.6
corresponds to the product of SPT activity on palmitoyl-CoA and [C14]-serine, KDS.
This was verified by utilising SpSPT as control for known SPT activity; products
were observed at the same Rf value for SpSPT and the four TgSPT constructs
(results omitted). The location of the catalysis product, KDS, was identified on the
TLC plate by comparison with SpSPT expressed in E. coli as a control (results not
shown). The spots appearing at larger Rf values of ∼ 0.9 are a secondary reaction
product that has not yet been identified.
The four SPT constructs all possess SPT activity in vitro; however, the two shorter
constructs, SPT ∆176 and SPT ∆180, are significantly less active as evidenced by
the faint spots for the product, KDS (Figure 4.21). The SPT activity assay was
employed to identify the minimally catalytically active domain. Full activity was
reached only with the longest protein construct, SPT ∆143.
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4.2.7.1 Condensation product verification by mass spectrometry
The identity of the major product formed during the condensation reaction,
KDS (C18H37NO2, MW = 299 g/mol), was confirmed by mass spectrometry. The
reaction was performed identically to the activity assay only the [C14]-serine was re-
placed by cold L-serine. SPT ∆158 was used. This experiment had previously been
performed with ∆143 but due to the stronger, more defined spots for the secondary
product observed in Figure 4.21 for ∆158, this particular construct was chosen in
order to attempt a characterisation of the secondary product, also.
Analysis was carried out by QToF Premier XE (Waters Ltd.) and the accurate mass
spectrum is shown in Figure 4.22 below.
Figure 4.22: Mass spectrum of lipid fraction extracted after SPT condensation assay
showing a major [M+H]+ peak at 300.2907 m/z with the proposed molecular formula
C18H38NO2 (KDS).
The spectrum in Figure 4.22 shows an [M+H]+ peak at 300.3 m/z at 100%
abundance. The proposed molecular formula is given as C18H38NO2, corresponding
to the [M+H]+ ion (quoted as 1.3 ppm). It is noteworthy that no secondary product
is identifiable from the mass spectrum. This result unambiguously confirms the
identity of the condensation reaction product as KDS.
4.2.7.2 SPT activity inhibition by myriocin
Myriocin (Figure 4.8) is a natural fungal product which is a known inhibitor
of SPT activity (bacterial, yeast as well as mammalian orthologues). It is known
to strongly bind the bacterial enzyme and was therefore chosen to be tested for
inhibitory effects on the recombinant TgSPTs as a first step of a later stage of drug
design.
The assay was performed as described in section 2.9.3 and myriocin was added to
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a final concentration of 100 µM (or CH3OH) and the mixtures were incubated for
60 minutess before the palmitoyl-CoA and [C14]-serine was added to the reaction
mixture.
Figure 4.23: Fluorographic imaging of TLC plate blotted with 8 µL of product from
SPT condensation of [C14]-serine and palmitoyl-CoA for SPT ∆143, SPT ∆143 with
100 µM myriocin, SPT ∆158 and SPT ∆158 with 100 µM of myriocin. The product
KDS is found at an Rf value of ∼ 0.6. The control was the assay performed without
the addition of SPT
Figure 4.23 shows strong spots for both SPT ∆143 and SPT ∆158, producing
the radiolabelled product, [C14]-KDS (as marked on the TLC plate). When adding
myriocin, the spot completely disappears when using SPT ∆143, whereas for SPT
∆158, a faint spot is still visible for [C14]-KDS.
Myriocin completely inhibits the SPT activity of SPT ∆143 at a concentration of
100 µM, whereas only partial inhibition is detected for SPT ∆158. It also inhibits
the members of the large and diverse SPT family, suggesting that the reaction
mechanism remains conserved in the family.
4.2.7.3 Characterisation of SPT inhibitor myriocin
To determine the IC50 value of myriocin on SPT ∆158 at 20 µM, the procedure
outlined in 2.9.3 was followed, except reaction volumes were reduced to 125 µL
and myriocin concentrations ranging from 0 - 100 µM were added to the reaction
mixture. The TLC plates were scanned using an AR-2000 radio TLC Imaging
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Scanner (Bioscan). A scan of each lane produced a spectrum of radioactive counts
and using the Laura software (LabLogic), the area under the peaks was determined.
The background measurements, of reaction mixture containing no SPT protein, were
subtracted from all other measurements. Figure 4.24 shows the radioactive counts
(averaged over 4 independent measurements) measured (across each 10 cm long lane
over 3 minutes) versus the myriocin concentration.
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Figure 4.24: Inhibition data of SPT ∆158 by myriocin. Data obtained at a constant
concentration of SPT ∆158 of 20 µM with concentrations of myriocin between 0
and 100 µM. The number of radioactive counts detected (normalised) on the TLC
plate for the [C14]-KDS is plotted against the myriocin concentration. Data based
on four independent measurements. Insert shows a the data points at myriocin
concentrations between 0 and 12.5 µM. Error bars emitted for clarity.
The data in Figure 4.24 does not show a clear trend and it is thus not possible
to draw any clear conclusions from this data or calculate any IC50 values, and further
experiments need to be conducted.
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4.2.8 Thermal stability assay with TgSPT
The goal of the thermal stability assays (TSAs) is to identify conditions that
increase the thermal stability of the soluble protein sample. Employing medium-
throughput methods developed in the laboratory allows for the identification of
conditions and ligands that have the potential to increase the likelihood of crys-
tallisation when used as additives.54 The aim was to vary salt concentration, ionic
strength or buffer type as much as possible with the various additives.
A graph showing the difference in melting temperature between the negative con-
trol (protein sample and dye with no additives) and conditions containing additives,
∆T, was plotted versus the additive concentration (linked to ionic strength). In
Figure 4.25, this data has been shown for the compounds Na2SO4, (NH4)2SO4,
Na2C3H2O4 (disodium malonate) and Na3C6H5O7 (trisodium citrate) and NH4Cl
for concentrations ranging from 0.2 M to 1.5 M.
Figure 4.25: Graph showing the measured melting temperature change, ∆T, ob-
served for SPT ∆158 at a final concentration of 0.8 mg/mL, 18 µM, plotted versus
the concentration of the additive solution. Data from single measurement.
Figure 4.25 shows the change in protein melting temperature achieved through
addition of varying concentrations of additives. The four compounds, Na2SO4,
(NH4)2SO4, Na2C3H2O4 and Na3C6H5O7 were found to have a stabilising effect
on SPT ∆158 (an increase in Tmelt is observed when additive is present) whilst
NH4Cl has a destabilising effect on SPT ∆158 (a decrease in Tmelt is observed when
172
additive is present).
All the results are shown in Tables 4.7 and 4.8, which also contain information about
additive solutions, concentrations, ionic strength and change in melting temperature
of SPT ∆158 kept at a constant concentration of 0.8 mg/mL.
The data show that, within the measured concentration range, Na3C6H5O7 appears
to increase the melting temperature of SPT ∆158 the most. However, larger con-
centrations of (NH4)2SO4 and Na2C3H2O4 were tested; Na2C3H2O4 gave rise to the
largest increase in stability of 10.7 ◦C at a 1.5 M concentration.
By plotting the measured temperature change versus the ionic strength (see
Figure 4.26), the effect of ionic strength on melting temperature of the protein be-
comes apparent compared to the variations in ions employed and associated effect
on protein interactions. Additives with high ionic strength tend to have a more sta-
bilising effect on SPT ∆158.195 Na2SO4 has the increase in Tmelt with ionic strength
whereas (NH4)2SO4 has the smallest increase in Tmelt with ionic strength (out of
the stabilising compounds). Na2C3H2O4 and Na3C6H5O7 are second and third.
Figure 4.26: Graph showing the measured melting temperature change, ∆T, ob-
served for SPT ∆158 at 18 µM, plotted versus the ionic strength of the additive
solution. Data from single measurement.
The results in Figure 4.26 clearly indicate that the ionic strength plays an
important role in the stabilising effect.
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Compound Concentration/M Tmelt/
◦C ∆Tmelt/ ◦C Ionic strength/M
Control (H2O) 56.6
TCA 7.5% Protein
denatured
MgSO4 1.0 57.0 0.4 4
MgSO4 0.8 55.0 - 1.6 3.2
MgSO4 0.6 54.0 - 2.6 2.4
MgSO4 0.4 52.0 - 4.6 1.6
MgSO4 0.2 51.0 - 5.6 0.8
Na2SO4 1.0 64.8 8.2 2.5
Na2SO4 0.8 61.9 5.3 2
Na2SO4 0.6 56.0 -0.6 1.5
Na2SO4 0.4 57.0 0.4 1
Na2SO4 0.2 54.8 -1.8 0.5
(NH4)2SO4 1.5 61.7 5.1 4.5
(NH4)2SO4 1.0 58.9 2.3 3
(NH4)2SO4 0.8 57.4 0.8 2.4
(NH4)2SO4 0.6 55.0 - 1.6 1.8
(NH4)2SO4 0.4 55.0 - 1.6 1.2
(NH4)2SO4 0.2 53.0 - 3.6 0.6
NaCl 1.5 52.0 - 4.6 1.5
NaCl 1.0 52.0 - 4.6 1
NaCl 0.8 51.0 - 5.6 0.8
NaCl 0.6 51.0 - 5.6 0.6
NaCl 0.4 51.0 - 5.6 0.4
NaCl 0.2 52.0 - 4.6 0.2
NH4Cl 1.5 45.0 -11.5 1.5
NH4Cl 1.0 45.3 -11.3 1
NH4Cl 0.8 46.2 -10.4 0.8
NH4Cl 0.6 47.3 -9.3 0.6
NH4Cl 0.4 48.1 -8.5 0.4
NH4Cl 0.2 50.7 -5.9 0.2
Na2malonate 1.5 67.3 10.7 4.5
Na2malonate 1.0 64.6 8 3
Na2malonate 0.8 62.3 5.7 2.4
Na2malonate 0.6 57.8 1.2 1.8
Na2malonate 0.4 56.3 -0.3 1.2
Na2malonate 0.2 54.9 -1.7 0.6
Na3citrate 0.5 61.0 4.4 3
Na3citrate 0.4 59.5 2.9 2.4
Na3citrate 0.2 55.9 -0.7 1.2
Na3citrate 0.1 55.0 - 1.6 0.6
KCl 0.5 51.0 - 5.6 0.5
KCl 0.2 52.0 - 4.6 0.2
LiCl 0.5 48.9 -7.7 0.5
LiCl 0.2 52.0 - 4.6 0.2
RbCl 0.5 50.6 - 6 0.5
RbCl 0.2 52.3 - 4.3 0.2
EDTA pH 8 0.005 56.9 0.3
EGTA pH 8.9 0.005 57.1 0.5
Table 4.7: Summary of the additives tested, their concentration, effect on melting
temperature of SPT ∆158 at 18 µM and ionic strength. The screen tests various
buffer, salt and ionic strength conditions.
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Compound Concentration/M Tmelt/
◦C ∆Tmelt/ ◦C Ionic strength/M
MgCl2 0.005 56.0 -0.6 0.005
CaCl2 0.005 55.5 -1.1 0.005
SrCl2 0.005 55.6 -1 0.005
MnCl2 0.001 55.5 -1.1 0.001
ZnCl2 0.001 44.3 -12.3 0.001
NiCl2 0.001 50.4 -6.2 0.001
FeSO4 0.001 46.5 -10.1 0.004
FeCl3 0.001 45.0 -11.6 0.006
CoCl2 0.001 Protein 0.003
denatured
CuCl2 0.001 33.7 -22.9 0.003
CdSO4 0.001 46.7 -9.9 0.004
MgCl2, CaCl2, ZnCl2 all 0.001 43.5 -13.1 0.009
NaF 0.4 57.2 0.6 0.4
NaF 0.1 56.2 -0.4 0.1
NaBr 0.4 47.3 -9.3 0.4
NaBr 0.1 52.7 -9.3 0.1
NaI 0.4 37.5 -19.1 0.4
NaI 0.1 49.9 -6.7 0.1
Na formate 0.5 55.0 -1.6 0.5
Na formate 0.2 56.3 -0.3 0.2
Na acetate 0.5 54.9 -1.7 0.5
Na acetate 0.2 55.1 -1.5 0.2
Na L-lactate 0.5 57.8 1.2 0.5
Na L-lactate 0.2 57.3 0.7 0.2
NaNO3 0.5 46.3 -10.3 0.5
NaNO3 0.2 49.9 -6.7 0.2
Na2HPO4 0.005 57.0 0.4 0.03
Na3VO4 0.005 49.0 -7.6 0.03
Na3WO4 0.005 57.0 0.4 0.03
Na2MoO4 0.005 57.0 0.4 0.015
Urea 4 29.7 -26.9
Urea 0.5 52.0 - 4.6
Glycerol 10% (V/V) 57.2 0.6
Glycerol 20% (V/V) 57.7 1.1
CsCl 0.5 49.9 - 6.7 0.5
CsCl 0.2 51.5 -5.1 0.2
Bicine pH 8.5 0.1 52.0 - 4.6
Tris-HCl pH 8.5 0.1 47.9 -8.7
Tricine pH 8 0.1 55.0 -1.6
PIPES pH 7.5 0.1 55.1 -1.5
HEPES pH 7.5 0.1 55.3 -1.3
MOPS pH 7 0.1 55.9 -0.7
phosphate pH 7 0.1 53.0 - 3.6
BisTrus propane pH 6.8 0.1 49.2 -7.4
BisTris methane pH 6.75 0.1 54.0 -2.6
MES pH 6.75 0.1 55.8 -0.8
Acetic acid-NaOH pH 5 0.1 32.8 -23.8
Na3 citrate-HCl pH 5 0.1 43.8 -12.8
Table 4.8: Summary of the additives tested, their concentration, effect on melting
temperature of SPT ∆158 at 18 µM and ionic strength. The screen tests various
buffer, salt and ionic strength conditions.
A commercial screen, the Hampton research Solubility and Stability HT Screen
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(HR2-072) was also used to test for stabilising additives for SPT ∆158 (Table 4.9).
Due to the large destabilising effect measured for most of the additives contained in
this screen, it was not used for crystallisation trials.
Compound Concentration/M Tmelt/
◦C ∆Tmelt/ ◦C
Water 57.4
Betaine monohydrate 2.5 61.8 4.4
Xylitol 2 61.2 3.8
D-Sorbitol 2 61.8 4.4
Sucrose 2 62.4 5
Trimethylamine N-oxide dihydrate 2.5 65.9 8.5
Sodium phosphate monobasic monohydrate, 0.7 63.3 5.9
Potassium phosphate dibasic 1.3
L-Arginine ethyl ester dihydrochloride 0.5 33.8 -23.6
L-Argininamide dihydrochloride 0.5 33.8 -23.6
Spermidine 0.5 26.7 -30.7
Adipic acid 0.08 27.3 -30.1
Ethylenediamine dihydrochloride 0.5 33.3 -24.1
N-Methylformamide 30% (w/V) 31.3 -26.1
GSH (L-Glutathione reduced), 0.01 32.1 -25.3
GSSG (L-Glutathione oxidized) 0.01
Ethylenediaminetetraacetic acid 0.1 29.0 -28.4
disodium salt dihydrate
Cadmium chloride hydrate, 0.1 28.3 -29.1
Cobalt(II) chloride hexahydrate 0.1
Non Detergent Sulfobetaine 201 1 26.3 -31.1
Ethylammonium nitrate 25% (w/V) 32.8 -24.6
Gadolinium(III) chloride hexahydrate 0.25 32.7 -24.7
Polyethylene glycol monomethyl ether 750 5% (w/V) 33.4 -24
Formamide 50% (V/V) 28.2 -29.2
Table 4.9: Summary of the additives tested, their concentration, effect on melting
temperature of SPT ∆158 at 18 µM. The screen tests various salt, sugars and amino
acid conditions
4.2.9 Crystallisation experiments of the SPT constructs
Crystallisation trays were set up for all four SPT constructs (section 2.9.6)
at various concentration using the available crystallisation screens. After setting
up crystallisation trays using all the available screens, none of the four constructs
yielded any crystals. Additives were then added to the trays in an attempt to
stabilise the enzymes.
For ∆143, 4200 conditions were tested up using different concentration of the protein.
Myriocin, Na2C3H2O4 and MgCl2 was added to some screens as an attempt to
stabilise the protein. 2500 conditions were tested for ∆158, 1400 were tested for
∆176 and 2200 were tested for ∆180.
Most drops formed dark, brown amorphous precipitate however some were clear or
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showed phase separation. Brown precipitate is often linked to denatured protein
indicating that the protein is not particularly stable over the long time course of
crystallisation in these conditions.
No crystalline conditions were found except for in the 96-well HTP tray of the
Structure Screen 1+259, 60 (Molecular Dimensions) for SPT ∆176 at 4.2 mg/mL. A
cluster of oblong octagons were found in condition E8 (0.2 M ammonium phosphate
monobasic, 0.1 M Tris pH 8.5, 50% (V/V) MPD) with a protein : reservoir ratio of
1 : 1. A month later, one of the crystals had grown larger (rectangular shape) and
the others had merged into two larger crystals (rectangular and square). However, a
week after that, the two smaller crystals had disappeared and the largest one shrunk
to half its original size.
(a) (b) (c)
Figure 4.27: SPT ∆176 in 0.2 M ammonium phosphate monobasic, 0.1 M Tris pH
8.5, 50% (V/V) MPD (E6, Structure Screen 1+2)59, 60. a) Oblong octagon shaped
crystals. b) More defined oblong octagon shaped crystals one month after (a). c)
Disintegrated crystals one week after (b).
The crystals were not tested in diffraction experiments as they deteriorated
before they could be harvested. However, the decomposition pattern occurring over
a short time-scale indicates that they could potentially be protein crystals.
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4.3 Discussion
4.3.1 Discussion of the SPT homology modelling
Building a model using an enzymatic homologue is a useful way of predicting
enzymatic function and comparing it to known protein structures. Even though
TgSPT and SmSPT only possess a 27.8% sequence identity, resulting in only the
conserved region being including in the model, it is still a good indicator of whether
an enzymatic mechanism is conserved or not. Despite the low sequence identity, the
active site residues surrounding the PLP cofactor still remain unchanged in TgSPT,
giving an indication that its active site and PLP binding site are very similar to that
of SmSPT. As the relevant residues are generally conserved, it strongly indicates
identical, conserved reaction mechanisms.
Before expression and purification of the various TgSPT constructs, the hypothesis
was that the enzyme was functional as a homodimer. Construction of the homology
model of TgSPT showed a conserved active site around the PLP cofactor combined
with interactions across a dimer interface, binding PLP with residues from each
dimer subunit, indicating that TgSPT is functional as a dimer. This is evolution-
arily sound as higher organisms have developed towards heterodimers with similar
monomer subunits having both evolved from the same precursor homodimer.
4.3.1.1 SPT expression
The small-scale over-expression experiments performed at the OPPF showed
that the best results for expressing the highest amount of pure protein were obtained
using Rosetta I (DE3) pLysS cells and the autoinduction method. This is probably
due to the fact that RosettaTM strains are derivatives of BL21 cells; they have
been modified to improve expression of eukaryotic proteins determined by specific
codons rarely employed by E. coli. This strain provides higher levels of tRNA which
recognises the mRNA linked to six extra DNA codons; AGA, AGG, AUA, CCC,
CUA and GGA. This ensures that the protein expression is no longer limited by the
E. coli codon usage (universal translation) and stabilises the recombinant vectors
(pET vectors, which the pOPIN are a derivative of). The codon usage for TgSPT
can be compared to that of E. coli utilising the gcua (graphical codon usage analyser)
software.196 The results are shown in Figure 4.28, where the red bars represent the
relative usage within the TgSPT gene compared to the relative usage within E. coli
represented by the black bars.
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Figure 4.28: Codon usage table created using the gcua software.196 This shows the
relative adaptiveness on the y-axis of the codons shown on the x-axis; the red bars
represent the relative usage within the TgSPT gene and the black ones represent
the relative usage within E. coli. The mean difference is 41.31%.
Therefore Rosetta E. coli cells, promote a higher and more successful trans-
lation rate of the proline, leucine, isoleucine, arginine and glycine codons. If the
cells also contained higher levels of tRNAs for leucine (CTC) and lysine (AAG),
expression levels could be further increased.
It is interesting to note that the constructs prefer different expression times.
SPT ∆143 expresses at higher levels when the expression cultures are left at 15 ◦C
degrees for 48 hours after the OD600 reaches 0.5 whereas SPT ∆158, SPT ∆176
and SPT ∆180 express higher levels of protein when left at 25 ◦C for 23 - 24 hours
after reaching an OD600 of 0.5. The expression levels achieved this way are large
but could potentially be increased by using Arctic ExpressTM cells.132 They grow at
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lower temperature leading to slower expression and higher expression levels of more
active protein. This could improve yield, as increasing the expression times whilst
lowering the temperature proved to have a desirable effect on expression levels.
4.3.1.2 TgSPT - a homodimer
In the eukaryotes studied so far, the first enzyme of the sphingolipid biosynthe-
sis pathway, SPT, is composed of a heterodimer with two closely related subunits.
In constrast, there is strong evidence that the T. gondii SPT, the target of this
investigation, forms a homodimer, more closely resembling its bacterial homologues.
The homology model presented in section 4.2.2 based on the structure of the bacte-
rial SmSPT homologue is perfectly consistent with the notion of dimer formation.
Furthermore, evidence for homodimer formation is clearly seen in the native gel
(Figure 4.16) which shows that ∆158 forms a dimer whereas ∆180 shows a band at
the correct mass for a monomer. This may be due to this truncation not being as
stable in solution as the others. As the ∆180 is the shortest construct, this suggests
that the N-terminus is involved in dimer stabilisation. This is consistent with the
observation that the shorter constructs are more prone to precipitation, particularly
during attempts to concentrate soluble protein samples.
SPT ∆158 was submitted for mass spectrometry analysis (section 4.2.5). The LC-
ESI-MS mass spectrum (Figure 4.17) shows an [M+H]+ peak at 46132 ±1 m/z
and a 2×[M+H]+ at 92264 ±1 m/z, consistent with the calculated mass of SPT
∆158 containing two additional residues (glycine and proline) which remain after
tag cleavage. It also provides evidence that the PLP cofactor is no longer bound
after ESI, presumably due to it not being covalently bound and therefore not being
able to withstand the forces of ionisation. Finally, Bio-SAXS experiments on sam-
ples of all four SPT constructs have confirmed homodimer formation in solution.
For SPT ∆158 and SPT ∆176, the data correlates well with the expected molecular
weight for a homodimer. For the longest, SPT ∆143. and shortest, SPT ∆180,
constructs, the data suggest that the former forms aggregates in solution whereas
the latter may be transient and exist both as a monomer and a homodimer in solu-
tion. However, it could be argued that the data is within the experimental accuracy
expected, suggesting that all four SPT constructs exist as homodimers in solution.
In summary, there is strong evidence that the T. gondii SPT forms a homod-
imer; it is evolutionary more closely related to the bacterial orthologues than the
eukaryotic orthologues. This is important as the specific differences between eu-
karyotic SPTs and this enzyme have to be exploited in order to design selective
drugs.
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4.3.2 TgSPT secondary structure determination by CD
spectroscopy
Analysis of the CD spectroscopy data revealed that the the three constructs;
SPT ∆158, SPT ∆176 and SPT ∆180, consist of between 33 and 55% α-helices;
this value gets smaller with construct size. SPT ∆176, has a smaller α-helix content
than the other constructs (at 33%), despite it being the second shortest construct.
This may be due to protein sample degradation or aggregation. Even though the
values calculated for secondary structure components are mostly useful as a guide-
line, the trend for the data suggests that SPT ∆176 should contain approximately
54% α-helices. The percentages calculated for the other structural elements of SPT
∆176, when compared to the values obtained for SPT ∆158 and SPT ∆180 suggest
that the SPT ∆176 sample quality had been affected.
The secondary structure elements were calculated by three programmes; CON-
TINLL, CDSSTR and SELCON3, which utilise the reference set input to calculate
values of molecular circular dichroism based on the data input into them. Data
shown (for percentage of secondary structure elements) was calculated by CON-
TINLL for the three proteins; this was chosen by comparing the experimentally
measured ∆  with the ∆  calculated by each of the programmes. The calculated
data showing the best overlap with the experimentally measured values was used to
predict the percentage of secondary structure elements.
Even though this data only gives an approximation of the structure of the pro-
teins, it can be compared to other SPTs from the PDB; SmSPT contains approxi-
mately 45% α-helices and 13% β-sheets. Despite only studying TgSPT truncations,
the measured structural elements occur with the same frequency as for this SPT ho-
mologue, suggesting that the proteins are properly folded as they have the expected
secondary structure percentages.
4.3.3 SPT activity assay
4.3.3.1 Identification of active domain of TgSPT
As SPT catalyses the condensation reaction of palmitoyl-CoA and L-serine,
the rate-limiting step of sphingolipid synthesis, an appropriate assay for identifying
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SPT activity is to monitor the inclusion of [C14]-serine into KDS, the product of the
condensation reaction.
The TLC plate displaying the extracted product shows that the SPT activity of the
four constructs decreases with size. The bands for radiolabelled KDS get fainter and
are only just visible for the two shortest constructs, SPT ∆176 and SPT ∆180. This
suggests that the deletions may be either disrupting protein folding, affecting sub-
strate interaction or formation of the homodimeric complex. Sequence alignment of
TgSPT and SmSPT indicates that the longer constructs completely contain the rel-
atively conserved domain whereas the two shorter constructs are lacking part of this
domain, potentially contributing to the diminished enzymatic activity. The amino
acid sequences alignment with the bacterial SPTs revealed that the N-terminal ex-
tension is not present; this domain contains a transmembrane region which does not
appear to have any effect on the enzymatic functionality of TgSPT in vitro. These
results have identified the active domain of TgSPT .
The size of the spots seen for the reaction product, KDS, in Figure 4.21, suggest
that SPT ∆143 is less active than SPT ∆158, in contrast with the results seen in
Figure 4.23. This may be a coincidence, but could also be linked to the inaccuracies
linked to the experimental protocol - in particular the step for product extraction.
In order to quantify the amount of product produced by the various constructs,
an alternative experiment could be applied. M. F. Ru¨tti et al 197 have developed a
method where KDS is reduced by NaBH4 and forms erythro- and threo-sphinganine
(the reaction is not stereospecific). Ortho-phthalaldehyde is used to derivatize the
reduction products which are separated by HPLC and subsequently quantified us-
ing fluorescence detection (all based on method developed by Riley et al.198 This
method both avoids the use of radio-labelled compounds and optimises the amount
of substrate needed.
Employing the standard [C14]-serine SPT activity assay, it is clear that the enzymatic
activity decreases with decreasing construct size, but that activity is detectable for
all four TgSPT constructs.
Combined with the data obtained from CD spectroscopy and Bio-SAXS, the
SPT constructs appear to have the expected secondary structure percentages and
form homodimers in solution. The activity assay thus also shows that TgSPT is
functionally active as a homodimer, as its prokaryotic SPT homologues and not as
a heterodimer as other eukaryotic SPTs (P. W. Denny, personal communication).
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4.3.3.2 Inhibition of SPT activity with myriocin
Myriocin (see Figure 4.8) is a known inhibitor of SPT183 at picomole concentra-
tions. Myriocin (fromMycelia sterilia) is an analogue of sphingosine, which possesses
antifungal antibiotic and immunosuppressive properties, and it resembles both sub-
strate and intermediate products of the SPT reaction. As such small quantities are
required for SPT inhibition, this was chosen for inhibition studies. Other inhibitors
(section 4.1.8.1) could be tested in future experiments.
It is clear from the experimental results (section 4.23) that myriocin inhibits the
SPT activity of TgSPT constructs SPT ∆143 and SPT ∆158. Complete inhibition
of SPT ∆143 is seen and almost complete inhibition of SPT ∆158. The reason for
the incomplete inhibition of SPT ∆158 may be due to less effective binding. This
could also be a result of the experimental protocol and the relative insolubility of
myriocin in CH3OH.
Calculating the IC50 value of myriocin on SPT ∆158 under the experimental
conditions employed was not possible; the results obtained were not sufficient to
calculate any definite values as the standard deviation error calculated based on the
four independent measurements were too high (ranging from 32 - 83%).
Myriocin is only soluble in CH3OH to a concentration of 2 mg/mL but in DMSO
it is soluble to a concentration of 25 mg/mL. The assay employed to determine the
IC50 value is not optimal, as a serial dilution of the myriocin is required and due to
the low solubility, large errors are difficult to avoid. An alternative solvent to use is
therefore DMSO.184
Myriocin inhibits SPT activity for SPT ∆143 fully and partly inhibits SPT∆158
enzymatic activity.
4.3.4 Discussion of crystallisation of SPT
No diffracting crystals were obtained for any of the four SPT constructs. The
crystals shown in Figure 4.27 were never tested but their decomposition suggests
that they may hay have been protein crystals. Several experimental adjustments
can be made to improve chances of crystallisation in the future.
Firstly, adjustments to the purifications conditions could be implemented to ensure
more homogeneous protein samples. SPT ∆158 and SPT ∆180 showed large differ-
ence in homogeneity on the Malvern DLS (data not shown) with the larger construct
being more homogeneous in solution than the shorter construct. This is also evident
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from observations of protein precipitation occurring for the shorter constructs after
12 hours at 4 ◦C. To stabilise the shorter constructs, the buffers used for purification
could contain a higher percentage of glycerol e.g. 10%. Another option would be to
purify the protein using an anion exchange column as well; this was attempted but
did not improve protein purity and resulted in loss of protein instead. To counteract
this, further stabilising compounds could be added to the purification buffer.
To aid crystallisation of a protein, co-crystallisation with ligands is often successful.
One option is to use identified inhibitors or sphingolipid derivatives or even different
amino acids such as L-serine or D-serine. Other ligands can be identified using ther-
mal stability assays. Several salts have been identified as having a stabilising effect
on ∆158. Na2C3H2O4 is an obvious choice, however a screen was set up with 1 M
Na2C3H2O4 added to the protein buffer but the protein precipitated, suggesting that
this compound is not so useful for stabilising TgSPT constructs for crystallisation.
Na2SO4 and Na3C6H5O7 were shown to stabilise SPT ∆158 with the TSA and the
ability to increase the ionic strength, especially of Na3C6H5O7, without reaching too
high salt concentrations, makes these two viable candidates for stabilising protein
during crystallisation trials. Even though Na3C6H5O7 shows less protein-ion inter-
action than Na2C3H2O4 and shows less increase in stability with ionic strength, it
may still be a better option than Na2C3H2O4, as it is easy to increase ionic strength
whilst keeping the concentration within an achievable range. Other strategies involve
addition of detergents or peptergents using available screens. Other useful screens
include solubility screens (in the case where no better buffer system is identified for
the protein) and pH precipitants. The Index HT screen (Hampton Research) is a
specific example of a screen which is a sparse matrix, grid screen involving facto-
rial screening where many know reagents, novel and traditional, are combined by
reagent class. To improve the quality of potential crystals, cryoprotectants can be
added to the crystallisation screens.
In some cases addition of trypsin to the soluble protein before setting up crystallisa-
tion screens has proved successful, as the protein may cleave in a favourable manner
for crystallisation.
Other crystallisation methods such as microbatch under oil, microdialysis or free
interface diffusion methods are other options that could be explored but perhaps
will not have as large an effect on the formation of TgSPT crystals.
Mutation of the SPT constructs could also be explored as well as other homologues
such as Eimeria tenella SPT. However, before resorting to those options, seeding
or microseeding using the crystals grown for SPT ∆158 could be used and if that
fails, then seeding with crystals of homologue crystals can present an alternative to
achieving protein crystallisation.
There are many possibilities that have not yet been explored but which could be
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promising with stable protein expression and purification protocols in place.
4.4 Chapter conclusions
The work demonstrated in this chapter shows a biophysical and biochemical
analysis of the T. gondii SPT drawing on multiple techniques.
Homology modelling of TgSPT based on the structure of SmSPT gave rise to a
predicted structure of TgSPT where the N-terminal end was missing, but where the
conserved domain and active sites were modelled. The resulting model showed a
PLP binding site very similar to that of both SmSPT and SpSPT; the correspond-
ing residues had the potential for hydrogen bonding to PLP and they were in the
correct conformation, leading to the conclusion that the active site of TgSPT is
highly likely to be similar to that of other SPTs and, by inference, so is the reaction
mechanism.
Successful transformation of four TgSPT constructs and expression of them using
an autoinduction method was demonstrated, resulting in expression levels between
3 and 32 mg of protein per litre of expression medium.
The resulting proteins were verified to be correctly folded by CD spectroscopy.
Mass spectrometry experiments on purified SPT ∆158 provided strong evidence
for TgSPT existing as a homodimer which was also supported by Bio-SAXS data.
Serine palmitoyltransferase activity was recorded for all four recombinant proteins;
the activity levels were seen to decrease with construct size. The product of the
condensation reaction occurring between serine and palmitoyl-CoA, KDS, was con-
firmed by LC-ESI mass spectrometry.
Inhibition with the known SPT inhibitor, myriocin, was also shown for constructs
SPT ∆143 and SPT ∆158. The attempt to establish the IC50 value of myriocin on
SPT ∆158 did not yield a specific result so further experiments are being conducted
under different solvent conditions.
Crystallisation trials for the four SPT constructs did not result in any diffracting
crystals. However, TSAs identified several stabilising conditions for SPT ∆158 which
suggest a starting point for future crystallisation experiments.
185
Chapter 5
Triosephosphate isomerase from
Sulfolobus solfataricus
5.1 Introduction
Triosephosphate isomerase (TPI) is an enzyme which catalyses the reversible
isomerisation of dihydroxyacetone phosphate (DHAP) to D-glyceraldehyde-3-phos-
phate (GAP) in the Embden-Meyerhof-Parnas (EMP) pathway of glucogenesis. The
enzyme adapts the most common fold in nature, the (β α)8-barrel, making it the
ideal enzyme for studying protein evolution. Sulfolobus solfataricus is a hyperther-
mophilic archaeon, and thus the SsTPI has adapted to the extreme environment in
which this organism exists.
The aim of this project was to crystallise the enzyme and solve both an unbound-
and a ligand-bound form allowing for comparison with other hyperthermophilic TPI-
barrels to further explore the determinants for thermostability.
5.1.1 The archaeon Sulfolobus solfataricus
Sulfolobus solfataricus is an extreme thermoacidophilic archaeon (single celled
procaryotic microorganism) which belongs to the phylum Crenarchaeota. Many
archaea are found living under extreme conditions. S. solfataricus grows at temper-
atures between 70 − 90 ◦C with optimal growth at 80 ◦C and at pH 2 - 4 (with an
optimal pH of 3.2).199
Sulfolobus, the genus, was first isolated by T. D Brock et al 200 from acidic hot
springs in Yellowstone National Park. Before this discovery, it was believed that
186
life was not sustainable at extreme temperatures and pH values.201 Since then, sev-
eral other species of the genus Sulfolobus have been discovered all over the world
in sulphur rich soils, marine ecosystems,202 acidic hot springs and thermal acidic
soils.203 The species Sulfolbus solfataricus was isolated by W. Zillig et al 199 in 1980
from terrestrial volcanic hot springs near Pisciarelli, Italy. It was originally believed
to be a bacterium possessing extraordinary properties, but a new classification sys-
tem showed that Sulfolobus belonged to a new prokaryotic domain, namely the
Archaea,204, 205 the only kingdom that can grow at temperatures above 95 ◦C.206
In the Sulfolobus species, all strains have been found to grow autotrophically and
heterotrophically, making them extremely versatile.203 S. solfataricus has the abil-
ity to grow aerobically203 on a wide range of materials such as peptides, sugars, on
plates and in liquid media,207 which makes it easy to manipulate. S. solfataricus is
a model organism for Archaea (as the Sulfolobus species are so abundant)203, 208 and
thus in 2001, sequencing of its genome (2.99 Mbp) was completed by Q. She et al.209
It was chosen for the possibility of gaining an understanding on the molecular basis
for thermoacidophilic adaptation, regulation of enzymatic pathways and eukaryotic
cellular evolution.
5.1.2 Triosephosphate isomerase structure
Triosephosphate isomerase is one of the most studied and structurally best
characterised enzymes. The protein adapts the most common fold for proteins found
in nature210 - the (β α)8-barrel fold, also known as the TPI-barrel (or TIM-barrel)
fold - which was first discovered in TPI.211 Approximately 10% of all solved protein
structures have been found to contain at least one domain with a TPI-barrel fold
and due to this prevalence, TPI-barrels make a useful model for studies of function,
stability and evolution of proteins.212
Most (β α)8-barrels consist of 200 - 250 amino acids which are divided into eight
parts. Each of these subunits are made up of a β-strand connected to an α-helix via
a βα-loop. The motifs are then connected by αβ-loops. A barrel is formed by the
eight β-strands that make up a central core which is surrounded by eight α-helices.
Each β-strand is slanted with respect to the central barrel by approximately 36 ◦
which results in a staggered β-sheet,213 leading to a shift of eight residues for every
turn when following the barrel.210 The approximate 4-fold symmetry of TPI-barrels
arises due to the layers formed inside the barrel core by the residue side-chains
(usually the side-chains arrange themselves perpendicularly to the barrel axis and
form a layer which is three or four thick). Four alternating residues from the odd-
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or even-numbered β-strands ((1, 3, 5, 7) or (2, 4, 6, 8)) make up each layer. The
stability of the fold is preserved by residues located in the core of the barrel (and at
the opposing end to the catalytically active residues) near the αβ-loops (this forms
the stability face). The active site residues identified in all the studied (β α)8-barrels
have been located at the C-terminal ends of the β-strands as well as in the βα-loops
(known as the catalytic face), as shown in Figure 5.1.214, 215
(a) (b)
Figure 5.1: Diagram of Pyrococcus woesei TPI monomer.210 (a) Sideways view with
the N- and C-terminals, catalytic and stability faces annotated. (b) View down the
barrel with all α-helices and β-sheets numbered.212
The structures shown in Figure 5.1 are of the P. woesei TPI.210 This was chosen
as the model as it is the closest homologue to the S. solfataricus TPI with a sequence
identity of 43%.
5.1.3 Enzymatic function of (β α)8-barrels
Apart from a few exceptions, all studied (β α)8-barrels are enzymes, functioning
either as isomerases, hydrolases, lyases, oxidoreductases or transferases (covering five
enzyme classes that the Enzyme Commission (EC) has defined).212 Approximately
two thirds of the (β α)8-barrels have substrates or cofactors which contain a phos-
phate group,216 as the active site contains a phosphate binding site. Furthermore,
it has been hypothesised that the catalytic face, and therefore also the active site of
the barrel, has a positive potential due to a dipolar electrostatic field associated with
the barrel, arising from the α-helices and the microdipoles linked to them. The elec-
trostatic field may be the force behind the (β α)8-barrel preference for metabolites
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with a negative charge.217
5.1.3.1 Enzymatic function of TPI
TPI catalyses the reversible isomerisation of the heatlabile intermediates dihy-
droxyacetone phosphate (DHAP, a ketose) and D-glyceraldehyde-3-phosphate (GAP,
an aldose), which is a vital reaction within the glycolysis pathway. The reaction
was first characterised by Meyerhof and Kissling,218 and is described in Equa-
tion 5.1.219, 220
E +DHAP −−⇀↽− E..DHAP −−⇀↽− E..GAP −−⇀↽− E +GAP (5.1)
where E is the enzyme which associated with DHAP to form GAP after which
the enzyme is recovered.
In TPI (β α)8-barrels, four resides have been identified as being crucial for the
isomerisation mechanism catalysed by TPI. The isomerisation reaction is based on
acid-base catalysis. The residues relevant for functionality are an asparagine and a
lysine in the substrate binding site and a histidine (electrophile) and a glutamate
(proton acceptor) in the active site. The asparagine (Asn9) and a lysine (Lys11)
residue, both located in the β1α1 loop, facilitate the substrate orientation, whilst a
histidine (His93) and glutamate (Glu141) residue, in loops β4α4 and β6α6 respec-
tively, are involved in the proton transfer steps (where the histidine residue acts as
the electrophile and the glutamate residue acts as the proton acceptor). A proton
is removed from carbon 1 from DHAP by the glutamate. The histidine residue do-
nates a proton to stabilise the negative charge associated with the carbon 2 carbonyl
group as a result of the extracted proton. The proton transfer results in the forma-
tion of an enediol intermediate. To complete the isomerisation to GAP, a proton is
withdrawn from the carbon 1 hydroxyl group by the histidine residue and a proton
is added to carbon 2 by the glutamate residue. The isomerisation is thus complete
and the enzyme is recovered. The process just described is known as the ”classical”
mechanism (see Figure 5.2).212, 221, 220
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Figure 5.2: Schematic of the ”classical” mechanism of TPI. This is shown in the
physiological direction which occurs during glycolysis (from left to right). The two
residues relevant for the reaction, His93 and Glu141, are shown with the DHAP
substrate, the formation of the enediol intermediate, the following proton withdrawal
and addition by His93 from carbon 1 hydroxyl group and from Glu141 to carbon 2
respectively. This results in completed isomerisation of DHAP to GAP.
When GAP is isomerised to DHAP, the enzyme behaves perfectly and the rate-
limiting step becomes the step where substrate and enzyme encounter each other
(which is limited by the rate of diffusion).221 Simulations have suggested that the
GAP is directed by the electrostatic potential of the active site.212
Theoretical models of the active site along with NMR experiments222 have supported
the proposition that the glutamate residue replaces the histidine residue’s role in the
mechanism; the glutamate residue donates a proton to the substrate oxygen atom
number 2 forming an enediol intermediate whereafter an enediolate is formed as
a proton is donated from the oxygen number 1 of the substrate to the glutamate
residue.
An alternative method of isomerisation, also know as the ”criss-cross” mechanism,
exists for the reaction following initial proton extraction from the carbon 1. This
proton is transferred to oxygen 2 on the substrate and not the adjacent substrate
carbon. The glutamate is the only residue involved in the catalysis reaction; the
resulting negative charge on the substrate is stabilised by the lysine, the asparagine
and the histidine that form two oxyanion holes.220, 223 This mechanism was suggested
by T. K. Harris et al,224 who observed that both mechanisms play a role for this
reaction for the wild-type TPI from Leishmania mexicana.223
The protein side chain is believed to shift as catalysis occurs, thus suppressing side
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reactions. It does not change conformation but simply opens and closes, even when
no ligand is bound.225 In the apo form protein, the β6α6 loop is interacting with the
β5α5 loop, but in the holo form, the former loop is positioned on top of the active
site, resulting in the glutamate residue re-positioning for catalytic activity as well
as allowing for tighter substrate binding.223
5.1.3.2 Function of the S. solfataricus TPI
S. solfataricus employs a sophisticated, branched central carbohydrate metabolism.
For glycolysis (sugar degradation of e.g. galactose and glucose) a branched Entner-
Doudoroff (ED) pathway is utilised involving a non-phosphorylative and a semi-
phosphorylative branch, whereas for gluconeogenesis, the Embden-Meyerhof-Parnas
(EMP) pathway is utilised, in which the SsTPI catalyses the DHAP and GAP in-
terconversion. TPI is of great interest as it controls the flow of DHAP and GAP,
the triose 3-phospate intermediates between glycolysis and gluconeogenesis.226, 227
5.1.4 TPI ligands and inhibitors
A substantial number of molecules have been identified as inhibitors for eu-
karyotic TPIs, from assays with pea seed TPI (similar experiments have been done
involving the Trypanosoma brucei brucei TPI).228 Inhibiting compounds include
the intermediate metabolites phosphoenol pyruvate (PEP), 2-P-glycerate, 2,3-P2-
glycerate, 3-P-glycerate and adenosine triphosphate (ATP) which are all interme-
diates between TPI acting as an isomerase and the production of pyruvate. Fructose-
1,6-P2, fructose-6-P, glucose-6-P, glucose-1-P and 6-P-gluconate (6-phospho-gluconate)
are also metabolites in the glycolysis pathway, occurring before TPI is involved,
and all bind to and inhibit TPI. As all of these compounds are intermediates in
the glycolytic pathway mechanism, it is assumed that they may play a regulatory
role and hence inhibit TPI functionality due to the similarity in structure to the
substrates. Further metabolites resulting in TPI inhibition are citrate and succi-
nate.228, 229 These compounds have not yet been tested against (hyper)thermophilic
TPIs but are expected to have an inhibitive effect on them.
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5.1.5 Evolution of the TPI-barrel fold
Enzymes evolve to improve the ability of an organism to thrive when its sur-
roundings change by obtaining different properties (such as new binding or catalytic
regions). As 10% of all solved enzyme structures adapt a (β α)8-barrel fold,
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which is a very stable fold capable of catalysing multiple reaction mechanisms, the
evolutionary relationship of TPIs is of great interest.212 , 230
Divergent evolution arises from random mutagenesis reactions and/or gene recom-
bination from a common ancestor, which can be easily replicated in laboratory
settings, and convergent evolution involves similar structural changes occurring in
different species to obtain a stable fold. Divergent evolution of TPIs is supported
by the fact that the structural features are conserved across the TPI-barrels but
convergent evolution is supported by the lack of sequence similarity and the variety
of functionality.214 Several studies have been carried out comparing the structure
and sequence similarities231 as well as active and binding sites of multiple hyper-
thermophilic TPIs.210, 216 Despite the contrast in catalytic properties, the active
site of TPI-barrels is always located at the end of the barrel β-sheets towards the
C-terminus pointing towards the theory of divergent evolution. Furthermore, the
structural conservation of a phosphate binding site in multiple TPIs is a strong in-
dication that all TPI-barrels share a common ancestor and have therefore evolved
via divergent evolution.230, 231
It is impossible to ascertain with absolute certainty which type of evolution is re-
sponsible for the development of the huge variety of TPI-barrels, however divergent
evolution from a common ancestor has been found to explain most of the data
comparisons.232
5.1.6 Protein stability under extreme conditions
The TPI enzyme is ubiquitous in nature and its function in the glycolytic
pathway is widely conserved across all three domains of life; Bacteria, Eucarya
and Archaea. Due to these extreme environmental conditions thermoacidophiles
inhabit, the proteins produced within them have higher thermal stabilities than
the mesophilic homologues whilst still maintaining protein fold characteristics of
specific proteins families.233, 234, 235, 236 There are several factors contributing to the
thermoadaptation mechanism of proteins as discussed below.
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5.1.6.1 Structural determinants of thermostability
Protein stability is governed by various factors including hydrogen bonds, van
der Waals interactions, salt bridges and the hydrophobic effect.206 The sum of all
these interactions are equal to the conformational stability of the protein which is
best described by ∆G, the free energy difference between folded and unfolded states.
The free energy difference is usually in the region of 40 kJ mol−1, in comparison to
individual residue stabilising interactions which have a magnitude of up to 25 kJ
mol−1.237 Thus, the mutation of a single residue can have a large effect on protein
stability, even if no effect is seen on the overall protein structure.204 Hyperther-
mophilic proteins may therefore only need a few more stabilising interactions to
increase the overall stability. Due to the difficulty of predicting the effect a struc-
tural change will have on stability, as the free energy difference is composed both of
folded and unfolded states and the fact that not all residues of any protein have been
found to contribute to stabilising interactions, the upper limit for conformational
stability can not be accurately predicted.
140 ◦C has been postulated as being the upper limit for protein conformational sta-
bility, as hydrophobic interactions are weak above this limit due to their temperature
dependence but this only remains an estimate as many other factors contribute to the
overall conformational stability.206 An inverse correlation has been noted between
specific activity and conformational stability via molecule flexibility.204, 238 The ac-
tivity of an enzyme depends on its flexibility and less flexible enzymes tend to be
more stable. This is supported by the observations that enzymes from thermophiles
are more stable but less active and less flexible than enzymes from mesophiles at any
temperature.206, 233, 238, 239 It is believed that enzymes from mesophiles are more un-
stable due to their catalytic functionality, where flexibility is essential. An enzyme’s
stability temperature (temperature above which the protein is no longer stable) is
generally not observed to be much higher than that required for functionality, as this
would result in less flexibility leading to less functional catalysis. It is a fine balance
between achieving optimal functionality as well as reaching high enough stability
which is necessary for a useful and long lifetime. The stabilising and destabilising
interactions must be balanced in order to ensure enzymatic stability and function.
Flexibility affects the stability of an enzyme either regionally or globally. Exper-
iments suggest that stability is affected more by changes in flexibility at certain
points in a protein than others.
Even though hyperthermophilic proteins are conformationally stable at high
temperatures, there is no single answer as to what influences irreversible degradative
processes have on the proteins.206 Irreversible processes usually occur as a result of
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alterations in covalent bonding within the protein. At high temperatures, several
processes with high activation energies can occur. These include deamidation of
the amine side chain of glutamine and asparagine, oxidation of cysteine, histidine,
methionine, tyrosine and tryptophan as well as succinimide formation in aspartic
and glutamic acid and all may be involved in protein inactivation.
5.1.6.2 Thermostability in hyperthermophilic TPIs
In order to gain a better understanding of the factors governing the stability
of proteins, the structures of several mesophilic and hyperthermophilic enzyme or-
thologues have been compared to gain a better understanding of the guiding factors
of protein stability.206 Proteins from hyperthermophilic organisms can be stabilised
via many routes.
TPI enzymes form dimers in Bacteria, Eukarya and mesophilic Archaea, but tend
to form tetramers (usually a dimer of dimers) in hyperthermophilic Archaea. An in-
creased oligomerisation state has therefore been identified as a potential mechanism
for hyperthermophilic proteins to fold and function correctly at elevated tempera-
tures.233 The hyperthermophilic TPI monomers are usually 10% shorter than the
bacterial and eukaryal TPI monomers; TPIs from archaea are generally between
215 - 230 residues compared to mesophilic TPIs of 240 - 250 residues.240, 219 An-
other common known factor is the formation of more salt bridges. Additionally,
disulfide bonds, a reduced number of thermolabile residues (such as asparagine and
glutamine), more hydrogen bonds between side-chains and maximisation of the over-
all electrostatic potential all stabilise proteins at higher temperatures.233
The studies of the stable TPI-barrel and its interface interactions have been
conducted comparing the inter- and intrastructural interactions. The interactions
can be divided into inner and outer barrel interactions. Interactions in the inner
barrel involve residues that have side-chains pointing towards the barrel core.240
These residues usually have bulky side-chains such as leucine, isoleucine and aro-
matic residues, thus holding the barrel β-sheets together with non-polar interactions
between the hydrophobic side-chains. All dimeric TPIs have a tyrosine residue point-
ing towards the inner barrel, but this is replaced by a glycine in archaeal TPIs, but
counteracted by the presence of an aromatic tyrosine residue, instead of alanine,
glycine or serine residue in dimeric TPIs. It seems that the mutation involving a
compensation is necessary for stability in tetrameric TPIs.240 Outer barrel interac-
tions involve the residues with side-chains pointing out from the barrel interacting
with the residues in the helices and loops. No aromatic residues are present in
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the outer barrel in tetrameric TPIs, and all the bulky aromatic resides present in
dimeric TPIs are replaced by small, hydrophobic residues, resulting in a more densely
packed structure. Overall, hydrophobic interactions and a few hydrogen bonds be-
tween residues located at the end of strands and main chain residues contribute
to stabilising TPIs. The number of inner and outer barrel interactions in archaeal
TPIs does not fully explain their thermostability, but the mutations of several key
residues, as mentioned above, influence the compactness of TPIs, which may have
an impact on protein stability.
Different protein families adapt to high temperatures through different struc-
tural solutions. The structural basis of thermostability is not clearly defined, but
includes oligomerisation, hydrophobic interactions and hydrogen bonding, a larger
number of subunit contacts (which often manifests itself as higher oligomerisation
states), polar interactions between surface and accessible surface regions,241 de-
creased loop size, decrease in the amount of protein cavities, resulting in tighter
packing of the protein.240, 242
It is impossible to define any one characteristic as the defining factor of protein
stability, as several elements contribute to enhancing stability in the different TPIs.
5.1.7 Archaeal TPIs
There are currently structures available for TPIs from three different Archaea
available in the RSCB Protein Data Bank (RSCB PDB); these are TPI from Pyrococ-
cus woesei 210 (PDS ID 1HG3), Methanocaldococcus jannaschii 240 (PDB ID 2H6R)
and Thermoproteus tenax 219 (PDB ID 1W0M). A Swiss Model Repository243 search
identifed four TPIs with sequence identities greater than 30% to SsTPI. The top
four solutions generated were for the TPIs from P. woesei, M. jannaschii, T. tenax
and T. molitor (PDB ID 2I9E), with sequence identities of 43%, 40%, 40% and
34% respectively. Out of these four results, the first three are from Archaea but
the latter, Tenebrio molitor,244 is a yellow mealworm beetle and was thus left out
of structural comparisons.
The TPI enzymes from P. woesei, M.jannaschii and T. tenax are all tetramers,
albeit with different properties as soluble proteins. The TtTPI enzyme adopts an
equilibrium and reversibly dissociates from an active tetramer to two inactive dimers,
suggesting that the interface interactions are weaker than for the other archaeabac-
terial TPIs (it has been found to be less stable than the PwTPI).
Figure 5.3 shows a sequence alignment of the four archaeal hyperthermophilic TPIs;
PwTPI, the Mj TPI, the TtTPI and the SsTPI. The sequences are all compared
to the secondary structure of the PwTPI (displayed above the alignment). The se-
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quence alignment highlights the highly conserved residues and the active site residues
amongst the compared TPIs.
Several structure-based sequence alignments have been carried out between mesophilic
and hyperthermophilic TPIs (dimeric and tetrameric enzymes) from various organ-
isms. Gayathri et al 240 highlighted the large insertions at the sites coinciding with
the tetramer interface in the dimeric TPIs. Insertions tend to occur in loop 4, near
helix 5 and on helix 6. Additionally, both helix 5 and loop 5 are shorter in tetrameric
TPIs than in dimeric TPIs, causing the helix to be closer to the barrel, thus making
the structure more compact. Structural comparisons have shown that the insertions
have a preventative effect on tetramer formation. Another contributing factor is
the charge of the surface residues; the region which corresponds to the tetramer in-
terface in archaeal TPIs is negatively charged in dimeric TPIs (containing residues
such as glutamic acid and aspartate), resulting in strong repulsive interactions, if
two dimers were to attempt to form a tetramer. In tetrameric TPIs, the correspond-
ing regions are mainly hydrophobic, resulting in a modified surface which favours
tetramerization.240PwTPI and Mj TPI both have a higher alanine content in helix 5,
suggesting that this residue has a stabilising effect on the helix after truncation.210
In TtTPI, which exists either as an active tetramer or inactive dimer, this interface
is not conserved, showing that all archaeal TPIs do not possess the same stabilising
mechanisms. This may be the reason why the latter TPI exists as a weaker TPI.
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Figure 5.3: Sequence alignment of four thermophilic TPI sequences of
PwTPI, Mj TPI, TtTPI and SsTPI, produced in ESPript 3121 (available at
http://espript.ibcp.fr). Residues enclosed in a red block are identical, residues en-
closed in blue frames with red letters are of similar type and the rest have a low
identity score. α denotes α-helices, β denotes β-sheets, TTT denotes strict α-turns
and η denotes 310-helices.
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5.1.8 Chapter objectives
In this chapter, the crystallisation of triosephosphate isomerase from the hyper-
thermophilic archaeon Solfolobus solfataricus is presented. SsTPI was crystallised
(without and with bound phosphoenol pyruvate (PEP)) and the the 3D structures
determined. TPI adapts the most common protein fold, the (β α)8-barrel, making it
a model enzyme to study for evolutionary purposes. The two crystal structures with-
out any ligands bound in the active site reveal that, as in other hyperthermophilic
archaea, SsTPI forms a tetramer in solution, in order to stabilise the enzyme un-
der the extreme conditions it is exposed to. Furthermore, the PEP bound form
shows conservation of the active site residues when compared with other TPIs from
hyperthermophilic organisms.
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5.2 Methods
5.2.1 Protein expression and purification
Purified SsTPI was obtained Dominik Esser, and Bettina Siebers (Department
of Chemistry, Molecular Enzyme Technology and Biochemistry, at the University of
Duisburg-Essen, in Essen, Germany), who had expressed and purified the protein
recombinantly in E. coli. Briefly, cells were lysed in 0.1 M HEPES/KOH pH 6.5
at 70 ◦C. Protein was obtained by heat precipitation at 80 ◦C whereafter it was
dialysed against 20 mM HEPES/KOH pH 6.5. The sample was loaded onto an
anion exchange-sepharose column and eluted using a 1 M NaCl linear gradient. The
relevant fractions were purified further on a HiLoad (26/60) gel filtration column
followed by HIC (Butyl sepharose). In the final step, the soluble protein was dialysed
against 20 mM HEPES pH 7, 100 mM NaCl.
The purity of all protein samples supplied by D. Esser and B. Siebers was verified
by SDS-PAGE as described in section2.5.6.
5.2.2 Protein crystallisation
HTP screening was undertaken using a Screenmaker 96+8TM Xtal liquid han-
dler from Innovadyne technologies Inc. to produce sitting drops. Two sitting drops
of 100 nL reservoir solution + 100 nL protein solution and of 200 nL reservoir solu-
tion + 100 nL protein solution respectively, were set up using the JCSG+,55 Pact
Premier,55 Structure Screen I and II59, 60 and Clear Strat 1 and 258 crystallisation
screens. After two weeks crystals were found in two conditions of the sparse matrix
JCSG+ screen:55
Condition A2: 0.1 M sodium citrate, pH 5.5, 20% PEG 3k.
Condition A5: 0.2 M magnesium formate, 20% PEG 3350.
Optimisation screens were designed around condition A5 (JCSG+), spanning
concentrations of 0.1 - 0.2 M magnesium formate whilst keeping the PEG 3350 con-
centration constant at 20%.
Four optimisation screens (24 conditions each) were set up using the hanging drop
trays with a reservoir volume of 1 mL and varied drop sizes. The protein concen-
tration was 6.3 mg/mL. For drops containing phosphoenol pyruvate (PEP), varying
amounts of 5 mM PEP in dH2O was added to the drops. All trays were kept at
19 ◦C.
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5.2.3 Data collection
Synchrotron radiation datasets were collected at the Diamond Light Source
(DLS) synchrotron in Oxfordshire, UK (Diamond House, Harwell Oxford, Didcot,
Oxfordshire, OX11 0DE) on the macromolecular crystallography beamlines, I02 and
I03 (Pilatus 6M-F detectors).245 Several crystals were tested.
Data were collected from a single crystal for each of the three crystal forms obtained
(to resolutions of 2.48 A˚ 2.28 A˚ and 2.10 A˚ respectively). Details of the data
collection statistics can be found in Table 5.1 below.
Crystal form I Crystal form II PEP bound
Beamline DLS I02 DLS I02 DLS I03
Wavelength (A˚) 0.9795 0.9795 0.9790
Energy (keV) 12.658 12.658 12.664
Omega start (◦) 155.0 220.0 0.0
Oscillation range (◦) 0.1 0.1 0.1
Exposure time (s) 0.1 0.2 0.1
Detector distance (mm) 510.7 464.4 433.7
Beam transmission (%) 10 20 20
Beam size at sample horizontal (µm) 100 100 80
Beam size at sample vertical (µm) 25 25 20
Table 5.1: Summary of data collection statistics.
Datasets for crystal forms I and II were collected by M. Grøftehauge and the
PEP bound dataset was collected by E. Pohl.
5.2.4 Data processing - structure solution and refinement
DLS datasets were (auto-)indexed in Mosflm124 using 3 images, thus finding
the basis vector and assigning Miller indices. At this stage, the unit cell constants
were refined. The Bravais lattice with the highest symmetry and lowest penalty is
usually the correct one, however the symmetry can not be determined with absolute
certainty at this point in the process.
All diffraction data were integrated using Mosflm.124 Scala from the CCP4 pack-
age246 was used to scale and merge intensities. Once all reflections have been con-
verted to structure factors, using Ctruncate, Rfree flags were added. Phaser MR
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(part of the CCP4 package)246 was used for maximum likelihood phasing of the data.
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A Swiss Model Repository243 search identified the TPI from Pyrococcus woesei210
(PwTPI) (PDB code 1HG3) as having a 43% identity to SsTPI. The pdb file for
PwTPI was trimmed to only contain one chain (ie. one monomer of the PwTPI
tetramer) in Pymol),192 in order to search for a single asymmetric unit (asu). For
datasets 2 (crystal form II) and 3 (PEP bound), a monomer of the structure of
dataset 1 (crystal form I) was used as the search model. Phenix247 (1.8.1-1168) was
used to refine the models built in Coot191 (version 0.7). This was done using iter-
ative cycles of model building in Coot followed by refinement using phenix.refine.
During the refinement process, the Ramachandran and rotamer outliers were care-
fully monitored. Water molecules were assigned manually for peaks larger than 3σ
with appropriate geometry.
All crystallographic parameters derived from the structure solution process can be
found in Table 5.3 in section 5.3.3.
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5.3 Results and Discussion
5.3.1 SDS-PAGE analysis of SsTPI
S. solfataricus TPI protein was received at a concentration of 6.2 mg/mL in
a 20 mM HEPES pH 7 and 100 mM NaCl buffer. Protein purity was assessed by
SDS-PAGE (section 2.5.6) as shown in Figure 5.4.
Figure 5.4: SDS-PAGE showing purified SsTPI. 31µg of purified protein resolved
on a 12% SDS-PAGE gel. Proteins were stained with Instant Blue (Expedeon)
and protein size was estimated relative to Thermo ScientificTM Spectra Multicolour
Broad Range Protein ladder.
Figure 5.4 shows approximately 95% pure SsTPI resolved on a 12% SDS-PAGE
gel. The lower, broader band at approximately 25 kDa is SsTPI and the higher band
at approximately 50 kDa represents dimerised protein (Ss TPI consists of 227 amino
acids and has a molecular weight of 24736 Da.)
5.3.2 Crystallisation conditions for SsTPI
Initial crystallisation conditions were were identified in condition A2 and A5 in
the JCSG+55 crystallisation screen. After collecting a full data set for crystals from
condition A5, optimisation screens focussed on similar conditions. The diffracting
crystals grew in various shapes. Sizes ranged from 100 × 150 µm to 200 × 300
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µm for unbound crystals forms, whereas the PEP bound crystals were smaller at
50 × 75 µm. The relevant crystals are shown in Figure 5.5 for the three conditions
yielding diffracting crystals and resulted in full data sets.
(a)
(b)
(c)
Figure 5.5: Pictures of SsTPI crystals in the crystallisation drops and the mounting
loops respectively. a) crystal form I; b) crystal form II and c) PEP bound.
The corresponding conditions which produced diffracting crystals and full data
sets are summarised in Table 5.2.
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Crystal structure Crystal form I Crystal form II PEP bound
SsTPI concentration (mg/mL) 5.9 6.2 6.2
Magnesium formate (MgCHOO) (M) 0.2 0.18 0.16
PEG 3350 (%) 20 20 20
Drop ratio (protein : PEP : reservoir (µL)) 0.1 : 0 : 0.1 1 : 0 : 1 1 : 2 : 1
Cryo-protectant (glycerol (%)) - 1.25 10
Table 5.2: Summary of the crystallisation conditions for the diffracting SsTPI crys-
tals.
5.3.3 Structure determination for SsTPI
Data were collected and refined for three different structures. Two of these were
crystal modifications of unbound TPI and one was a holo structure of TPI bound
to PEP.
The X-ray data and refinement statistics are summarised in Table 5.3. The statistics
calculated by RAMPAGE248 (available at http://www-cryst.bioc.cam.ac.uk/rampage/,
utilised to generate Ramachandran plots), concerning the position of the individual
residues are summarised at the bottom of Table 5.3.
All structures are well-refined as shown by the R-factors ranging from 16.1 to 21.5%.
The bond length rmsd (bond) values are between 0.007 and 0.009 A˚ with excellent
geometry.249 For crystal form I, the Ramachandran plot (Figure 5.6) reveals a pro-
line outlier (Pro157, chain A). It is the only residue falling into the outlier region.
The resolution of the structure is not high enough to determine its exact conforma-
tion. Six residues are located in the allowed region, corresponding to 2.8% of the
residues. This is higher than the ideal 2% but falls within the experimental error.
Pro157 is located near the poorly modelled region where residues 148 to 150 are
missing, and near the active site residue number 141.
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Figure 5.6: Ramachandran plot generated in RAMPAGE248 of the SsTPI crystal
form I.
For crystal form II, the Ramachandran plot (Figure 5.7) shows one alanine
outlier (Ala150, chain B).
Figure 5.7: Ramachandran plot generated in RAMPAGE248 of the SsTPI crystal
form II.
The Ramachandran plot for the PEP bound structure (Figure 5.8) shows two
outlier alanine residues (Ala179, chains A and B). This residue is facing the PEP
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binding site in both chains and is pushed away to a distance of approximately 3 A˚ by
the double bonded carbon due to unfavourable interactions making this a structural
feature. Only 10 residues are located in the allowed regions, corresponding to 2.2%
of the residues.
Figure 5.8: Ramachandran plot generated in RAMPAGE248 of the PEP bound
SsTPI.
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Crystal form I Crystal form II PEP bound
Lattice Orthorhombic Orthorhombic Orthorhombic
Space group I222 P21212 P21212
a (A˚) 57.1 100.6 57.01
b (A˚) 91.6 60.2 90.95
c (A˚) 102.2 91.2 99.45
α, β, γ (◦) 90, 90, 90 90, 90, 90 90, 90, 90
Resolution range (A˚) 51.08-2.48 51.67-2.28 49.51-2.10
Reflections 9722 25614 30328
Rmerge(%)(∗) 5.6 (17.7) 13.5 (63.6) 13.6 (77.0)
I/σ(I)(∗) 15.4 (7.1) 7.3 (2.6) 6.7 (1.7)
Completeness (%) 98.97 98.82 98.37
Wilson B factor (A˚2) 27.84 36.49 30.15
R (workingset+test set)(%) 16.4 21.9 19.1
R (working set)(%) 16.1 21.5 18.9
Rfree (%)(based on 5% of data) 22.4 29.2 23.7
No of residues 1-147, A: 1-146, A: 1-226
151-223 149-226
B: 1-146, B: 1-225
149-226
No of PEP 0 0 2
No of waters 151 215 286
Rmsd bond length (A˚) 0.007 0.009 0.008
Rmsd bond angles (◦) 1.103 1.226 1.121
Number of residues in favoured region 209 416 435
96.8% 94.3% 97.3%
Number of residues in allowed region 6 24 10
2.8% 5.4% 2.2%
Number of residues in outlier region 1 1 2
0.5% 0.2% 0.4%
Outlier residue(s) Pro157 Ala150 (B) Ala179 (A and B)
Table 5.3: Diffraction data and refinement statistics for the SsTPI crystal form
I, crystal form II and PEP bound crystals. *The number in parentheses refers to
the highest resolution shell. The bottom of the table contains Ramachandran plot
statistics generated in RAMPAGE248 stating the number of residues in each region
of the plot for the three SsTPI crystal structures. The residues in outlier regions
are also specified.
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5.3.4 Overall SsTPI structure
5.3.4.1 Crystal form I
The overall structure of SsTPI in the three crystal forms is essentially similar,
and therefore the structure will be described based on the SsTPI crystal form I.
The crystal form I structure of SsTPI was refined at a resolution of 2.48 A˚ in the
space group I222. There was no clear electron density for residues 148 - 150, so they
were not modelled. Residues 224 to 227 (C-terminus) were not modelled, either.
One monomer was found in the asymmetric unit as shown by the 3-dimensional
representation in Figure 5.9 (a). The structure of it forms a tetramer (arranged as
a dimer of dimers) (Figure 5.9 (b)). The SsTPI crystal form I shows the expected,
classical TPI-barrel fold, as shown in Figure 5.9 below. The active site resides at
the catalytic face of the (β α)8-barrel, near the C-terminus, are shown and are all in
the expected conformation pointing towards the centre of the barrel (Figure 5.9 (a)).
(a) (b)
Figure 5.9: (a) View down the barrel of the SsTPI crystal form I with the four
active site residues highlighted. (b) Tetramer of the SsTPI crystal form I. Figures
were prepared using PyMOL.192
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5.3.4.2 Crystal form II
The crystal form II structure of SsTPI was refined at a resolution of 2.28 A˚ in
the space group P21212. A few more residues were built into this model, and only
residues 147, 148 and 227 are missing from the model in both chains A and B. A
dimer was found in the asymmetric unit (Figure 5.10 (a)). Figure 5.10 (b) shows
the dimer of dimers. Apart from the region surrounding residues 148 to 150 as well
as residues 224 to 226, the overall fold is identical to that described for crystal form
I (section 5.3.4.1).
(a) (b)
Figure 5.10: (a) Sideview of the SsTPI crystal form II dimer. (b) Tetramer of the
SsTPI crystal form II. Figures were prepared using PyMOL.192
5.3.4.3 PEP bound structure
The PEP bound SsTPI was refined at a resolution of 2.10 A˚ in the space group
P21212. The structure is almost fully modelled only missing residue 227 from chain A
and residues 226 and 227 from chain B. A dimer was found in the asymmetric unit
(Figure 5.10 (a)). The dimer of dimers is shown in Figure 5.10 (b)). Apart from
loop 6, which is fully modelled, due to a PEP molecule being bound in the active
site, thus closing the loop and creating stability, the overall fold is identical to that
described for crystal form I (see 5.3.4.1).
The unbiased 2Fo - Fc electron density before the ligand was added is shown in
Figure 5.11 (a) and the density with the final model added (stick representation)
is shown in Figure 5.11 (b). It clearly shows a large green density where the PEP
ligand fits (shown in Figure 5.12).
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(a)
(b)
Figure 5.11: (a) The unbiased 2Fo - Fc electron density at 1σ level before the ligand
was added. (b) The 2Fo - Fc electron density at 1σ level with the final model in stick
representation superimposed in the active site density. H-bonds are also indicated.
Figures are screenshots from Coot.191
Figure 5.12: Structure of phosphoenolpyruvic acid (PEP) with phosphoenolpyruvate
as the anion.
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The binding sites of PEP in the tetramer are shown below in Figure 5.13.
Figure 5.13: The SsTPI tetramer with PEP bound in the active site of each
monomer. Figure was prepared using PyMOL.192
A close-up of the active site in Figure 5.14 reveals the intermolecular interaction
between the ligand and the active site residues.
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Figure 5.14: Close-up of active site showing the binding site and active site residues,
the PEP molecule as well as interaction distances. Figure was prepared using Py-
MOL.192
The binding site consists of Asn9 and Lys11 where the interactions occur with
the oxygen in the -COOH group. The Lys11 residue could also potentially interact
with the O atom of the phosphate group which links it to the rest of the PEP
molecule. Loop 6 has been fully modelled and is shown to have closed in, thus
keeping the ligand in the active site. It is important to note that PEP is structurally
very similar to the substrate, DHAP, and can thus interact with the active site in a
similar manner.250 The active site residues, His93 and Glu141, are also positioned
close enough to PEP for interactions occur.
The binding site is largely conserved compared to native rabbit muscle TPI,250 the
only solved PEP-bound TPI structure. A direct comparison, however, is impossible
due to the size difference between mesophilic and hyperthermophilic TPIs, but the
conserved nature of the binding site suggest evolution of TPIs from a common
ancestor.
5.3.5 Structural comparisons of the SsTPI crystal forms
A superposition of Crystal I form, Crystal II form and the PEP bound form of
SsTPI shows that the structures are nearly identical apart from the orientation of
the active site residue Glu141, and loop β6α6, as shown in Figure 5.15.
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Figure 5.15: Superposition of all three SsTPI structures with crystal form I (blue),
crystal form II (yellow) and the PEP bound structure (green). A PEP molecule is
shown in the active site and the active site and binding site residues are also shown.
The Figure was prepared using PyMOL.192
The B-factors for the main chain atoms of crystal form I for residues 147 to 151
is 50.0 to 61.7 A˚2. For the main chain atoms of crystal form II for residues 146 to
151 chain A, the B-factors range from 84.5 to 146.2 A˚2 and for chain B from 99.9 to
151.3 A˚2. The B-factors for the PEP bound structure main chain atoms 147 to 151
range between 21.4 and 32.1 A˚2 for chain A and between 31.3 to 39.4 A˚2 for chain
B. The values are significantly higher than the overall average in crystal form II for
the region between residues 147 and 151 than for crystal form I and the PEP bound
form, indicating significant disorder which could be due to the different environment
in the crystal structure or to an inherent mobility of these resides.
When comparing the two unbound forms and the PEP bound structure of SsTPI,
loop β6α6 is of particular interest. Loop β6α6 is located near the active site and
is the link between helix 6 and strand 6 in all analysed TPI-barrels. It has been
identified in two different conformations - open or closed.212 The closed form is
usually found in TPI structures containing a ligand and the open form for unliganded
structures. In the two unbound forms of SsTPI structures, the loop does not appear
to change much. For crystal form II, the loop appears to be closer in conformation
to that of the PEP bound structure, which may be due to the low data quality for
this part of the structure. It could also suggest that this crystal form and space
group forces the loop to be more ordered. Only in the PEP bound form has it been
fully modelled. This suggests that the loop may be switching between open and
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closed conformations in the unbound structures, but is only fully stabilised in the
closed conformation for holo structures, in this case the PEP bound structure, by
the PEP molecule.240, 251
This is all due to the side chain shifting as catalysis occurs in order to suppress side
reactions. The β6α6 loop and the β5α5 loop interact in the unbound structures, but
when a ligand is bound in the active site, the β6α6 loop positions itself to close in
on the active site which also results in the glutamate (Glu141) residue re-positioning
for catalytic activity225 which is clearly visible in Figure 5.15.
5.3.6 Structural comparisons of the archaeal TPIs
All archaeal TPIs are homotetrameric enxymes which can be described as a
dimer of dimers. A superposition of the four archaeal TPIs, PwTPI, TtTPI, Mj TPI
and SsTPI shows that the four structures are very similar, as shown in Figure 5.16.
Figure 5.16: Superposition of the archaeal TPI structures with PwTPI (red), TtTPI
(green), Mj TPI (orange) and SsTPI (blue). Figure was prepared using PyMOL.192
The rmsd values (calculated using PyMOL)192 are listed below in Table 5.4
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rmsd (A˚) PwTPI TtTPI Mj TPI SsTPI
PwTPI - 1.66 0.96 1.85
TtTPI 1.66 - 0.96 2.87
Mj TPI 0.96 1.95 - 1.52
SsTPI 1.85 2.87 1.52 -
Table 5.4: Summary of the rmsd values (based on all atoms) between the archaeal
TPI tetrameric structures.
The rmsd values show that apart from TtTPI and SsTPI, the structures have
rmsd lower than 2 A˚. The structures are very similar with no significant changes
along the main chain and the larger rmsd values occurring are due to the flexible
loops and end terminii. Given the relatively low sequence identities with respect
to SsTPI, ranging from 40% to 43%, these results support the notion that protein
structure is generally more conserved than the sequence.230
SsTPI shows similar features contributing to enzyme stability as observed for other
archaeal TPIs. The increased oligomerisation state resulting in the formation of
a tetramer is a mechanism employed by archaeal TPIs to increase acid- and ther-
mostability. An increase in the subunit contacts as well as hydrophobic interactions
is a result of the higher oligomerisation state of archaeal TPIs. The reduced number
of residues compared to other TPIs is also an important factor as is the nature of the
residues as it results in tighter packing of the tetramer units (section 5.1.6.2).210, 230
5.4 Chapter conclusion
Using a standard crystallisation method of setting up trays employing several
commercially available crystallisation screens, SsTPI was crystallised and further
crystals were grown by using condition optimisation.
Three full datasets were collected and solved for three different structure; two differ-
ent unbound structures (in the I222 and the P21212 space groups) and one holo form
with PEP bound in the active site (space group P21212). PEP is an intermediate in
the glycolysis pathway and resembles DHAP, the enzyme substrate.
As expected for a TPI from a hyperthermophilic archaeon, the SsTPI forms tetramers.
Comparing the two unbound structures and the PEP bound structure reveals that
the β6α6 loop could only be modelled for the PEP bound structure, as the PEP
in the active site stabilises it. In crystal form I, the loop appears to be completely
open, in crystal form II it appears to be in between the open and closed conforma-
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tion, whereas it is completely closed on the active site in the PEP bound structure.
Furthermore, the active site Glu141 shifts in position when the ligand is bound in
the active site, which is required for catalysis reactions to occur.
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Appendices
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Appendix A
Additional information for PlcH
constructs
A.1 Summary of PlcH primers and vectors
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Construct
label
Vector Fusion tag Parent vector Forward primer exten-
sion
Reverse primer exten-
sion
1 pOPINE ...KHHHHHH pTriEx2 AGGAGATATACC
ATGACCGAAA
ACTGGAAATT
CCGC
GTGATGGTGAT
GTTTGGTCGCT
GCGATGTCGAG
2 pOPINF MAHHHH
HHSSG
LEVLFQ
GP...
pTriEx2 AAGTTCTGTTT
CAGGGCCCGAC
CGAAAACTGGA
AATTCCGC
ATGGTCTAGAAA
GCTTTAGGTC
GCTGCGATGT
CGAG
3 pOPINE ...KHHHHHH pTriEx2 AGGAGATATACC
ATGGAGCCGG
ACATCCGCACC
GTGATGGTGAT
GTTTGCGTAAC
AGCCACACTTCAC
4 pOPINF MAHHHH
HHSSG
LEVLFQ
GP...
pTriEx2 AAGTTCTGTTT
CAGGGCCCGGA
GCCGGACATCC
GCACC
ATGGTCTAGAAA
GCTTTAGCGT
AACAGCCACA
CTTCAC
5 pOPINE ...KHHHHHH pTriEx2 AGGAGATATACC
ATGGAGCCG
GACATCCGCA
CC
GTGATGGTGAT
GTTTGCTGGCG
GTCACGCTGAG
6 pOPINF MAHHHH
HHSSG
LEVLFQ
GP...
pTriEx2 AAGTTCTGTTT
CAGGGCCCGGA
GCCGGACATCC
GCACC
ATGGTCTAGAAA
GCTTTAGCTG
GCGGTCACG
CTGAG
7 pOPINE ...KHHHHHH pTriEx2 AGGAGATATACC
ATGGAGCCGG
ACATCCGCACC
GTGATGGTGAT
GTTTGGTCGCT
GCGATGTCGAGC
8 pOPINF MAHHHH
HHSSG
LEVLFQ
GP...
pTriEx2 AAGTTCTGTTT
CAGGGCCCGGA
GCCGGACATCC
GCACC
ATGGTCTAGAAA
GCTTTAGGTC
GCTGCGATGT
CGAGC
9 pOPINE ...KHHHHHH pTriEx2 AGGAGATATACC
ATGATCCAGG
ACGTCCAGCA
CG
GTGATGGTGA
TGTTTGTGTCC
GGCCAGGCGGC
10 pOPINF MAHHHH
HHSSG
LEVLFQ
GP...
pTriEx2 AGTTCTGTTTC
AGGGCCCGATC
CAGGACGTCC
AGCACG
ATGGTCTAGAAA
GCTTTAGTGT
CCGGCCAGG
CGGC
11 pOPINE ...KHHHHHH pTriEx2 AGGAGATATACC
ATGATCCAGG
ACGTCCAGCA
CG
GTGATGGTGAT
GTTTGACGTTG
GTCAGGTCGGG
12 pOPINF MAHHHH
HHSSG
LEVLFQ
GP...
pTriEx2 AAGTTCTGTTT
CAGGGCCCGAT
CCAGGACGTCC
AGCACG
ATGGTCTAGAAA
GCTTTAGACG
TTGGTCAGGT
CGGG
Table A.1: Summary of the 2×12 primers and the vectors employed for PlcH.
Columns summarise construct label, vector, fusion tag, parent vector, DNA se-
quence of the forward and reverse primers. The primers are written 5’ to 3’; the
italicised sequence signifies start and stop codons (ATG and TAG), the sequence to
the left of the codon is homologous with the plasmid sequence and the sequence in
bold is homologous with the construct specific sequence. All vectors carry antibiotic
resistance against ampicillin.
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Appendix B
Additional data for Chapter 3
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B.2 CD data analysis for PlcH 2
Figure B.2: Experimental CD data and data calculated using the CONTINLL,
CDSSTR and SELCON3 programmes, plotted against wavelength, for PlcH 2.
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B.3 CD data analysis for PlcH 4
Figure B.3: Experimental CD data and data calculated using the CONTINLL,
CDSSTR and SELCON3 programmes, plotted against wavelength, for PlcH 4.
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Appendix C
Additional data for Chapter 4
C.1 CD data analysis for SPT ∆158
Figure C.1: Experimental CD data and data calculated using the CONTINLL,
CDSSTR and SELCON3 programmes, plotted against wavelength, for SPT ∆158.
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C.2 CD data analysis for SPT ∆176
Figure C.2: Experimental CD data and data calculated using the CONTINLL,
CDSSTR and SELCON3 programmes, plotted against wavelength, for SPT ∆176.
227
C.3 CD data analysis for SPT ∆180
Figure C.3: Experimental CD data and data calculated using the CONTINLL,
CDSSTR and SELCON3 programmes, plotted against wavelength, for SPT ∆180.
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